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The Trans-Atlantic Inter-Society Consensus Document
on Management of Peripheral Arterial Disease (TASC)
was published in January 20001e3 as a result of cooper-
ation between fourteen medical and surgical vascular,
cardiovascular, vascular radiology and cardiology so-
cieties in Europe and North America. This comprehen-
sive document had a major impact on vascular care
amongst specialists. In subsequent years, the field
has progressed with the publication of the CoCaLis
document4 and the American College of Cardiology/
American Heart Association Guidelines for the Man-
agement of Peripheral Arterial Disease.5 Aiming to
continue to reach a readership of vascular specialists,
but also physicians in primary health care who see pa-
tients with peripheral arterial disease (PAD), another
consensus process was initiated during 2004. This
new consensus document has been developed with
a broader international representation, including
Europe, North America, Asia, Africa and Australia,
and with amuch larger distribution and dissemination
of the information. The goals of this new consensus are
to provide an abbreviated document (compared with
the publication in 2000), to focus on key aspects of di-
agnosis and management, and to update the informa-
tion based on new publications and the newer
guidelines, but not to add an extensive list of refer-
ences. Unreferenced statements are, therefore, to be
found, provided they are recognized as common prac-
tice by the authors, with existing evidence. The
*Corresponding authors.
E-mail addresses: lars.norgren@orebroll.se, will.hiatt@uchsc.edurecommendations are graded according to levels of ev-
idence. It should also be emphasized that good practice
is based on a combination of the scientific evidence
described below, patients’ preferences, and local avail-
ability of facilities and trained professionals. Good
practice also includes appropriate specialist referral.
Process
Representatives of sixteen societies fromEurope,North
America, Australia, South Africa and Japan were elec-
ted from their respective society and were called
together in 2004 to form the newWorking Group. Spe-
cialists in health economics, health outcomes and
evidence-based medicine were also included to elabo-
rate on the text for the following sections: history,
epidemiology and risk factors; management of
risk factors; intermittent claudication; critical limb
ischemia; acute limb ischemia; and technologies
(intervention/revascularization and imaging).
The Working Group reviewed the literature and, af-
ter extensive correspondence and meetings, proposed
a series of draft documents with clear recommenda-
tions for the diagnosis and treatment of PAD. Each
participating society reviewed and commented on
these draft consensus documents. The liaison member
from each society then took these views back to the
Working Group, where all of the amendments, addi-
tions and alterations suggested by each participating
society were discussed, and the final Consensus
Document was agreed upon.
The participating societies were then again invited
to review the final document and endorse it if they
agreed with its contents. If an individual participatingEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
S6 L. Norgren and W. R. Hiatt et al.society did not accept any specific recommendation,
this is clearly indicated in the final document.
Therefore, except where such specific exclusions are
indicated, this Consensus Document represents the
views of all of the participating societies.
Compared with the original TASC, more emphasis
has been put on diabetes and PAD. The text is pre-
sented in such a way that vascular specialists will still
find most of the information they require, while gen-
eral practitioners and primary health physicians will
easily find guidance for diagnosis and diagnostic pro-
cedures, referral of patients and expected outcome of
various treatment options.
Grading of recommendations
Recommendations and selected statements are rated
according to guidance issued by the former US Agency
for Health Care Policy and Research,6 now renamed
the Agency for Healthcare Research and Quality:
Grade Recommendation
A Based on the criterion of at least
one randomized, controlled clinical trial as
part of the body of literature of overall
good quality and consistency addressing
the specific recommendation
B Based on well-conducted clinical studies
but no good quality randomized clinical
trials on the topic of recommendation
C Based on evidence obtained from expert
committee reports or opinions and/or
clinical experiences of respected
authorities (i.e. no applicable studies of
good quality)
Note that the grade of recommendation is based on the
level of available evidence and does not necessarily
relate to the clinical importance.
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SECTION A e EPIDEMIOLOGY OF PERIPHERAL
ARTERIAL DISEASE
A1 Epidemiology
The management of the patient with peripheral arte-
rial disease (PAD) has to be planned in the context
of the epidemiology of the disease, its natural history
and, in particular, the modifiable risk factors for the
systemic disease as well as those that predict deteri-
oration of the circulation to the limb.
A1.1 Incidence and prevalence of asymptomatic
peripheral arterial disease
Total disease prevalence based on objective testing has
been evaluated in several epidemiologic studies and is
in the range of 3% to 10%, increasing to 15% to 20% in
persons over 70 years.7e9 The prevalence of asymptom-
atic PAD in the leg can only be estimated by using non-
invasive measurements in a general population. The
most widely used test is the measurement of
the ankle-brachial systolic pressure index (ABI). (For
detailed discussion of the ABI, see Section C2.1.) A
resting ABI of 0.90 is caused by hemodynamically-
significant arterial stenosis and is most often used as
a hemodynamic definition of PAD. In symptomatic
individuals, an ABI 0.90 is approximately 95% sensi-
tive in detecting arteriogram-positive PAD and almost
100% specific in identifying healthy individuals. Using
this criterion, several studies have looked at symptom-
atic and asymptomatic PADpatients in the same popu-
lation. The ratio of the two is independent of age and is
usually in the range of 1:3 to 1:4. The EdinburghArtery
Study found that, using duplex scanning, a third of the
patientswith asymptomatic PADhad a complete occlu-
sion of amajor artery to the leg.10 The PARTNERS (PAD
Awareness, Risk, and Treatment: New Resources for
Survival) study screened 6979 subjects for PAD using
the ABI (with PADdefined as anABI of0.90 or a prior
history of lower extremity revascularization). Subjects
were evaluated if they were aged 70 years or aged
50e69 years with a risk factor for vascular disease
(smoking, diabetes) in 320 primary care practices in
the United States.11 PAD was detected in 1865 patients
which was 29% of the total population. Classic claudi-
cation was present in 5.5% of the newly diagnosed pa-
tients with PAD and 12.6% of the patients with a prior
diagnosis of PAD had claudication. The National
Health and Nutritional Examination Survey recently
S7TASC II Inter-Society Consensus on Peripheral Arterial Diseasereported on an unselected population of 2174 subjects
aged 40 years.9 The prevalence of PAD, as defined
by an ABI of 0.90, ranged from 2.5% in the age group
50e59 years to 14.5% in subjects >70 years (there was
no information about the proportion of subjects with
an ABI of0.90 who had symptoms in the legs). In au-
topsies of unselected adults, 15% of men and 5% of
women who were asymptomatic, had a 50% or greater
stenosis of an artery to the leg. It is interesting to com-
pare this with the finding that 20% to 30% of subjects
with complete occlusion of at least one coronary artery
on autopsy are asymptomatic. Some of the apparent
inconsistency regarding data on the prevalence of
symptomatic PAD is due to methodology, but in sum-
mary it can be concluded that for every patient with
symptomatic PAD there are another three to four sub-
jects with PAD who do not meet the clinical criteria
for intermittent claudication.
A1.2 Incidence and prevalence of symptomatic
peripheral arterial disease
Intermittent claudication (IC) (see section C1.1 for def-
inition) is usually diagnosed by a history of muscular
leg pain on exercise that is relieved by a short rest.
Several questionnaires have been developed for epi-
demiological use. In looking at methods for identify-
ing IC in the population, it must be remembered
that while it is the main symptom of PAD, the mea-
surement of this symptom does not always predict
the presence or absence of PAD. A patient with quite
severe PAD may not have the symptom of IC because
some other condition limits exercise or they are seden-
tary. In contrast, some patients with what seems to be
IC may not have PAD (for example, spinal stenosis
can produce symptoms like IC in the absence ofvascular disease). Likewise, patients with very mild
PAD may develop symptoms of IC only when they
become very physically active.
The annual incidence of IC is more difficult to mea-
sure and probably less important than its prevalence
(unlike the case of the relatively very much smaller
number of patients with critical limb ischemia [CLI]).
The prevalence of IC would appear to increase from
about 3% in patients aged 40 to 6% in patients aged
60 years. Several large population studies have looked
at the prevalence of IC and Fig. A1 shows a calculated
mean prevalenceweighted by study sample size. In the
relatively younger age groups, claudication is more
common in men but at older ages there is little differ-
ence between men and women. A surprising finding
in population screening studies is that between 10%
and 50% of patients with IC have never consulted
a doctor about their symptoms.
A1.3 Epidemiology of peripheral arterial disease
in different ethnic groups
Non-white ethnicity is a risk factor for PAD. Black
ethnicity increases the risk of PAD by over two-fold,
and this risk is not explained by higher levels of other
risk factors such as diabetes, hypertension or obesity.12
A high prevalence of arteritis affecting the distal arteries
of young black South Africans has also been described.
A2 Risk Factors for Peripheral Arterial Disease
Although the various factors described in this section
are usually referred to as risk factors, in most cases the
evidence is only for an association. The criteria used
to support a risk factor require a prospective, con-
trolled study showing that altering the factor altersFig. A1. Weighted mean prevalence of intermittent claudication (symptomatic PAD) in large population-based studies.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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been shown for smoking cessation or treatment of dys-
lipidemia. Risk may be conferred by other metabolic
or circulatory abnormalities associated with diabetes.
A2.1 Race
The National Health and Nutrition Examination Sur-
vey in the United States found that an ABI 0.90 was
more common in non-Hispanic Blacks (7.8%) than in
Whites (4.4%). Such a difference in the prevalence of
PADwas confirmedby the recentGENOA (Genetic Ep-
idemiology Network of Arteriopathy) study,13 which
also showed that the difference was not explained by
a difference in classical risk factors for atherosclerosis.
A2.2 Gender
The prevalence of PAD, symptomatic or asymptom-
atic, is slightly greater in men than women, particu-
larly in the younger age groups. In patients with IC,
the ratio of men to women is between 1:1 and 2:1.
This ratio increases in some studies to at least 3:1 in
more severe stages of the disease, such as chronic
CLI. Other studies have, however, shown amore equal
distribution of PAD between genders and even a
predominance of women with CLI.
A2.3 Age
The striking increase in both the incidence and preva-
lence of PAD with increasing age is apparent from the
earlier discussion of epidemiology (Fig. A1).
A2.4 Smoking
The relationship between smoking and PAD has been
recognized since 1911, when Erb reported that IC
was three-times more common among smokers than
among non-smokers. Interventions to decrease or
eliminate cigarette smoking have, therefore, long
been advocated for patients with IC. It has been sug-
gested that the association between smoking and PAD
may be even stronger than that between smoking
and coronary artery disease (CAD). Furthermore, a
diagnosis of PAD is made approximately a decade
earlier in smokers than in non-smokers. The severity
of PAD tends to increase with the number of cigarettes
smoked. Heavy smokers have a four-fold higher risk
of developing IC compared with non-smokers.
Smoking cessation is associated with a decline in the
incidence of IC. Results from the Edinburgh Artery
Study10 found that the relative risk of IC was 3.7 inEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007smokers compared with 3.0 in ex-smokers (who had
discontinued smoking for less than 5 years).
A2.5 Diabetes mellitus
Many studies have shown an association between
diabetes mellitus and the development of PAD. Over-
all, IC is about twice as common among diabetic
patients than among non-diabetic patients. In patients
with diabetes, for every 1% increase in hemoglobin
A1c there is a corresponding 26% increased risk of
PAD.14 Over the last decade, mounting evidence has
suggested that insulin resistance plays a key role in
a clustering of cardiometabolic risk factors which
include hyperglycemia, dyslipidemia, hypertension
and obesity. Insulin resistance is a risk factor for
PAD even in subjects without diabetes, raising the
risk approximately 40% to 50%.15 PAD in patients
with diabetes is more aggressive compared to non-
diabetics, with early large vessel involvement coupled
with distal symmetrical neuropathy. The need for
a major amputation is five- to ten-times higher in
diabetics than non-diabetics. This is contributed to
by sensory neuropathy and decreased resistance to
infection. Based on these observations, a consensus
statement from the American Diabetes Association
recommends PAD screening with an ABI every 5 years
in patients with diabetes.16
A2.6 Hypertension
Hypertension is associated with all forms of cardio-
vascular disease, including PAD. However, the rela-
tive risk for developing PAD is less for hypertension
than diabetes or smoking.
A2.7 Dyslipidemia
In the Framingham study, a fasting cholesterol level
greater than 7 mmol/L (270 mg/dL) was associated
with a doubling of the incidence of IC but the ratio
of total to high-density lipoprotein (HDL) cholesterol
was the best predictor of occurrence of PAD. In an-
other study, patients with PAD had significantly
higher levels of serum triglycerides, very low-density
lipoprotein (VLDL) cholesterol, VLDL triglycerides,
VLDL proteins, intermediate density lipoprotein
(IDL) cholesterol, and IDL triglycerides and lower
levels of HDL than controls.17 Although some studies
have also shown that total cholesterol is a powerful
independent risk factor for PAD, others have failed
to confirm this association. It has been suggested that
cigarette smoking may enhance the effect of
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ment of hyperlipidemia reduces both the progression
of PAD and the incidence of IC. An association be-
tween PAD and hypertriglyceridemia has also been re-
ported and has been shown to be associated with the
progression and systemic complications of PAD. Lipo-
protein(a) is a significant independent risk factor for
PAD.
A2.8 Inflammatory markers
Some recent studies have shown that C-reactive pro-
tein (CRP) was raised in asymptomatic subjects who
in the subsequent five years developed PAD com-
pared to an age-matched control group who remained
asymptomatic. The risk of developing PAD in the
highest quartile of baseline CRP was more than twice
that in the lowest quartile.18
A2.9 Hyperviscosity and hypercoagulable states
Raised hematocrit levels and hyperviscosity have been
reported in patients with PAD, possibly as a conse-
quence of smoking. Increased plasma levels of fibrino-
gen, which is also a risk factor for thrombosis, have
been associated with PAD in several studies. Both
hyperviscosity and hypercoagulability have also been
shown to be markers or risk factors for a poor
prognosis.
A2.10 Hyperhomocysteinemia
The prevalence of hyperhomocysteinemia is high in the
vascular disease population, compared with 1% in the
general population. It is reported that hyperhomo-
cysteinemia is detected in about 30% of young patients
with PAD. The suggestion that hyperhomocysteinemia
may be an independent risk factor for atherosclerosis
has now been substantiated by several studies. It may
be a stronger risk factor for PAD than for CAD.
A2.11 Chronic renal insufficiency
There is an association of renal insufficiency with PAD,
with some recent evidence suggesting it may be causal.
In the HERS study (Heart and Estrogen/Progestin
Replacement Study), renal insufficiency was inde-
pendently associated with future PAD events in
postmenopausal women.19A2.12 Summary
Fig. A2 summarizes graphically the approximate influ-
ence or association between some of the above factors
and PAD, taking a global view of the existing evidence.
A3 Fate of the Leg
A3.1 Asymptomatic
Evidence suggests that the progression of the under-
lying PAD is identical whether or not the subject has
symptoms in the leg. There is nothing to suggest
that the risk of local deterioration, with progression
to CLI, is dependent on the presence or absence of
symptoms of intermittent claudication. Whether
symptoms develop or not depends largely on the level
of activity of the subject. This is one of the reasons
why some patients’ initial presentation is with CLI,
in the absence of any earlier IC. For example, a patient
who has a reduction in their ABI just above the ische-
mic rest pain level but who is too sedentary to claudi-
cate, may develop CLI because of wounds resulting
from relatively minor (often self inflicted) trauma
Fig. A2. Approximate range of odds ratios for risk factors
for symptomatic peripheral arterial disease. Treatment of
risk factors and the effect on the outcomes of PAD are
described in Chapter B.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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tant to detect this subgroup of patients at a time when
protective foot care and risk factor control have their
greatest potential to ameliorate outcomes. Functional
decline over two years is related to baseline ABI and
the nature of the presenting limb symptoms.20 A
lower ABI was associated with a more rapid decline
in, for example, 6-minute walk distance.
A3.2 Intermittent claudication
Although PAD is progressive in the pathological
sense, its clinical course as far as the leg is concerned
is surprisingly stable in most cases. However, the
symptomatic PAD patient continues to have signifi-
cant functional disability. Large population studies
provide the most reliable figures. All of the evidence
over the last 40 years since the classic study by Bloor
has not materially altered the impression that only
about a quarter of patients with IC will ever signifi-
cantly deteriorate. This symptomatic stabilization
may be due to the development of collaterals, meta-
bolic adaptation of ischemic muscle, or the patient
altering his or her gait to favor non-ischemic muscle
groups. The remaining 25% of patients with ICEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007deteriorate in terms of clinical stage; this is most fre-
quent during the first year after diagnosis (7%e9%)
compared with 2% to 3% per year thereafter. This clin-
ical stability is relevant to the patient’s perception of
their severity of claudication. When these patients
have a comprehensive assessment of their actual func-
tional status, measured walking distance does
progressively deteriorate over time.20
More recent reviews also highlight that major am-
putation is a relatively rare outcome of claudication,
with only 1% to 3.3% of patients with IC needing ma-
jor amputation over a 5-year period. The Basle and
Framingham studies,21,22 which are the two large-
scale studies that have looked at unselected patients,
found that less than 2% of PAD patients required ma-
jor amputation. Although amputation is the major
fear of patients told that they have circulatory disease
of the legs, they can be assured that this is an unlikely
outcome, except in diabetes patients (Fig. A3).
It is difficult to predict the risk of deterioration in
a recent claudicant. The various risk factors mentioned
in section A2 (above) probably all contribute to the
progression of PAD. A changing ABI is possibly the
best individual predictor, because if a patient’s ABI
rapidly deteriorates it is most likely to continue to doFig. A3. Fate of the claudicant over 5 years (adapted from ACC/AHA guidelines5). PAD e peripheral arterial disease;
CLI e critical limb ischemia; CV e cardiovascular; MI e myocardial infarction. Adapted with permission from Hirsch AT
et al. J Am Coll Cardiol 2006;47:1239e1312.
S11TASC II Inter-Society Consensus on Peripheral Arterial Diseaseso in the absence of successful treatment. It has been
shown that in patients with IC, the best predictor of
deterioration of PAD (e.g. need for arterial surgery or
major amputation), is an ABI of <0.50 with a hazard
ratio of more than 2 compared to patients with an
ABI >0.50. Studies have also indicated that in those
patients with IC in the lowest strata of ankle pressure
(i.e. 40e60 mmHg), the risk of progression to severe
ischemia or actual limb loss is 8.5% per year.
A3.3 Critical limb ischemia
The only reliable large prospective population studies
on the incidence of CLI showed a figure of 220 new
cases every year per million population.23 However,
there is indirect evidence from studies looking at the
progression of IC, population surveys on prevalence
and assumptions based on the major amputation rates.
Surprisingly, the incidence calculated using these
different methodologies is very similar. There will be
approximately between 500 and 1000 new cases of
CLI every year in a European or North American
population of 1 million.
A number of studies have allowed an analysis
of the risk factors that seem to be associated with
the development of CLI. These are summarized in
Fig. A4. These factors appear to be independent and
are, therefore, probably additive.
It is no longer possible to describe the natural
history of patients with CLI because the majority of
these patients now receive some form of active
Fig. A4. Approximate magnitude of the effect of risk factors
on the development of critical limb ischemia in patients
with peripheral arterial disease. CLI e critical limb
ischemia.treatment. Treatment very much depends on the cen-
ter to which the patient is referred. Large surveys sug-
gest that approximately half the patients with CLI will
undergo some type of revascularization, although in
some, particularly active, interventional centers an at-
tempt at reconstruction is reported in as many as 90%
of CLI patients. Fig. A5 provides an estimate of the
primary treatment of these patients globally and their
status a year later.
There are some good-quality data from multicenter,
closely monitored trials of pharmacotherapy for CLI.
These only relate to a subgroup of patients who are un-
reconstructable or in whom attempts at reconstruction
have failed. (It is only such patients who are entered
into randomized, placebo-controlled, clinical pharma-
cotherapy trials.) The results for this subgroup reveal
the appalling prospect that approximately 40% will
lose their leg within 6 months, and up to 20% will die
(note that these data refer to 6 months’ follow-up and
cannot be directly compared with the 1-year data in
Fig. A5).
A3.4 Acute leg ischemia
Acute limb ischemia denotes a quickly developing or
sudden decrease in limb perfusion, usually producing
new or worsening symptoms and signs, and often
threatening limb viability. Progression of PAD from
claudication to rest pain to ischemic ulcers or gan-
grene may be gradual or progress rapidly reflecting
sudden worsening of limb perfusion. Acute limb is-
chemia may also occur as the result of an embolic
event or a local thrombosis in a previously asymptom-
atic patient.
There is little information on the incidence of
acute leg ischemia, but a few national registries and
regional surveys suggest that the incidence is around
140/million/year. Acute leg ischemia due to emboli
has decreased over the years, possibly as a consequence
of less cardiac valvular disease from rheumatic fever
and also better monitoring and anticoagulant manage-
ment of atrial fibrillation. Meanwhile the incidence of
thrombotic acute leg ischemia has increased. Even
with the extensive use of newer endovascular tech-
niques including thrombolysis, most published series
report a 10% to 30% 30-day amputation rate.
A3.5 Amputation
There is an ongoing controversy, often fuelled by
unverified retrospective audit data from large and
changing populations, as to whether there is a signifi-
cant reduction in amputations as a result of moreEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
S12 L. Norgren and W. R. Hiatt et al.Fig. A5. Fate of the patients presenting with chronic critical leg ischemia. CLI e critical limb ischemia.revascularization procedures in patients with CLI.
Careful, independent studies from Sweden, Denmark
and Finland all suggest that increased availability and
use of endovascular and surgical interventions have
resulted in a significant decrease in amputation for
CLI. In the United Kingdom, the number of major
amputations has reached a plateau, possibly reflecting
increasingly successful limb salvage, but older studies
in the United States have not shown benefit of revas-
cularization on amputation rates.24
The concept that all patients who require an ampu-
tation have steadily progressed through increasingly
severe claudication to rest pain, ulcers and, ultimately,
amputation, is incorrect. It has been shown that more
than half of patients having a below-knee major am-
putation for ischemic disease had no symptoms of
leg ischemia whatsoever as recently as 6 months pre-
viously.25 The incidence of major amputations from
large population or nation-wide data varies from
120 to 500/million/year. The ratio of below-knee toabove-knee amputations in large surveys is around
1:1. Only about 60% of below-knee amputations heal
by primary intention, 15% heal after secondary proce-
dures and 15% need to be converted to an above-knee
level. 10% die in the peri-operative period. The dismal
1- to 2-year prognosis is summarized in Fig. A6.
A4 Co-existing Vascular Disease
Because PAD, CAD and cerebral artery disease are all
manifestations of atherosclerosis, it is not surprising
that the three conditions commonly occur together.
A4.1 Coronary
Studies on the prevalence of cardiovascular disease in
patients with PAD show that the history, clinical exam-
ination and electrocardiogram identify a prevalence of
CAD and cerebral artery disease in 40% to 60% of suchFig. A6. Fate of the patient with below-knee amputation.
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screened had an ABI of 0.90 and no symptomatic
CAD or cerebral artery disease, 16% had both PAD
and symptomatic CAD or cerebral artery disease,
and 24% had symptomatic CAD and cerebral artery
disease and a normal ABI.11 As with asymptomatic
PAD, the diagnosis of CAD depends on the sensitivity
of the methods used. In the primary care setting, ap-
proximately half of those patients diagnosed with
PAD also have CAD and cerebral artery disease; in
PAD patients referred to hospital, the prevalence of
CAD is likely to be higher. The extent of the CAD,
both by angiography and by computed tomography
(CT) measured coronary calcium, correlates with the
ABI. Not surprisingly, patients with documented
CAD are more likely to have PAD. The prevalence of
PAD in patients with ischemic heart disease varies in
different series from around 10% to 30%. Autopsy
studies have shown that patients who die from a myo-
cardial infarction are twice as likely to have a signifi-
cant stenosis in the iliac and carotid arteries as
compared to patients dying from other causes.
A4.2 Cerebral artery disease
The link between PAD and cerebral artery disease
seems to be weaker than that with CAD. By duplex ex-
amination, carotid artery disease occurs in 26% to 50%
of patients with IC, but only about 5% of patients with
PAD will have a history of any cerebrovascular event.
There is also a good correlation between carotid inti-
mal thickness and the ABI. There is a range of overlap
in disease in the cerebral, coronary and peripheralcirculations reported in the literature, represented
semi-quantitatively in Fig. A7. In the REACH (Reduc-
tion of Atherothrombosis for Continued Health) sur-
vey26 of those patients identified with symptomatic
PAD, 4.7% had concomitant CAD, 1.2% had concomi-
tant cerebral artery disease and 1.6% had both. Thus
in this survey, about 65% of patients with PAD had
clinical evidence of other vascular disease. However,
in one prospective study of 1886 patients aged 62 or
over only 37% of subjects had no evidence of disease
in any of the three territories.27
A4.3 Renal
Studies have also looked at the prevalence of renal ar-
tery stenosis in patients with PAD. The prevalence of
renal artery stenosis of 50% or over ranges from 23%
to 42% (compare this to the prevalence of renal artery
stenosis in the hypertensive general population,
which is around 3%). Although it has not been studied
specifically it is very likely that renal artery stenosis
is also a partly independent risk factor for mortality
in patients with PAD since renal artery stenosis of
50% or over is associated with a 3.3-fold higher
mortality rate than in the general population.
A5 Fate of the Patient
A5.1 Asymptomatic and claudicating peripheral
arterial disease patients
The increased risk of cardiovascular events in patients
with PAD is related to the severity of the disease inFig. A7. Typical overlap in vascular disease affecting different territories.26 Based on REACH data. PAD e peripheral
arterial disease.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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nual overall major cardiovascular event rate (myocar-
dial infarction, ischemic stroke and vascular death) is
approximately 5%e7%.
Excluding those with CLI, patients with PAD have
a 2% to 3% annual incidence of non-fatal myocardial
infarction and their risk of angina is about two- to
three- times higher than that of an age-matched popu-
lation. The 5-, 10- and 15-year morbidity and mortality
rates from all causes are approximately 30%, 50% and
70%, respectively (Fig. A3). CAD is by far the most
common cause of death among patients with PAD
(40%e60%), with cerebral artery disease accounting
for 10% to 20% of deaths. Other vascular events, mostly
ruptured aortic aneurysm, cause approximately 10% of
deaths. Thus, only 20% to 30% of patients with PADdie
of non-cardiovascular causes.
Of particular interest are the studies in which the
difference in mortality rates between patients with IC
and an age-matched control population was largely
unchanged despite the adjustment for risk factors
such as smoking, hyperlipidemia and hypertension.
These surprising, but consistent, results suggest that
the presence of PAD indicates an extensive and severe
degree of systemic atherosclerosis that is responsible
for mortality, independent of the presence of risk fac-
tors. Fig. A8 summarizes the results from all studies
comparing mortality rates of claudicating patients
with those of an age-matched control population. As
expected, the two lines diverge, indicating that, on
average, the mortality rate of claudicant patients is
2.5-times higher than that of non-claudicant patients.
A5.2 Severity of peripheral arterial disease and survival
Patients with chronic CLI have a 20% mortality in the
first year after presentation, and the little long-term
Fig. A8. Survival of patients with peripheral arterial disease.
IC e intermittent claudication; CLI e critical limb ischemia.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007data that exists suggests that mortality continues at
the same rate (Fig. A8). The short-term mortality of
patients presenting with acute ischemia is 15% to
20%. Once they have survived the acute episode, their
pattern of mortality will follow that of the claudicant
or patient with chronic CLI, depending on the out-
come of the acute episode.
There is a strong correlation between ABI, as a mea-
sure of the severity of the PAD, and mortality. A
number of studies, using different ABI ‘cut-off’ points
have demonstrated this relationship. For instance, in
a study of nearly 2000 claudicants, patients with an
ABI <0.50 had twice the mortality of claudicants
with an entry ABI of >0.50.28 The Edinburgh Artery
Study10 has also shown that the ABI is a good predic-
tor of non-fatal and fatal cardiovascular events as well
as total mortality, in an unselected general population.
It has also been suggested that there is an almost lin-
ear relationship between ABI and fatal and non-fatal
cardiovascular events; each decrease in ABI of 0.10 be-
ing associated with a 10% increase in relative risk for
a major vascular event. In a study of patients with
type 2 diabetes (Fig. A9), the lower the ABI the higher
the 5-year risk of a cardiovascular event.29
SECTION B e MANAGEMENT OF CARDIO-
VASCULAR RISK FACTORS AND
CO-EXISTING DISEASE
B1 Risk Factors
B1.1 Identifying the peripheral arterial disease patient
in the population
Patients with peripheral arterial disease (PAD) have
multiple atherosclerosis risk factors and extensive
Fig. A9. Adjusted odds of a cardiovascular event by ankle-
brachial index.29 Data from the placebo arm of the Appro-
priate Blood Pressure Control in Diabetes study29 show an
inverse correlationbetweenABI andodds of amajor cardiovas-
cular event. ABI e ankle-brachial index; CV e cardiovascular;
MI e myocardial infarction. Reproduced with permission
fromMehler PS et al. Circulation 2003;107:753e756.
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increased risk for cardiovascular events, similar to
patients with established coronary artery disease
(CAD).30 A reduced blood pressure in the ankle rela-
tive to the arm pressure indicates the presence of
peripheral atherosclerosis, and is an independent
risk factor for cardiovascular events. This has been
most recently studied in a meta-analysis of 15 popula-
tion studies and showed that an ankle-brachial index
(ABI) 0.90 was strongly correlated with all-cause
mortality independent of the Framingham Risk
Score.31 Thus, current recommendations from numer-
ous consensus documents, including the recent
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines on PAD, identify
patients with PAD as a high-risk population who
require intensive risk factor modification and need
antithrombotic therapy.5 This section will discuss an
approach to identification of PAD as a means to define
a high-risk population and the management of each of
the major risk factors to reduce the incidence of
cardiovascular events.
Over two-thirds of the patientswith PADare asymp-
tomatic or have atypical leg symptoms and thus may
not be recognized as having a systemic cardiovascular
disease. Also, approximately half of the patients with
PADhavenot yet sufferedamajor cardiovascular event.
Therefore, many patients with PAD are not identified,
resulting in inadequate identification and treatment of
their atherosclerosis risk factors.11
The initial clinical assessment for PAD is a history
and physical examination. A history of intermittent
claudication is useful in raising the suspicion ofPAD, but significantly underestimates the true pre-
valence of PAD. In contrast, palpable pedal pulses
on examination have a negative predictive value of
over 90% that may rule out the diagnosis in many
cases. In contrast, a pulse abnormality (absent or di-
minished) significantly overestimates the true preva-
lence of PAD. Thus, objective testing is warranted in
all patients suspected of having PAD. The primary
non-invasive screening test for PAD is the ABI (see
section C2 for further discussion of the ABI and ABI
screening criteria). In the context of identifying a
high-risk population, persons who should be consid-
ered for ABI screening in the primary care or commu-
nity setting include: (1) subjects with exertional leg
symptoms, (2) subjects aged 50e69 years who also
have cardiovascular risk factors and all patients over
the age of 70 years,11 and (3) subjects with a 10-year
risk of a cardiovascular event between 10% and 20%
in whom further risk stratification is warranted. Car-
diovascular risk calculators are readily available in
the public domain, such as the SCORE for use in
Europe (www.escardio.org) and the Framingham for
the US (www.nhlbi.nih.gov/guidelines/cholesterol).
Patients with PAD, defined as an ABI 0.90, are
known to be at high risk for cardiovascular events
(Fig. B1). As discussed in section A, mortality rates
in patients with PAD average 2% per year and the
rates of non-fatal myocardial infarction, stroke and
vascular death are 5% to 7% per year.32,33 In addition,
the lower the ABI, the higher the risk of cardiovascu-
lar events, as shown in Fig. B2.34 A similar increased
mortality risk has also been observed in patients
with an increased ABI as shown in Fig. B2. Therefore,Fig. B1. Algorithm for use of the ABI in the assessment of systemic risk in the population. Primary prevention: No antipla-
telet therapy; LDL (low density lipoprotein) <3.37 mmol/L (<130 mg/dL) except in patients with diabetes where the LDL
goal is <2.59 mmol/L (<100 mg/dL) even in the absence of CVD (cardiovascular disease); appropriate blood pressure
(<140/90 mmHg and <130/80 mmHg in diabetes/renal insufficiency). Secondary prevention: Prescribe antiplatelet
therapy; LDL <2.59 mmol/L (<100 mg/dL) (<1.81 mmol/L [<70 mg/dL] in high risk); appropriate blood pressure
(<140/90 mmHg and <130/80 mmHg in diabetes/renal insufficiency). See section B1.2 and surrounding text for references.
In patients with diabetes, HbA1c <7.0%. See text for references. ABI e ankle-brachial index; PAD e peripheral arterial
disease; CLI e critical limb ischemia.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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ABI e ankle-brachial index. Reproduced with permission from Resnick HE et al. Circulation 2004;109(6):733e739.an abnormal ABI identifies a high-risk population that
needs aggressive risk factor modification and anti-
platelet therapy.
B1.2 Modification of atherosclerotic risk factors
As highlighted above, patients with PAD typically
have multiple cardiovascular risk factors, which puts
them at markedly increased risk for cardiovascular
events. This section will discuss an approach to each
of the major risk factors of this disorder.
B1.2.1 Smoking cessation
Smoking is associated with a marked increased risk
for peripheral atherosclerosis. The number of pack
years is associated with disease severity, an increased
risk of amputation, peripheral graft occlusion and
mortality. Given these associations, smoking cessation
has been a cornerstone of the management of PAD
as is the case for CAD.35 Other drugs for smoking
cessation are becoming available.
In middle-aged smokers with reduced pulmonary
function, physician advice to stop smoking, coupled
with a formal cessation program and nicotineEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007replacement is associated with a 22% cessation rate
at 5 years compared with only a 5% cessation rate in
the usual care group.36 By 14 years, the intervention
group had a significant survival advantage. A number
of randomized studies have supported the use of bu-
propion in patients with cardiovascular disease, with
3-, 6- and 12-month abstinence rates of 34%, 27% and
22%, respectively, compared with 15%, 11% and 9%,
respectively, with placebo treatment.37 Combining bu-
propion and nicotine replacement therapy has been
shown to be more effective than either therapy alone
(Fig. B3).38 Thus, a practical approach would be to
encourage physician advice at every patient visit,
combined with behavior modification, nicotine re-
placement therapy and the antidepressant bupropion
to achieve the best cessation rates.
The roleof smokingcessation in treating thesymptoms
of claudication is not as clear; studies have shown
that smoking cessation is associated with improved
walking distance in some, but not all patients. There-
fore, patients should be encouraged to stop smoking
primarily to reduce their risk of cardiovascular events,
as well as their risk of progression to amputation and
progression of disease, but should not be promised im-
proved symptoms immediately upon cessation. RecentFig. B3. Percent abstinence for bupropion SR, nicotine replacement, or both, versus placebo.38 Reproduced with permission
from Jorenby DE et al. N Engl J Med 1999;340(9):685e691.
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failure after bypass surgery with continued smoking
with a reduction in that risk to that of non-smokers
with smoking cessation.39
B1.2.2 Weight reduction
Patients who are overweight (body mass index [BMI]
25e30) or who are obese (BMI>30) should receive
counseling for weight reduction by inducing negative
caloric balance with reduction of calorie intake,
carbohydrate restriction and increased exercise.
B1.2.3 Hyperlipidemia
Independent risk factors for PAD include elevated
levels of total cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides, and lipoprotein(a).
Factors that are protective for the development of
PAD are elevated high-density lipoprotein (HDL)
cholesterol and apolipoprotein (a-1) levels.
Direct evidence supporting the use of statins to
lower LDL cholesterol levels in PAD comes from the
Heart Protection Study (HPS).33 The HPS enrolled
over 20,500 subjects at high risk for cardiovascular
events including 6748 patients with PAD, many of
whom had no prior history of heart disease or stroke.
Patients were randomized to simvastatin 40 mg, anti-
oxidant vitamins, a combination of treatments, or
placebo using a 2 2 factorial design, with a 5-year
follow up. Simvastatin 40 mg was associated with
a 12% reduction in total mortality, 17% reduction in
vascular mortality, 24% reduction in coronary heart
disease events, 27% reduction in all strokes and
a 16% reduction in non-coronary revascularizations.
Similar results were obtained in the PAD subgroup,
whether they had evidence of coronary disease at
baseline or not. Furthermore, there was no threshold
cholesterol value below which statin therapy was
not associated with benefit. Thus, the HPS demon-
strated that in patients with PAD (even in the absence
of a prior myocardial infarction or stroke), aggressive
LDL lowering was associated with a marked
Recommendation 1. Smoking cessation in peri-
pheral arterial disease
 All patients who smoke should be strongly and
repeatedly advised to stop smoking [B].
 All patients who smoke should receive a pro-
gram of physician advice, group counseling
sessions, and nicotine replacement [A].
 Cessation rates can be enhanced by the addition
of antidepressant drug therapy (bupropion)
and nicotine replacement [A].reduction in cardiovascular events (myocardial infarc-
tion, stroke and vascular death). A limitation of the
HPS was that the evidence in PAD was derived
from a subgroup analysis in patients with symptom-
atic PAD. Despite these limitations, all patients with
PAD should have their LDL cholesterol levels lowered
to <2.59 mmol/L (<100 mg/dL). To achieve these
lipid levels, diet modification should be the initial
approach, however, in most cases, diet alone will be
unable to decrease the lipids levels to the values men-
tioned above; therefore, pharmacological treatment
will be necessary.
A more recent meta-analysis of statin therapy
concluded that in a broad spectrum of patients,
a 1 mmol/L (38.6 mg/dL) reduction in LDL choles-
terol level was associated with a 20% decrease in the
risk of major cardiovascular events.40 This benefit
was not dependent on the initial lipid levels (even pa-
tients with lipids in the ‘‘normal’’ range responded),
but did depend on the baseline assessment of cardio-
vascular risk. Since patients with PAD are at high risk,
and were included as a subgroup in this meta analy-
sis, the majority of these patients would be considered
candidates for statin therapy.
Current recommendations for the management of
lipid disorders in PAD are to achieve an LDL choles-
terol level of<2.59 mmol/L (<100 mg/dL) and to treat
the increased triglyceride and low HDL pattern.41,42
The recent ACC/AHA guidelines recommend as a
general treatment goal achieving an LDL cholesterol
level <2.59 mmol/L (<100 mg/dL) in all patients with
PAD and in those at high risk (defined as patients with
vascular disease in multiple beds) the goal should be
an LDL cholesterol level <1.81 mmol/L (<70 mg/dL).5
In patients with PAD who have elevated triglyceride
levels where the LDL cholesterol cannot be accurately
calculated, the recommendation is to achieve a non-
HDL-cholesterol level <3.36 mmol/L (<130 mg/dL),43
and in the highest risk patients (with vascular disease
inmultiple beds) the non-HDL-cholesterol goal should
be <2.56 mmol/L (<100 mg/dL).
Patients with PAD commonly have disorders of
HDL cholesterol and triglyceride metabolism. The
use of fibrates in patients with coronary artery disease
who had an HDL cholesterol level <1.04 mmol/L
(<40 mg/dL) and an LDL cholesterol level
<3.63 mmol/L (>140 mg/dL) was associated with a
reduction in the risk of non-fatal myocardial infarction
and cardiovascular death.44 Niacin is a potent drug
used to increase HDL cholesterol levels, with the
extended-release formulation providing the lowest
risk of flushing and liver toxicity. In patients with
PAD, niacin has been associated with regression of
femoral atherosclerosis and reduced progression ofEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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niacin will reduce the progression of peripheral ather-
osclerosis or reduce the risk of systemic cardiovascular
events in patients with PAD is not yet known.
B1.2.4 Hypertension
Hypertension is associated with a two- to three-fold
increased risk for PAD. Hypertension guidelines
support the aggressive treatment of blood pressure
in patients with atherosclerosis, indicating PAD. In
this high-risk group the current recommendation is
a goal of <140/90 mmHg, and <130/80 mmHg if
the patient also has diabetes or renal insufficiency.47,48
Regarding drug choice, all drugs that lower blood
pressure are effective at reducing the risk of cardiovas-
cular events. Thiazide diuretics are first-line agents,
angiotensin converting enzyme (ACE) inhibitors or an-
giotensin receptor blockers should be used in patients
with diabetic renal disease or in congestive heart
failure, and calcium channel blockers for difficult to
Recommendation 2. Lipid control in patients
with peripheral arterial disease (PAD)
 All symptomatic PAD patients should have
their low-density lipoprotein (LDL)-cholesterol
lowered to <2.59 mmol/L (<100 mg/dL) [A].
 In patients with PAD and a history of vascular
disease in other beds (e.g. coronary artery dis-
ease) it is reasonable to lower LDL cholesterol
levels to <1.81 mmol/L (<70 mg/dL) [B].
 All asymptomatic patients with PAD and no
other clinical evidence of cardiovascular disease
should also have their LDL-cholesterol level
lowered to <2.59 mmol/L (<100 mg/dL) [C].
 In patients with elevated triglyceride levels
where the LDL cannot be accurately calculated,
the LDL level should be directly measured and
treated to values listed above. Alternatively, the
non-HDL (high-density lipoprotein) cholesterol
level can be calculated with a goal of <3.36
mmol/L (<130 mg/dL), and in high-risk patients
the level shouldbe<2.59 mmol/L (<100 mg/dL).
 Dietary modification should be the initial inter-
vention to control abnormal lipid levels [B].
 In symptomatic PAD patients, statins should be
theprimaryagents to lowerLDLcholesterol levels
to reduce the risk of cardiovascular events [A].
 Fibrates and/or niacin to raise HDL-cholesterol
levels and lower triglyceride levels should be
considered in patients with PAD who have
abnormalities of those lipid fractions [B].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007control hypertension. Most patients will require multi-
ple agents to achieve desired blood pressure goals. The
ACE inhibitor drugs have also shown benefit in PAD,
possibly beyond blood-pressure lowering in high-risk
groups. This was documented by specific results from
the HOPE (Heart Outcomes Prevention Evaluation)
study in 4046 patients with PAD.49 In this subgroup,
there was a 22% risk reduction in patients randomized
to ramipril compared with placebo, which was inde-
pendent of lowering of blood pressure. Based on this
finding, theUnited States FederalDrugAdministration
hasnowapproved ramipril for its cardioprotective ben-
efits in patients at high risk, including those with PAD.
Thus, in termsof adrug class, theACE inhibitorswould
be recommended in patients with PAD.
Beta-adrenergic blocking drugs have previously
been discouraged in PAD because of the possibility
of worsening claudication symptoms. However, this
concern has not been borne out by randomized
trials; therefore, beta-adrenergic-blocking drugs can
be safely utilized in patients with claudication.50 In
particular, patients with PAD who also have concomi-
tant coronary disease may have additional cardio-
protection with beta-adrenergic-blocking agents.
Therefore, beta-adrenergic-blocking agents may be
considered when treating hypertension in patients
with PAD.
B1.2.5 Diabetes [see also section D2.4]
Diabetes increases the risk of PAD approximately
three- to four-fold, and the risk of claudication two-
fold. Most patients with diabetes have other cardio-
vascular risk factors (smoking, hypertension and
Recommendation 3. Control of hypertension in
peripheral arterial disease (PAD) patients
 All patients with hypertension should have
blood pressure controlled to <140/90 mmHg
or <130/80 mmHg if they also have diabetes
or renal insufficiency [A].
 JNC VII and European guidelines for the
management of hypertension in PAD should
be followed [A].
 Thiazides and ACE inhibitors should be consid-
ered as initial blood-pressure lowering drugs
in PAD to reduce the risk of cardiovascular
events [B].
 Beta-adrenergic-blocking drugs are not contra-
indicated in PAD [A].
S19TASC II Inter-Society Consensus on Peripheral Arterial Diseasedyslipidemia) that contribute to the development
of PAD. Diabetes is also associated with peripheral
neuropathy and decreased resistance to infection,
which leads to an increased risk of foot ulcers and
foot infections.
Several studies of both type 1 and type 2 diabetes
have shown that aggressive blood-glucose lowering
can prevent microvascular complications (particu-
larly retinopathy and nephropathy); this has not
been demonstrated for PAD, primarily because the
studies conducted to date examining glycemic con-
trol in diabetes were neither designed nor powered
to examine PAD endpoints.51,52 The current American
Diabetes Association guidance recommends hemo-
globin A1C of <7.0% as the goal for treatment of di-
abetes ‘‘in general’’, but points out that for ‘‘the
individual patient,’’ the A1C should be ‘‘as close to
normal (<6%) as possible without significant hypo-
glycemia.’’ However, it is unclear whether achieving
this goal will effectively protect the peripheral circu-
lation or prevent amputation.53 A single study in
patients with type 2 diabetes and a history of cardio-
vascular disease did not show a benefit of lowering
blood glucose levels with the insulin-sensitizing
agent pioglitazone on the primary endpoint of the
study (cardiovascular morbidity and mortality) but
did show a reduction in the risk of a secondary end-
point of myocardial infarction, stroke and vascular
death.51,54 Additional studies will be necessary to
define the role of insulin sensitizing agents in the
management of cardiovascular complication of diabetes
in patients with PAD.
B1.2.6 Homocysteine
An elevated plasma homocysteine level is an indepen-
dent risk factor for PAD. While supplement with
B-vitamins and/or folate can lower homocysteine
levels, high-level evidence for the benefits in terms
of preventing cardiovascular events is lacking. Two
studies of supplemental B vitamins and folic acid in
patients with CAD demonstrated no benefit and
Recommendation 4. Control of diabetes in
peripheral arterial disease (PAD)
 Patients with diabetes and PAD should have
aggressive control of blood glucose levels
with a hemoglobin A1c goal of <7.0% or as
close to 6% as possible [C].even a suggestion of harm, so this therapy cannot
be recommended.55,56
B1.2.7 Inflammation
Markers of inflammation have been associated with
the development of atherosclerosis and cardiovascu-
lar events. In particular, C-reactive protein is indepen-
dently associated with PAD.
B1.2.8 Antiplatelet drug therapy
Aspirin/acetylsalicylic acid (ASA) is a well-recog-
nized antiplatelet drug for secondary prevention
that has clear benefits in patients with cardiovascu-
lar diseases. Numerous publications from the An-
tithrombotic Trialists’ Collaboration have concluded
that patients with cardiovascular disease will realize
a 25% odds reduction in subsequent cardiovascular
events with the use of aspirin/ASA.57 These find-
ings particularly apply to patients with coronary ar-
tery and cerebral artery diseases. This most recent
meta-analysis has also clearly demonstrated that
low-dose aspirin/ASA (75e160 mg) is protective,
and probably safer in terms of gastrointestinal
bleeding than higher doses of aspirin/ASA. Thus,
current recommendations would strongly favor the
use of low-dose aspirin/ASA in patients with car-
diovascular diseases. However, the initial Antith-
rombotic Trialists’ Collaboration meta-analysis did
not find a statistically significant reduction in car-
diovascular events in PAD patients treated with as-
pirin/ASA who did not have other evidence of
vascular disease in other territories.58 However, in
the more recent meta-analysis, when the PAD data
were combined from trials using not only aspirin/
ASA but also clopidogrel, ticlopidine, dipyridamole
and picotamide, there was a significant 23% odds
reduction in ischemic events in all subgroups of pa-
tients with PAD. Antiplatelet drugs are clearly indi-
cated in the overall management of PAD, although
the efficacy of aspirin/ASA is uniformly shown only
when PAD and cardiovascular disease coexist.59
Recommendation 5. Use of folate supplementa-
tion in peripheral arterial disease (PAD)
 Patients with PAD and other evidence of car-
diovascular disease should not be given folate
supplements to reduce their risk of cardiovas-
cular events [B].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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platelet thromboxane A2 synthase and antagonizes
thromboxane receptors that has a mortality benefit
in the subgroup of patients with PAD who also
have diabetes.60 In that study, the drug signifi-
cantly reduced 2-year, all-cause mortality, but not
the incidence of non-fatal cardiovascular events.
Based on these data, further study is warranted
before a recommendation can be made in regards
to picotamide.
In addition to aspirin/ASA, the thienopyridines
are a class of antiplatelet agents that have been stud-
ied in patients with cardiovascular disease. Ticlopi-
dine has been evaluated in several trials in patients
with PAD, and has been reported to reduce the risk
of myocardial infarction, stroke and vascular death.61
However, the clinical usefulness of ticlopidine is lim-
ited by side effects such as neutropenia and thrombo-
cytopenia. Clopidogrel was studied in the CAPRIE
(Clopidogrel versus Aspirin in Patients at Risk of
Ischemic Events) trial and shown to be effective
in the symptomatic PAD population to reduce the
risk of myocardial infarction, stroke and vascular
death. The overall benefit in this particular group
was a 24% relative risk reduction over the use of
aspirin/ASA.32 This represents a number needed to
treat with clopidogrel compared with aspirin/ASA
of 87 patients to prevent an event. Clopidogrel
has a safety profile similar to aspirin/ASA, with
only rare reports of thrombocytopenia. Patients
undergoing surgical procedures are at increased
risk of bleeding when taking anti-thrombotics includ-
ing heparins, aspirin/ASA or clopidogrel. Thus,
temporary cessation of these drugs should be indi-
vidualized based on the type of surgery and/or
endovascular intervention/revascularization to reduce
bleeding risks.
Recent publications in patients with acute coro-
nary syndromes suggest that combination therapy
with aspirin/ASA and clopidogrel is more effective
than with aspirin/ASA alone, but at a higher risk
of major bleeding.62 A recent study of clopidogrel
combined with aspirin/ASA (versus aspirin/ASA
alone) was performed in a high-risk population con-
sisting of patients with established cardiovascular
disease (including PAD) and patients without a his-
tory of cardiovascular disease but who had multiple
risk factors. This study showed no overall benefit of
the combination of antiplatelet drugs as compared
with aspirin/ASA alone on the outcome of myo-
cardial infarction, stroke and vascular death.63
Thus, combination therapy cannot be recommended
in patients with stable PAD, and if clopidogrel is
considered it should be used as monotherapy.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007B2 Health Economics of Risk-factor Management
For all cardiovascular risk factors, including smoking
cessation, the most effective and cost-effective inter-
ventions are those that combine a government-led
action with individual prevention interventions. In
other words, laws that reduce the amount of added
salt in processed foods and that increase taxes on to-
baccoaremore cost effective than individualprevention
alone, but a combination of both is best.64
The issue in dealing with risk factors is the overall
budgetary impact of enforcing compliance to pub-
lished guidelines. This is due to the large size of the
population at risk and the difficulty of organizing
the follow up of chronic patients treated by numerous
health professionals. An additional difficulty for
payers is that the health and economic benefits are
delayed while resources for treatment have to be
expended at once. Studies on dyslipidemia, diabetes
and hypertension have shown that compliance with
guidelines is usually cost effective, within the range
of $20e30,000 per added year of life. This holds true
when several risk factors are associated.65,66
The effectiveness and cost-effectiveness of a num-
ber of lifestyle interventions, including smoking ces-
sation, exercise and diet, have been assessed by the
Cochrane Collaboration.
B2.1 Cost-effectiveness of smoking cessation interventions
For smoking cessation, the performance of professionals
in detection and interventions (including follow-up
Recommendation 6. Antiplatelet therapy in
peripheral arterial disease (PAD)
 All symptomatic patients with or without
a history of other cardiovascular disease should
be prescribed an antiplatelet drug long term to
reduce the risk of cardiovascular morbidity and
mortality [A].
 Aspirin/ASA is effective in patients with PAD
who also have clinical evidence of other forms
of cardiovascular disease (coronary or carotid)
[A].
 The use of aspirin/ASA in patients with PAD
whodo not have clinical evidence of other forms
of cardiovascular disease can be considered [C].
 Clopidogrel is effective in reducing cardiovas-
cular events in a subgroup of patients with
symptomatic PAD, with or without other clini-
cal evidence of cardiovascular disease [B].
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is improved by training, although the overall effect
on quit rates is modest. However, ‘‘training can be
expensive, and simply providing programs for health
care professionals, without addressing the constraints
imposed by the conditions in which they practice, is
unlikely to be a wise use of health care resources’’.67
Advising patients to use the telephone services is an
effective strategy.67
The unit cost of advice alone is estimated $5 per
patient, while counseling costs $51 per patient. Adding
pharmacologic agents to counseling increases the quit
rate and is cost effective: assuming that a long-term
quitter increases his life expectancy by an average
2 years, the cost-effectiveness ratio of added pharmaco-
logical intervention ranges from $1 to $3,000 per
life-year gained.68
B2.2 Cost-effectiveness of exercise interventions
Exercise interventions are heterogenic, including
one-to-one counseling/advice or group counseling/
advice; self-directed or prescribed physical activity;
supervised or unsupervised physical activity; home-
based or facility-based physical activity; ongoing
face-to-face support; telephone support; written
education/motivation material; and self monitoring.
The intervention can be delivered by one or a number
of practitioners including physicians, nurses, health
educators, counselors, exercise leaders, and peers.
Interventions ‘‘have a positive moderate sized effect
on increasing self-reported physical activity and
measured cardio-respiratoryfitness, at least in the short
to mid-term’’.69 Assuming an adherence of 50% in
the first year and 30% in subsequent years, the cost-
effectiveness ratio of unsupervised exercise is less
than $12,000 per life year gained. Supervised exercise
has a cost-effectiveness ratio ranging from $20,000e
$40,000 per life year gained (the strategies are more
efficient in elderly males with multiple risk factors).70
B2.3 Cost-effectiveness of pharmacologic interventions
It is difficult to recommend one drug over another
for risk factor modification on cost-effectiveness con-
siderations because drug prices are subject to varia-
tions between countries and over time. Although this
is true for all interventions, the case of a newer drug
used in prevention of cardiac risk factors is particular
in that the medical benefits of one treatment over
another are usually small and, therefore, the cost-
effectiveness ratio is highly dependent on drug prices.
The global cost-effectiveness analysis on the reductionof cardiovascular disease risk63 found that treatment
by a combination of statin, beta blocker, diuretic and
aspirin was most efficient in avoiding death and dis-
ability. When oral anti-platelet agents are considered,
assuming a threshold of up to £20,000e40,000 per ad-
ditional quality-adjusted life year (QALY), clopidogrel
would be considered cost effective for treatment dura-
tion of 2 years in patients with peripheral arterial
disease. For a lifetime treatment duration, clopidogrel
would be considered more cost effective than aspirin
as long as treatment effects on non-vascular deaths
are not considered.71
Because recent studies have often failed to demon-
strate a benefit onmortality, the efficiency of drug treat-
ments has been measured in ‘cost per major event
averted’ and is, therefore, not comparable to ‘cost per
life year gained’, although there is a relationship
between the two. For example, the cost effectiveness
of 40 mg/day simvastatin in high-risk patients is
£4,500 (95% CI: 2,300e7,400) per major vascular event
averted, but the result is highly sensitive to the statin
cost. In this context, it is likely that the use of an off-
patent statin would provemore efficient.72 For patients
with high cardiovascular risk, the use ofACE inhibitors
appears very cost effective in most countries, as shown
by the results of the HOPE study: less than $10,000 per
event averted in the various developed countries
where the economic analyses were undertaken.73
In conclusion, the risk-management strategy chosen
may differ depending on whether the individual or
populationperspectivesareconsidered. Inapopulation
perspective with an objective of sustainability and
access, public interventions to reduce smoking, salt
and fat intake, combinedwith the prescription of cheap
and off-patent drugs, are preferred. If the individual
perspective is considered, however, newer and more
expensive drugs offer additional health benefits at
reasonable cost-effectiveness ratios.
B3 Future Aspects of Controlling Ischemic
Risk Factors
It is clear that decreasing the level of any risk factor,
such as blood pressure and LDL cholesterol, can
help improve prognosis. However, it is not clear
what the optimal values are in the general popula-
tion and in individual disease states. Future studies
are also needed to define guidelines for different
clinical presentations: should blood pressure be
lowered to 140/90 mmHg in patients with PAD, or
should it be lower? Should these values also
be usable in critical leg ischemia? Is there a
J-shaped curve (an increased risk at very low blood
pressure values)?Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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beneficial as changing only one. Combination therapy
with several drugs will become inevitable. However,
what is the compliance of the patients who are faced
with such combination therapy? Future studies
should clarify whether the ‘polypill’ (several drugs
in one pill) could help in achieving the goals of im-
proved risk factor modification. Calculations should
be made on the costs of such combination therapy
versus the change in long-term prognosis.
Diabetes sharply increases total cardiovascular
risk; are the current goals for blood pressure and
lipids strict enough to control this risk? Studies are
needed to show whether the choice of antihyperten-
sive drugs should be guided by their influence on
insulin resistance or other metabolic parameters.
It is becoming evident that inflammatory processes
play an important role in the atherosclerotic process.
It is not yet clear if drugs that target chronic inflam-
mation (e.g. antibiotics) would add to usual risk factor
management in controlling the progress of the ather-
osclerotic process.
B4 Co-existing Coronary Artery Disease
The prevalence of CAD in patients with PAD is high,
which strongly increases the risk for cardiac mortality
and morbidity in these patients (see section A4.1).4,26
Therefore, all PAD patients should be considered at
high risk for clinically significant CAD, for which sev-
eral guidelines exist.74,75 Patients should be evaluated
for evidence of CAD.
Treatment decisions for coexisting CAD should
be based on current practice standards, and patients
who have unstable symptoms (acute coronary
syndrome, decompensated heart failure) should be
referred to a cardiovascular physician for appropri-
ate diagnosis and treatment. For patients with stable
CAD, management should be guided by the sever-
ity of the symptoms and co-morbid conditions.
Most patients with severe cardiac symptoms will
require coronary angiography to determine the
appropriate means for revascularization. All patients
should be given appropriate medical therapy to
treat symptoms and atherosclerotic risk factors (see
section B1).
Cardiac assessment scores may be useful in the
context of patients being considered for peripheral
revascularization.76 In patients with a high cardiac
risk assessment score, current guidelines recommend
further evaluation of the patient for possible coronary
revascularization.76 However in the recent CoronaryEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007Artery Revascularization Prophylaxis (CARP) trial of
patients with peripheral vascular disease who were
considered high risk for perioperative complications
and had significant CAD, coronary revascularization
did not reduce overall mortality or perioperative
myocardial infarction.77 In addition, patients who un-
derwent coronary revascularization had a significantly
longer time to vascular surgery compared with
patients who did not. Therefore, this strategy of
a pre-emptive coronary revascularization prior to
peripheral vascular surgery should not normally
be pursued.
In most patients, perioperative use of beta-
adrenergic-blocking agents is associated with
reduced cardiovascular risks of surgery. Recent stud-
ies have shown that beta-adrenergic blockade with
bisoprolol significantly decreased the risk for cardio-
vascular events during vascular surgery and
afterwards.78,79 Besides controlling symptoms of
myocardial ischemia, treatment with beta-blocking
agents also has the benefit of favorably influencing
prognosis in these patients.80
Recommendation 7. Management of coronary
artery disease (CAD) in peripheral arterial disease
patients
 Patients with clinical evidence of CAD (angina,
ischemic congestive heart failure) should be
evaluated and managed according to current
guidelines [C].
 Patients with PAD considered for vascular sur-
gery may undergo further risk stratification
and those found to be at very high risk man-
aged according to current guidelines for coro-
nary revascularization [C].
 Routine coronary revascularization in prepara-
tion for vascular surgery is not recommended
[A].
Recommendation 8. Use of beta-blocking agents
before vascular surgery
 When there are no contraindications, beta-
adrenergic blockers should be given periopera-
tively to patients with peripheral arterial
disease undergoing vascular surgery in order
to decrease cardiacmorbidity andmortality [A].
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The prevalence of carotid artery disease in PAD
patients is also high (see section A4.2); and patients
with PAD are at an increased risk for cerebrovascular
events. Evaluation of the carotid circulation should
be based on a history of transient ischemic attack or
stroke. Further evaluation and consideration for revas-
cularization should be based on current guidelines.81,82
B6 Co-existing Renal Artery Disease
Patients with PAD are at an increased risk for reno-
vascular hypertension. The management of patients
with PAD and atherosclerotic renal artery disease is
focused on control of hypertension and preservation
of renal function. In such cases, evaluation and treat-
ment should be based on current guidelines.5,83,84
These patients should be referred to an appropriate
cardiovascular physician.
SECTION C e INTERMITTENT CLAUDICATION
C1 Characterization of Patients
C1.1 Definition of intermittent claudication and limb
symptoms in peripheral arterial disease
The majority of patients with peripheral arterial dis-
ease (PAD) have limited exercise performance and
walking ability. As a consequence, PAD is associated
Recommendation 9. Management of carotid ar-
tery disease in peripheral arterial disease (PAD)
patients
 The management of symptomatic carotid ar-
tery disease in patients with PAD should be
based on current guidelines [C].
Recommendation 10. Management of renal ar-
tery disease in peripheral arterial disease (PAD)
patients
 When renal artery disease is suspected in PAD
patients, as evidenced by poorly controlled
hypertension or renal insufficiency, patients
should be treated according to current guide-
lines and consider referral to a cardiovascular
physician [C].with reduced physical functioning and quality of life.
In patients with PAD, the classical symptom is inter-
mittent claudication (which means to limp), which is
muscle discomfort in the lower limb reproducibly
produced by exercise and relieved by rest within
10 minutes. Patients may describe muscle fatigue, ach-
ing or cramping on exertion that is relieved by rest. The
symptoms aremost commonly localized to the calf, but
may also affect the thigh or buttocks. Typical claudica-
tion occurs in up to one-third of all patients with PAD.
Importantly, patients without classical claudication
also have walking limitations that may be associated
with atypical or no limb symptoms.85 Typical claudica-
tion symptoms may not occur in patients who have co-
morbidities that prevent sufficient activity to produce
limb symptoms (i.e. congestive heart failure, severe
pulmonary disease, musculoskeletal disease) or in
patients who are so deconditioned that exercise is not
performed. Therefore, patients suspected of having
PAD should be questioned about any limitations they
experience during exercise of the lower extremities
that limits their walking ability.
PAD is caused by atherosclerosis that leads to
arterial stenosis and occlusions in the major vessels
supplying the lower extremities. Patients with inter-
mittent claudication have normal blood flow at rest
(and, therefore, have no limb symptoms at rest).
With exercise, occlusive lesions in the arterial supply
of the leg muscles limits the increase in blood flow,
resulting in a mismatch between oxygen supply and
muscle metabolic demand that is associated with
the symptom of claudication. Acquired metabolic
abnormalities in the muscle of the lower extremity
also contribute to the reduced exercise performance
in PAD.
C1.2 Differential diagnosis
Table C1 shows the differential diagnosis of intermit-
tent claudication (IC); Table C2 shows potential causes
of occlusive arterial lesions in the lower extremity
arteries potentially causing claudication.
C1.3 Physical examination
The physical examination should assess the circula-
tory system as a whole. Key components of the general
examination include measurement of blood pressure
in both arms, assessment of cardiac murmurs, gallops
or arrhythmias, and palpation for an abdominal aortic
aneurysm (does not exclude the presence of an an-
eurysm). Less specific aspects of the physical examina-
tion for PAD include changes in color and temperatureEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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Condition Location Prevalence Characteristic Effect of
exercise
Effect of
rest
Effect of
position
Other
characteristics
Calf IC Calf muscles 3e5% of
adult
population
Cramping,
aching
discomfort
Reproducible
onset
Quickly
relieved
None May have atypical
limb symptoms on
exercise
Thigh and
buttock IC
Buttocks, hip,
thigh
Rare Cramping,
aching discomfort
Reproducible
onset
Quickly
relieved
None Impotence
May have normal
pedal pulses with
isolated iliac artery
disease
Foot IC Foot arch Rare Severe pain on
exercise
Reproducible
onset
Quickly
relieved
None Also may present
as numbness
Chronic
compartment
syndrome
Calf muscles Rare Tight, bursting
pain
After much
exercise
(jogging)
Subsides
very slowly
Relief with
elevation
Typically heavy
muscled athletes
Venous
claudication
Entire leg,
worse in calf
Rare Tight, bursting
pain
After walking Subsides
slowly
Relief speeded
by elevation
History of
iliofemoral deep
vein thrombosis,
signs of venous
congestion, edema
Nerve root
compression
Radiates
down leg
Common Sharp lancinating
pain
Induced by
sitting, standing
or walking
Often present
at rest
Improved by
change in
position
History of back
problems
Worse with sitting
Relief when supine
or sitting
Symptomatic
Bakers cyst
Behind knee,
down calf
Rare Swelling,
tenderness
With exercise Present
at rest
None Not intermittent
Hip arthritis Lateral hip,
thigh,
Common Aching discomfort After variable
degree of
exercise
Not quickly
relieved
Improved
when not
weight bearing
Symptoms variable
History of
degenerative
arthritis
Spinal
stenosis
Often bilateral
buttocks,
posterior leg
Common Pain and weakness May mimic IC Variable relief
but can take a
long time to
recover
Relief by
lumbar spine
flexion
Worse with
standing and
extending spine
Foot/ankle
arthritis
Ankle, foot,
arch
Common Aching pain After variable
degree of
exercise
Not quickly
relieved
May be relieved
by not bearing
weight
Variable, may relate
to activity level and
present at rest
IC e intermittent claudication.of the skin of the feet, muscle atrophy from inability
to exercise, decreased hair growth and hypertrophied,
slow-growing nails. The presence of a bruit in the
region of the carotid, aorta or femoral arteries may
arise from turbulence and suggest significant arterial
Table C2. Causes of occlusive arterial lesions in lower extremity
arteries potentially causing claudication
Atherosclerosis (PAD)
Arteritis
Congenital and acquired coarctation of aorta
Endofibrosis of the external iliac artery (iliac artery syndrome in
cyclists)
Fibromuscular dysplasia
Peripheral emboli
Popliteal aneurysm (with secondary thromboembolism)
Adventitial cyst of the popliteal artery
Popliteal entrapment
Primary vascular tumors
Pseudoxanthoma elasticum
Remote trauma or irradiation injury
Takayasu’s disease
Thromboangiitis obliterans (Buerger’s disease)
Thrombosis of a persistent sciatic arteryEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007disease. However, the absence of a bruit does not
exclude arterial disease.
The specific peripheral vascular examination re-
quires palpation of the radial, ulnar, brachial, carotid,
femoral, popliteal, dorsalis pedis and posterior tibial
artery pulses. The posterior tibial artery is palpated
at the medial malleolus. In a small number of
healthy adults, the dorsalis pedis pulse on the dor-
sum of the foot may be absent due to branching of
the anterior tibial artery at the level of the ankle. In
this situation, the distal aspect of the anterior tibial
artery may be detected and assessed at the ankle.
Also, a terminal branch of the peroneal artery may
be palpated at the lateral malleolus. For simplicity,
pulses may be graded from 0 (absent), 1 (dimin-
ished) and 2 (normal). An especially prominent pulse
at the femoral and/or popliteal location should raise
the suspicion of an aneurysm. A diminished or
absent femoral pulse suggests aorto-iliac artery
occlusive disease, which reduces inflow to the limb.
In contrast, a normal femoral, but absent pedal,
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Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007pulse suggests significant arterial disease in the leg
with preserved inflow. Pulses should be assessed in
both legs and pulse abnormalities correlated with
leg symptoms to determine the lateralization of
the disease.
Patients with an isolated occlusion of an internal
iliac (hypogastric) artery may have normal femoral
and pedal pulses at rest and after exercise, but buttocks
claudication (and impotence in males). Similar symp-
toms may occur in patients with stenosis of the com-
mon or external iliac artery. These patients may also
have normal pulses at rest, but loss of the pedal pulses
after exercise. The loss of the pedal pulse is coincident
with a drop in ankle pressure due to the inability of the
large vessels (in the presence of occlusive disease) to
provide sufficient flow to maintain distal pressure
with muscle vasodilation during exercise.
Despite the utility of the pulse examination, the
finding of absent pedal pulses tends to over-diagnose
PAD, whereas if the symptom of classic claudication
is used to identify PAD, it will lead to a significant
under-diagnosis of PAD.86 Thus, PAD must be con-
firmed in suspected patients with non-invasive testing
using the ankle-brachial index, or other hemodynamic
or imaging studies described below.
C2 Diagnostic Evaluation of Patients with
Peripheral Arterial Disease
C2.1 Ankle pressure measurements
(ankle-brachial index)
Measuring the pressure in the ankle arteries has be-
come a standard part of the initial evaluation of
patients with suspected PAD. A common method of
Recommendation 11. History and physical
examination in suspected peripheral arterial
disease (PAD)
 Individuals with risk factors for PAD, limb
symptoms on exertion or reduced limb func-
tion should undergo a vascular history to eval-
uate for symptoms of claudication or other
limb symptoms that limit walking ability [B].
 Patients at risk for PAD or patients with re-
duced limb function should also have a vascular
examination evaluating peripheral pulses [B].
 Patients with a history or examination sugges-
tive of PAD should proceed to objective testing
including an ankle-brachial index [B].measurement uses a 10e12 cm sphygmomanometer
cuff placed just above the ankle and a Doppler instru-
ment used to measure the systolic pressure of the
posterior tibial and dorsalis pedis arteries of each
leg (Fig. C1). These pressures are then normalized to
the higher brachial pressure of either arm to form
the ankle-brachial index (ABI). The index leg is often
defined as the leg with the lower ABI.
The ABI provides considerable information. A
reduced ABI in symptomatic patients confirms the
existence of hemodynamically significant occlusive
disease between the heart and the ankle, with a lower
ABI indicating a greater hemodynamic severity of oc-
clusive disease. The ABI can serve as an aid in differen-
tial diagnosis, in that patients with exercise-related leg
pain of non-vascular causes will have a normal ankle
pressure at rest and after exercise. In patients with
PAD who do not have classic claudication (are either
asymptomatic or have atypical symptoms) a reduced
ABI is highly associated with reduced limb function.
This is defined as reduced walking speed and/or
a shortened walking distance during a timed 6-minute
walk. From a systemic perspective, a reduced ABI is
a potent predictor of the risk of future cardiovascular
events, as discussed in section B1.1. This risk is re-
lated to the degree of reduction of the ABI (lower
ABI predicts higher risk) and is independent of
other standard risk factors. The ABI thus has the
potential to provide additional risk stratification in
patients with Framingham risk between 10% and
20% in 10 years, in that an abnormal ABI in this in-
termediate-risk group would move the patient to
high risk in need of secondary prevention whereas
a normal ABI would lower the estimate of risk indi-
cating the need for primary prevention strategies
(see Fig. B1).
The ABI should become a routine measurement in
the primary care practice of medicine. When used in
this context, screening of patients aged 50e69 years
who also had diabetes or a smoking history, or screen-
ing all persons over the age of 70 resulted in a preva-
lence of PAD of 29%.11 The reproducibility of the ABI
varies in the literature, but it is significant enough that
reporting standards require a change of 0.15 in an
isolated measurement for it to be considered clinically
relevant, or >0.10 if associated with a change in clin-
ical status. The typical cut-off point for diagnosing
PAD is 0.90 at rest.
The value of a reduced ABI is summarized as
follows:
 Confirms the diagnosis of PAD
 Detects significant PAD in (sedentary) asymptom-
atic patients
S26 L. Norgren and W. R. Hiatt et al.Fig. C1. Measurement of the ABI. ABI e ankle-brachial index. Used in the differential diagnosis of leg symptoms
to identify a vascular etiology
 Identifies patients with reduced limb function (in-
ability to walk defined distances or at usual walking
speed)
 Provides key information on long-term prognosis,
with an ABI 0.90 associated with a 3e6-fold in-
creased risk of cardiovascular mortality
 Provides further risk stratification, with a lower ABI
indicating worse prognosis
 Highly associated with coronary and cerebral artery
disease
 Can be used for further risk stratification in patients
with a Framingham risk score between 10%e20%.
In somepatientswithdiabetes, renal insufficiency, or
other diseases that cause vascular calcification, the tib-
ial vessels at the ankle become non-compressible. This
leads to a false elevation of the ankle pressure. These
patients typically have an ABI >1.40 and, in some of
these patients, the Doppler signal at the ankle cannot
be obliterated even at cuff pressures of 300 mmHg. In
these patients additional non-invasive diagnostic test-
ing should be performed to evaluate the patient for
PAD (discussed in section G1.3). Alternative tests in-
clude toe systolic pressures, pulse volume recordings,
transcutaneous oxygen measurements or vascular
imaging (most commonly with duplex ultrasound).Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007When any of these tests is abnormal, a diagnosis of
PAD can be reliably made.
C2.2 Exercise testing to establish the diagnosis
of peripheral arterial disease
As discussed above, patients with claudication who
have an isolated iliac stenosis may have no pressure
decrease across the stenosis at rest and, therefore,
Recommendation 12. Recommendations for
ankle-brachial index (ABI) screening to detect
peripheral arterial disease in the individual
patient.
An ABI should be measured in:
 All patients who have exertional leg symptoms
[B].
 All patients between the age of 50e69 and who
have a cardiovascular risk factor (particularly
diabetes or smoking) [B].
 All patients age 70 years regardless of risk-
factor status [B].
 All patients with a Framingham risk score
10%e20% [C].
S27TASC II Inter-Society Consensus on Peripheral Arterial Diseasea normal ABI at rest. However, with exercise the
increase inflow velocity will make such lesions hemo-
dynamically significant. Under these conditions, exer-
cise will induce a decrease in the ABI that can be
detected in the immediate recovery period and thus
establish the diagnosis of PAD. The procedure requires
an initial measurement of the ABI at rest. The patient is
then asked towalk (typically on a treadmill at 3.2 km/h
(2 mph), 10%e12% grade) until claudication pain
occurs (or a maximum of 5 minutes), following which
the ankle pressure is again measured. A decrease in
ABIof 15%e20%wouldbediagnostic ofPAD. If a tread-
mill is not available then walking exercise may be per-
formed by climbing stairs or in the hallway.
C2.3 Alternative stress tests for patients who cannot
perform treadmill exercise
Certain patient populations should not be asked to
undergo treadmill testing as previously described,
including those who have severe aortic stenosis, uncon-
trolled hypertension or patients with other exercise-
limiting co-morbidities, including advanced congestive
heart failure or chronicobstructivepulmonarydisease.87
Patients who cannot perform treadmill exercise can
be tested with active pedal plantar flexion. Active
pedal plantar flexion has demonstrated excellent
correlation with treadmill testing, and should be
considered an appropriate alternative to treadmilltesting. A second alternative is to inflate a thigh cuff
well above systolic pressure for 3 to 5 minutes, pro-
ducing a similar degree of ‘‘reactive’’ hyperemia.
The decrease in ankle pressure 30 seconds after cuff
deflation is roughly equivalent to that observed
1 minute after walking to the point of claudication
on a treadmill. Unfortunately, many patients do not
tolerate the discomfort associated with this degree
and duration of cuff inflation and, in modern vascular
laboratories, this is rarely performed.
Discussion of additional diagnostic tests to estab-
lish the diagnosis of PAD can be found in section G.
Fig. C2 shows an algorithm for the diagnosis of PAD.
C3 Outcome Assessment of Intermittent
Claudication in Clinical Practice
Intermittent claudication is a symptom of peripheral
arterial disease that profoundly limits the patient’s
ability to walk and as a result is associated with a re-
duced exercise performance. This reduction in exercise
performance can be easily quantified with a graded
treadmill test where the time of onset of claudication
pain (claudication onset time) and peak walking time
can be determined at baseline. The treadmill test will
also allow the clinician to determine if the patient
experiences typical claudication pain with exercise,
or other symptoms that limit exercise. This assessment
will help guide therapy because if claudication is notFig. C2. Algorithm for diagnosis of peripheral arterial disease. TBI e toe brachial index; VWF e velocity wave form; PVR e
pulse volume recording. Reproduced with permission from Hiatt WR. N Engl J Med 2001;344:1608e1621.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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claudication therapies may not be indicated.
Once claudication is established as the major symp-
tom limiting exercise, then the primary goal of claudi-
cation therapy is to relieve the symptoms during
walking and improve exercise performance and com-
munity activities. Appropriate treatment of the claudi-
cant must address both the specific lower-extremity
disability and the systemic impact of the disease. Ide-
ally, treatment will result in an improvement in both
the vascular status of the lower extremity and reduce
the patient’s subsequent risk of fatal and non-fatal car-
diovascular events. In clinical trials of claudication
therapy, the primary endpoint is usually a treadmill
test of the peak walking time or distance as well as
the time or distance for the onset of claudication.88
The same parameters can be assessed to determine
the clinical benefit of any claudication therapy in an in-
dividual patient. In addition, changes in the physical
domains of the Medical Outcomes Short Form 36 (SF-
36) or the Walking Impairment Questionnaire (WIQ)
serve as patient-based measures of treatment effect.
The complete assessment of the outcomes of treatment
of the claudicant, therefore, requires the use of both
clinical and patient-based parameters.
C4 Treatment of Intermittent Claudication
C4.1 Overall strategy and basic treatment
for intermittent claudication
C4.1.1 Overall strategy
Patientswith claudication experience reversiblemuscle
ischemia during walking that is characterized by
cramping and aching in the affected muscle. These
Recommendation 13. Determining success of
treatment for intermittent claudication.
Patient-based outcome assessment (including
a focused history of change in symptoms) is the
most important measure; however, if quantitative
measurements are required the following may be
used:
1. Objective measures include an increase in peak
exercise performance on a treadmill [B].
2. Patient-based measures would include an
improvement on a validated, disease-specific
health status questionnaire; or the physical
functioning domain on a validated generic
health status questionnaire [B].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007symptoms result in a severe limitation in exercise per-
formance andwalking ability. The exercise limitation is
associated with marked impairments in walking dis-
tance, walking speed and overall function. Patients
with claudication are physically impaired and, there-
fore, the treatment goals are to relieve symptoms,
improve exercise performance and daily functional
abilities. The initial approach to the treatment of limb
symptoms should focus on structured exercise and,
in selected patients, pharmacotherapy to treat the exer-
cise limitation of claudication (risk factor modification
and antiplatelet therapies are indicated to decrease the
risk of cardiovascular events and improve survival).
Failure to respond to exercise and/or drug therapy
would lead to the next level of decision making, which
is to consider limb revascularization. However, in pa-
tients in whom a proximal lesion is suspected (findings
of buttocks claudication, reduced or absent femoral
pulse) the patient could be considered for revasculari-
zation without initially undergoing extensive medical
therapy. The overall strategy is summarized in Fig. C3.
C4.1.2 Exercise rehabilitation
In patients with claudication, there is a considerable
body of evidence to support the clinical benefits of
a supervised exercise program in improving exercise
performance and community-based walking ability.
This intervention has been thoroughly reviewed,
both in terms of mechanism of the training effect,
as well as practical guidelines for the exercise
program.89,90 Several studies have suggested that
some level of supervision is necessary to achieve opti-
mal results (general, unstructured recommendations
to exercise by the physician do not result in any clinical
benefit). In prospective studies of supervised exercise
conducted for 3 months or longer, there are clear in-
creases in treadmill exercise performance and a lessen-
ing of claudication pain severity during exercise.91
The predictors of response to the training program
include achieving a high level of claudication pain dur-
ing the training sessions and 6 months or longer of
formal training and walking exercise (versus other
training modalities). Training on a treadmill has been
shown to be more effective than strength training or
combinations of trainingmodalities. However, different
modes of exercise training have been applied including
upper extremity cycle ergometer exercise that is
associated with a training response. The mechanisms
of response to exercise training have been reviewed
previously and include improvements in walking effi-
ciency, endothelial function and metabolic adaptations
in skeletal muscle.90
The exercise prescription should be based on
exercise sessions that are held three times a week,
S29TASC II Inter-Society Consensus on Peripheral Arterial DiseaseFig. C3. Overall treatment strategy for peripheral arterial disease. BP e blood pressure; HbA1c e hemoglobin A1c; LDL e
low density lipoprotein; MRA e magnetic resonance angiography; CTA e computed tomographic angiography.
Reproduced with permission from Hiatt WR. N Engl J Med 2001;344:1608e1621.beginningwith 30 minutes of training but then increas-
ing to approximately 1 hour per session. During the ex-
ercise session, treadmill exercise is performed at
a speed and grade that will induce claudication within
3e5 minutes. The patient should stop walking when
claudication pain is considered moderate (a less
optimal training response will occur when the patient
stops at the onset of claudication). The patient will then
rest until claudication has abated, after which the
patient should resume walking until moderateclaudication discomfort recurs. This cycle of exercise
and rest should be at least 35 minutes at the start of
the program and increase to 50 minutes as the patient
becomes comfortable with the exercise sessions
(but always avoiding excessive fatigue or leg discom-
fort). In subsequent visits, the speed or grade of the
treadmill is increased if the patient is able to walk for
10 minutes or longer at the lower workload without
reaching moderate claudication pain. Either speed
or grade can be increased, but an increased grade isEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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(3.2 km/h). An additional goal of the program is to
increase patient walking speed up to the normal
3.0 mph (4.8 km/h) from the average PAD patient
walking speed of 1.5e2.0 mph (approximately 2.4e
3.2 km/h).
Many patients may have contraindications for exer-
cise (e.g. severe CAD, musculoskeletal limitations or
neurological impairments). Other patients may be un-
willing to participate in supervised sessions if they
have long distances to travel to the exercise facility, if
an appropriate rehabilitation program is not available
in their area, or if the expenses incurred are too great.
The prevalence of contraindications to an exercise pro-
gram ranges from 9%e34% depending on the popula-
tion studied. The major limitation of exercise
rehabilitation is the lack of availability of a supervised
setting to refer patients. Though exercise therapy is of
proven effectiveness, some patients are simply not
willing to persist with an exercise program in order to
maintain the benefit. In addition, a claudication
exercise program in a patient with diabetes who has
severe distal neuropathy may precipitate foot lesions
in the absence of proper footwear.
C4.2 Pharmacotherapy for intermittent claudication
Patients with IC should all receive drug and lifestyle
treatment for their cardiovascular risk factors and coex-
isting diseases to prevent cardiovascular events
(myocardial infarction, stroke and death) associated
with atherosclerosis. However, this approach will typ-
ically not provide a significant reduction or elimination
of symptoms of claudication. Thus, claudication drug
therapy for relief of symptoms typically involves differ-
ent drugs than those that would be used for risk reduc-
tion (an exception may be lipid-lowering therapy).
However, a number of types of drugs have been
Recommendation 14. Exercise therapy in inter-
mittent claudication
 Supervised exercise should be made available
as part of the initial treatment for all patients
with peripheral arterial disease [A].
 The most effective programs employ treadmill
or track walking that is of sufficient intensity
to bring on claudication, followed by rest,
over the course of a 30e60 minute session. Ex-
ercise sessions are typically conducted three
times a week for 3 months [A].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007promoted for symptom relief, with varying levels of
evidence to support their use. Not all the drugs
presented in this section are universally available, so
access to certain agents may be limited in certain coun-
tries. Finally, current drug therapy options do not
provide the samedegree of benefit as does a supervised
exercise program or successful revascularization.
C4.2.1 Drugs with evidence of clinical utility in
claudication
Note that not all these drugs are available in every country
Cilostazol
Cilostazol is a phosphodiesterase III inhibitor with
vasodilator, metabolic and antiplatelet activity. The
benefits of this drug have been described in a meta-
analysis of six randomized, controlled trials involving
1751 patients, including 740 on placebo, 281 on cilos-
tazol 50 mg twice-daily (BID), 730 on cilostazol
100 mg BID. The 73 on cilostazol 150 mg BID and
232 on pentoxifylline 400 mg thrice-daily (TID) were
excluded from the analysis.92 This analysis demon-
strated that the net benefit of cilostazol over placebo
in the primary endpoint of peak treadmill perfor-
mance ranged from 50e70 meters depending on the
type of treadmill test performed. Cilostazol treatment
also resulted in a significant overall improvement in
the quality of life measures from the WIQ and SF-
36. In a study comparing cilostazol to pentoxifylline,
cilostazol was more effective.93 Side effects included
headache, diarrhea, and palpitations. An overall
safety analysis of 2702 patients revealed that the rates
of serious cardiovascular events, and all-cause and
cardiovascular mortality was similar between drug
and placebo groups.94 However, since the drug is in
the phosphodiesterase III inhibitor class of drugs, it
should not be given to patients with any evidence of
congestive heart failure because of a theoretical con-
cern for increased risk of mortality. This drug has
the best overall evidence for treatment benefit in
patients with claudication.
Naftidrofuryl
Naftidrofuryl has been available for treating in-
termittent claudication for over 20 years in several
European countries. It is a 5-hydroxytryptamine
type 2 antagonist and may improve muscle metabo-
lism, and reduce erythrocyte and platelet aggregation.
In a meta-analysis of five studies involving a total of
888 patients with intermittent claudication, naftidro-
furyl increased pain-free walking distance by 26%
compared with placebo ( p¼ 0.003).95 Similar results
showing benefits on treadmill performance and quality
of life were confirmed in three recent studies of over
1100 patients followed for 6e12 months.96e98 In all
three studies the same dose of 600 mg/day was
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different to placebo; most frequently occurring com-
plaints in the different studies were mild gastro-
intestinal disorders.
C4.2.2 Drugs with supporting evidence of clinical
utility in claudication
Carnitine and Propionyl-L-Carnitine
Patients with peripheral arterial disease develop
metabolic abnormalities in the skeletal muscles of
the lower extremity. Thus, claudication is not simply
the result of reduced blood flow, and alterations
in skeletal muscle metabolism are part of the patho-
physiology of the disease. L-carnitine and propionyl-
L-carnitine interact with skeletal muscle oxidative
metabolism, and these drugs are associated with im-
proved treadmill performance. Propionyl-L-carnitine
(an acyl form of carnitine) was more effective than
L-carnitine in improving treadmill walking distance.
In two multicenter trials of a total of 730 patients,
initial and maximal treadmill walking distance
improved more with propionyl-L-carnitine than
placebo.99,100 The drug also improved quality of life
and had minimal side effects as compared with
placebo. Additional trials in the broad population
of patients with claudication will be necessary to es-
tablish the overall efficacy and clinical benefit of
these drugs.
Lipid lowering drugs
Patients with PAD have endothelial and metabolic
abnormalities secondary to their atherosclerosis,
which may be improved with statin therapy. There
are several promising studies evaluating the effects
of statin drugs on exercise performance. While the re-
sults are preliminary, several positive trials suggest
that further study is warranted.101,102 Further studies
are ongoing to determine the clinical benefits of
these observations, including prevention of disease
progression in addition to symptom relief.
C4.2.3 Drugs with insufficient evidence of clinical
utility in claudication
Pentoxifylline
Pentoxifylline lowers fibrinogen levels, improves red
cell and white cell deformability and thus lowers blood
viscosity. While early trials were positive on the end-
point of improvement in treadmill exercise perfor-
mance, later studies demonstrated that pentoxifylline
was nomore effective than placebo on improving tread-
mill walking distance or functional status assessed
by questionnaires. Several meta-analyses have con-
cluded that the drug is associatedwithmodest increases
in treadmill walking distance over placebo, but theoverall clinical benefits were questionable.103e105
The clinical benefits of pentoxifylline in improving
patient-assessed quality of life have not been exten-
sively evaluated. While tolerability of the drug is
acceptable, pentoxifylline does not have an extensive
safety database.
Isovolemic hemodilution
Isovolemic hemodilution has been advocated for
the treatment of claudication, presumably by lower-
ing viscosity of whole blood, but it is still uncertain
whether the increase in blood flow compensates for
the decrease in oxygen-carrying capacity of the blood.
There are insufficient trials to support this therapy
and it is only of historical interest.
Antithrombotic agents
Aspirin/ASA and other antiplatelet agents (clopi-
dogrel) are important in the long-term treatment of
patients with PAD to reduce their risk of cardiovascu-
lar events with well established efficacy. However, no
studies have shown a benefit of antiplatelet or anti-
coagulant drugs in the treatment of claudication.106
Vasodilators
Arteriolar vasodilators were the first class of
agents used to treat claudication. Examples include
drugs that inhibit the sympathetic nervous system
(alpha blockers), direct-acting vasodilators (papaver-
ine), beta2-adrenergic agonists (nylidrin), calcium
channel blockers (nifedipine) and angiotensin-
converting enzyme inhibitors. These drugs have not
been shown to have clinical efficacy in randomized,
controlled trials.107 There are several theoretical
reasons why vasodilators may not be effective, in-
cluding the possibility that vasodilator drugs may
create a steal phenomenon by dilating vessels in
normally perfused tissues thus shifting the distribu-
tion of blood flow away from muscles supplied by
obstructed arteries.
L-Arginine
L-arginine has the ability to enhance endothelium-
derived nitric oxide and, thus, improve endothelial
function. One study of nutritional supplementation
with L-arginine improved pain-free but not peak
walking time.108 However, a recent study of L-arginine
treatment in acute myocardial infarction showed no
clinical benefit and excess mortality.108 Further studies
would be needed to determine if this treatment would
have benefit and no unacceptable risk.
Acyl coenzyme A-cholesterol acyltransferase inhibitors
Drugs in this class may reduce cholesterol accumu-
lation in arterial plaque, thus affecting the natural
history of atherosclerosis. A study with avasimibe
in claudication demonstrated no clear evidence of
efficacy and possible adverse effects on low-density
lipoprotein cholesterol levels.109Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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Ketanserin is a selective serotonin (S2) antagonist
that lowers blood viscosity and also has vasodilator
and antiplatelet properties. Controlled trials of this
drug have shown it not to be effective in treating
claudication.110 Importantly, the drug has been associ-
ated with increased risk of mortality in a subgroup of
patients treated with potassium-wasting diuretics,
precluding its role for any indication.111
AT-1015 is a selective 5-hydroxytryptamine antago-
nist that was studied in multiple doses in claudication.
The drug was ineffective, and there were toxicity con-
cerns at the highest dose.112 Therefore, this drug cannot
be recommended at this time.
Sarpogrelate showed promising results in 364 pa-
tients followed for 32weeks, without safety concerns.113
Additional trials will be necessary to determine the
overall benefits and safety of drugs in this class.
Prostaglandins
Prostaglandins have been used in several studies in
patients with critical leg ischemia with some success
in wound healing and limb preservation. In patients
with claudication, prostaglandin E1 (PGE1) has been
best studied. Intravenous administration of a prodrug
of PGE1 showed positive effects on treadmill per-
formance.114 Several studies have been performed
with oral beraprost. While there was a positive trial
in Europe, there have been negative trials in the
USA.115,116 While intravenous administration of
PGE1 may have modest benefits, the overall evidence
does not support the use of this drug class for
claudication.
Buflomedil
Buflomedil has an alpha-1 and -2 adrenolytic effects
that result in vasodilatation. This drug has antiplatelet
effects, results in improvements in red cell deformabil-
ity and weakly antagonizes calcium channels. Two rel-
atively small studies have shown marginally positive
effects on treadmill performance.117,118 However, con-
cerns have been raised about publication bias of only
positive trials. Therefore, evidence is insufficient to
support the use of this agent at this time.
Defibrotide
Defibrotide is a polydeoxyribonucleotide drug
with antithrombotic and hemorheological properties.
Several small studies suggest a clinical benefit, but
larger trials would be necessary to better understand
the clinical benefits and any risks of therapy.119e121
Other agents
Several studies have evaluated the role of Vitamin E,
chelation therapy, omega-3 fatty acids, ginko-biloba
and lowering of homocysteine levels in the treat-
ment of claudication. None of these therapies have
proven effective.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007C5 Future Treatments for Claudication
Angiogenic growth factors
Vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF) are mitogenic
agents that stimulate the development of new vessels.
When bFGF protein was given intra-arterially,
patients with claudication had an improvement in ex-
ercise performance.122 Newer applications deliver the
agent as gene therapy in a viral vector given intra-
muscularly. Unfortunately, initial studies have not
been positive with VEGF.123 Therefore, more studies
will be needed to address the overall efficacy and
modes and frequency of administration of angiogenic
factors in the treatment of claudication.
SECTION D e CHRONIC CRITICAL
LIMB ISCHEMIA
D1 Nomenclature and Definitions
Critical limb ischemia (CLI) is a manifestation of pe-
ripheral arterial disease (PAD) that describes patients
with typical chronic ischemic rest pain (see Table D1,
Fontaine and Rutherford classifications, respectively)
or patients with ischemic skin lesions, either ulcers
or gangrene. The term CLI should only be used in
relation to patients with chronic ischemic disease,
defined as the presence of symptoms for more than
2 weeks. It is important to note in this section that
there are limited data available compared with the
other sections. CLI populations are difficult to study,
with large numbers of patients lost to follow-up or
dying in longitudinal studies, leading to incomplete
data sets.
The diagnosis of CLI should be confirmed by the
ankle-brachial index (ABI), toe systolic pressure or
transcutaneous oxygen tension. Ischemic rest pain
most commonly occurs below an ankle pressure of
50 mmHg or a toe pressure less than 30 mmHg. Other
Recommendation 15. Pharmacotherapy for
symptoms of intermittent claudication
 A 3- to 6-month course of cilostazol should
be first-line pharmacotherapy for the relief of
claudication symptoms, as evidence shows
both an improvement in treadmill exercise
performance and in quality of life [A].
 Naftidrofuryl can also be considered for treat-
ment of claudication symptoms [A].
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in a patient with an ankle pressure above 50 mmHg,
although CLI could be the cause.
Some ulcers are entirely ischemic in etiology; others
initially have other causes (e.g. traumatic, venous, or
neuropathic) but will not heal because of the severity
of the underlying PAD. Healing requires an inflam-
matory response and additional perfusion above
that required for supporting intact skin and underly-
ing tissues. The ankle and toe pressure levels needed
for healing are, therefore, higher than the pressures
found in ischemic rest pain. For patients with ulcers
or gangrene, the presence of CLI is suggested by an
ankle pressure less than 70 mmHg or a toe systolic
pressure less than 50 mmHg. (It is important to under-
stand that there is not complete consensus regarding
the vascular hemodynamic parameters required to
make the diagnosis of CLI.)
D1.1 Patients presumed at risk for critical limb ischemia
A subgroup of PAD patients fall outside the definition
of either claudication or CLI. These patients have
severe PAD with low perfusion pressures and low
ankle systolic pressures, but are asymptomatic. They
are usually sedentary and, therefore, do not claudicate,
or they may have diabetes with neuropathy and
Table D1. Classification of peripheral arterial disease: Fontaine’s
stages and Rutherford’s categories
Fontaine Rutherford
Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild claudication I 1 Mild claudication
IIb Moderate to
severe
claudication
I 2 Moderate
claudication
I 3 Severe
claudication
III Ischemic rest pain II 4 Ischemic rest pain
IV Ulceration or
gangrene
III 5 Minor tissue loss
III 6 Major tissue loss
Recommendation 16. Clinical definition of criti-
cal limb ischemia (CLI)
 The term critical limb ischemia should be used
for all patients with chronic ischemic rest pain,
ulcers or gangrene attributable to objectively
proven arterial occlusive disease. The term
CLI implies chronicity and is to be distin-
guished from acute limb ischemia [C].reduced pain perception. These patients are presumed
vulnerable to develop clinical CLI. The natural
history of this subgroup of severe PAD is not well-
characterized, but outcomes of excess mortality and
amputation would be expected. The term ‘chronic sub-
clinical ischemia’ has been ascribed to this subgroup.
Natural history studies of claudication document
that few patients progress to CLI. Many patients who
present with CLI are asymptomatic prior to its devel-
opment.54 However, research in this area is lacking,
understandably, for patients who are asymptomatic
and can only be detected by more routine ABI testing.
D1.2 Prognosis
It is important to diagnose CLI because it confers
a prognosis of high risk for limb loss and for fatal
and non-fatal vascular events, myocardial infarction
and stroke. In general, the prognosis is much worse
than that of patients with intermittent claudication.
Observational studies of patients with CLI who are
not candidates for revascularization suggest that
a year after the onset of CLI, only about half the
patients will be alive without a major amputation,
although some of these may still have rest pain,
gangrene or ulcers (see section A). Approximately
25% will have died and 25% will have required
a major amputation. Their prognosis is in many
ways similar to that of some malignancies. The
diagnosis of CLI thus predicts a poor prognosis for
life and limb. Patients should have aggressive modi-
fication of their cardiovascular risk factors and should
be prescribed antiplatelet drugs. Ultimately, much of
the care of CLI patients is palliative in nature, an
issue that is very important when considering
revascularization or amputation.
D2 Clinical Presentation and Evaluation
D2.1 Pain
CLI is dominated by pedal pain (except in diabetic pa-
tients, where superficial pain sensation may be altered
and they may experience only deep ischemic pain,
Recommendation 17. Cardiovascular risk modifi-
cation in critical limb ischemia (CLI)
 CLI patients should have aggressive modifica-
tion of their cardiovascular risk factors [A].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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most cases, the pedal pain is intolerably severe; it
may respond to foot dependency, but otherwise re-
sponds only to opiates. The pain is caused by ische-
mia, areas of tissue loss, ischemic neuropathy or
a combination of these; it occurs or worsens with re-
duction of perfusion pressure. In most cases, walking
capacity is very severely impaired, with walking often
becoming almost impossible.
Ischemic rest pain most typically occurs at night
(when the limb is no longer in a dependent position)
but in severe cases can be continuous. The pain is local-
ized in the distal part of the foot or in the vicinity of an
ischemic ulcer or gangrenous toe. The pain oftenwakes
the patients at night and forces them to rub the foot, get
up, or take a short walk around the room. Partial relief
may be obtained by the dependent position, whereas
elevation and cold increase the severity of the pain. Of-
ten, patients sleep with their ischemic leg dangling
over the side of the bed, or sitting in an armchair; as
a consequence ankle and foot edema develop. In severe
cases, sleep becomes impossible because pain sets in
after only a short period of supine rest, causing in
many patients a progressive further decline of their
general physical and psychological condition.
Ischemic rest pain is often accompanied by pain
caused by peripheral ischemic neuropathy, the mecha-
nism of which is not well established. This results in
severe, sharp, shooting pain that does not necessarily
follow the anatomic distribution of the nerves but usu-
ally is most pronounced at the distal part of the extrem-
ity. The pain often occurs at night, with episodes lasting
minutes to hours but with constant diffuse pain re-
maining in between. Ischemic rest pain should not be
confused with neuropathic pain (see section D4.1).
D2.2 Ulcer and gangrene
Patients with CLI may also present with ischemic ul-
cers or gangrene. It is important to note that some pa-
tients may progress through rest pain into tissue loss.
However, in many patients, notably those with dia-
betic neuropathy, the initial presentation is with a neu-
roischemic ulcer or gangrene. There are significant
differences between patients with and without diabe-
tes at this stage of CLI; these are delineated in section
D2.4 which specifically addressed diabetic foot ulcers.
Gangreneusually affects the digits or, in a bedridden
patient, the heel (as this is a pressure point). In severe
cases, gangrenemay involve the distal parts of the fore-
foot. It is usually initiated by a minor local trauma.
Local pressure (ill fitting shoes) or the use of local
heat (increasing metabolic demands) can also lead toEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007ulcer and gangrene formation on other locations on
the foot or leg. Gangrenous tissue, if not infected, can
form an eschar, shrink and eventually mummify and,
if the underlying circulation is adequate enough (or
has been made adequate enough by treatment) to sup-
port the process, spontaneous amputation may follow.
In contrast to the focal and proximal atherosclerotic
lesions of PAD found typically in other high-risk
patients, in patients with CLI and diabetes the occlu-
sive lesions are more likely to be more diffuse and dis-
tally located, particularly in infrageniculate arteries.
Importantly, PAD in patients with diabetes is usually
accompanied by peripheral neuropathy with impaired
sensory feedback, enabling the silent progression of
the ischemic process. Thus, a patient with diabetes
and severe, asymptomatic PAD could also have a ‘piv-
otal event’ that leads acutely to an ischemic ulcer and
a limb-threatening situation. A common example is
the use of new, tight or ill fitting shoes in a patient
with neuropathy. Thus, an asymptomatic, usually
undiagnosed patient can lapse, apparently abruptly,
into CLI. By identifying a patient with sub-clinical dis-
ease and instituting preventive measures, it may be
possible to avoid CLI or at least prompt early referral
if the patient develops CLI.
D2.3 Differential diagnosis of ulcers
The majority of lower-leg ulcers above the ankle have
a venous origin whereas ulcers in the foot are most
likely due to arterial insufficiency (see Fig. D1).
Table D2 depicts the common characteristics of foot
and leg ulcers.
D2.4 Diabetic foot ulcers
While CLI is a significant risk factor for non-healing
of diabetic foot ulcers, it is not the sole major factor
associated with the development of diabetic foot
lesions. Diabetic foot ulcers are, therefore, discussed
separately in this section. Fig. D2 demonstrates
the distribution of diabetic foot ulcers. Diabetic foot
complications are the most common cause of non-
traumatic lower extremity amputations in the world.
It is estimated that 15% of people with diabetes
will develop a foot ulcer during their lifetime and
approximately 14%e24% of people with a foot ulcer
will require an amputation. Up to 85% of amputations
may be prevented by early detection and appropriate
treatment.124 Risk factors for ulcer formation include
peripheral neuropathy, which leads to an insensate
foot and structural foot deformity. It is estimated
that approximately 30% of people with diabetes
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Many diabetic foot ulcers and lower extremity ampu-
tations can be prevented through early identification
of the patient at risk and preventive foot care, by
Fig. D1. Approximate frequencies of various ulcer
etiologies.both the health care provider and the patient, as
described in the section D6 on the prevention of CLI.
D2.4.1 Pathways to ulceration
The most common pathway associated with the
development of diabetic ulcers include: neuropathy
(loss of protective sensation), coupled with pressure
points (foot deformity) and repetitive activity.126
Motor nerve defects and limited joint mobility
can cause foot deformities, with pressure points
further predisposing the patient to foot lesions.
Consequences of autonomic neuropathy include loss
of sweating, dry fissured skin and increased arteriove-
nous shunting. Healing requires a greater increase in
perfusion than needed to maintain intact skin.
D2.4.2 Types of ulcers and presentation
Diabetic foot ulcerations can be divided into three
broad categories: ischemic, neuro-ischemic and neu-
ropathic ulcers. The presentation of the classical neu-
ropathic and ischemic ulcers is depicted in Table D3.
Although the majority of diabetic ulcers are neuro-
pathic (Fig. D3), ischemia has to be excluded in all
ulcers given its major impact on outcome. All patients
with a foot ulcer should have an objective assessment
of their vascular status at first presentation and on
a regular basis; the assessment should include history
(claudication), pulses and ABI. Pulse examination
alone is an inadequate vascular examination in these
patients. Any diabetic patient with a foot ulcer should
be further evaluated in the vascular laboratory (see
section G).
Increased arteriovenous shunt blood flow, due to
autonomic neuropathy, can result in a relatively
warm foot, falsely reassuring the clinician. The clini-
cian should be aware of the relative incompressibility
of calcified distal arteries in a diabetic, such that theTable D2. Characteristics of common foot and leg ulcers
Origin Cause Location Pain Appearance Role of
revascularization
Arterial Severe PAD, Buerger’s
disease,
Toes, foot, ankle Severe Various shape,
pale base, dry
Important
Venous Venous insufficiency Malleolar, esp. medial Mild Irregular, pink
base, moist
None
Mixed venous/arterial Venous
insufficiencyþ PAD
Usually malleolar Mild Irregular, pink base If non-healing
Skin infarct Systemic disease,
embolism
Lower third of leg, malleolar Severe Small, often multiple None
Neuropathic Neuropathy from
diabetes, vitamin
deficiency, etc
Foot/plantar surface
(weight-bearing),
associated deformity
None Surrounding callus,
often deep, infected
None
Neuroischemic Diabetic
neuropathyþ ischemia
Locations common to both
ischemic and neuroischemic
As arterial
Reduced
due to
neuropathy
As arterial As arterialEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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1999; 157e162. Modified with permission from The American Diabetes Association.ABI may be within normal limits. Due to the possibil-
ity of a falsely elevated ABI, the importance of toe
pressures and tcPO2 measurements cannot be under-
estimated (see section D5). Some patients have clear
signs of critical limb ischemia e for example a toe or
tcPO2 pressure <30 mmHg e while in others the
blood flow is impaired to a lesser degree e for exam-
ple toe pressures between 30e70 mmHg e but they
are still unable to heal foot lesions.
Symptoms and signs of neuropathic versus ischemic
ulcers appear in Table D3.
Table D3. Symptoms and signs of neuropathic versus ischemic
ulcers
Neuropathic ulcer Ischemic ulcer
Painless Painful
Normal pulses Absent pulses
Regular margins, typically
punched-out appearance
Irregular margins
Often located on plantar
surface of foot
Commonly located on toes,
glabrous margins
Presence of calluses Calluses absent
or infrequent
Loss of sensation, reflexes
and vibration
Variable sensory findings
Increase in blood flow
(AV shunting)
Decrease in blood flow
Dilated veins Collapsed veins
Dry, warm foot Cold foot
Bony deformities No bony deformities
Red appearance Pale, cyanotic
Recommendation 18. Evaluation of peripheral
arterial disease (PAD) in patients with diabetes
 All diabetic patients with an ulceration should
be evaluated for PADusing objective testing [C].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007D3 Macrocirculatory Pathophysiology in
Critical Limb Ischemia
CLI occurs when arterial lesions impair blood flow to
such an extent that the nutritive requirements of the
tissues cannot be met. This is usually caused by mul-
tilevel arterial occlusive disease.128 In some cases, the
hemodynamic consequences of arterial lesions may be
compounded by a decreased cardiac output.
CLI is considered to be the result of multisegment
arterial occlusive disease in most cases. Realizing
this is most important in managing patients with pre-
sumed rest pain, as the influence of circulation on the
pain syndrome can be difficult to determine, partic-
ularly in a patient with neuropathy.
 Patients with diffuse multisegment disease, both
supra and infrainguinal are significant management
problems, as proximal revascularizations may not
remain patent due to lack of arterial outflow with-
out additional infrainguinal procedures. Should
a major amputation be required, the risk of non-
healing is considerable due to proximal occlusive
disease
 In patients with diabetes, arteries proximal to the
knee joint are often spared or moderately diseased,
and the majority of occlusions occur at the tibial pe-
roneal trunk and distally. Often, the peroneal artery
and the dorsalis pedis artery are open beyond these
occlusions and serve as potential distal targets for
a bypass.
D3.1 Skin microcirculation
The skin microcirculation is unusual in many ways,
most notably that nutritional capillary blood flow
only represents approximately 15% of the normal total
blood flow in the foot, the remainder having a non-
nutritive thermoregulatory function only. Patients
with CLI develop microcirculatory defects including
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white blood cell activation and inflammation. The nor-
mal function of the skinmicrocirculation can be consid-
ered in regard to two aspects: a complex microvascular
flow regulatory system and a series of defense mecha-
nisms. The microvascular flow-regulating system
includes extrinsic neurogenic mechanisms, intrinsic
localmediators andmodulation by circulatinghumoral
and blood-borne factors. The endothelium also partici-
pates in the regulation of flow by the release of vasodi-
latory mediators such as prostacyclin and nitric oxide
and several endothelium-derived contractile factors
(e.g. endothelin). In addition to the microvascular
flow-regulating system, there are several microvascu-
lar defense mechanisms. In CLI, there is a maldistribu-
tion of the skin microcirculation in addition to
a reduction in total blood flow. The importance of the
local microcirculatory response in individual patients
with CLI is suggested by the wide overlap in ankle or
toe blood pressure, which assess the macrocirculation,
in patients with and without CLI.
Capillary microscopy studies have confirmed an
heterogeneous distribution of skin microcirculatory
flow. This is also accompanied by a reduction in
tcPO2.
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In summary, although PAD is the underlying and
principal defect in patients with CLI, the low tissue
perfusion pressure sets up a number of complex local
microcirculatory responses, which may contribute to
rest pain and trophic changes. Many of these pro-
cesses can be viewed as an inappropriate response
of the microcirculatory flow regulatory mechanism
and its normal defense mechanisms. Therefore, al-
though the primary aim of treatment must be the cor-
rection of the PAD, attempts to manipulate and
normalize the microcirculatory changes pharmacolog-
ically may enhance the results of revascularization
and may be one option in patients in whom revasc-
ularization is impossible or has failed.D4 Differential Diagnosis of Ischemic Rest Pain
The various causes of foot pain that may be mistaken
for ischemic rest pain are considered in their appro-
ximate order of frequency.
D4.1 Diabetic neuropathy
Diabetic neuropathy usually results in a decrease in
sensation. In some patients neuropathy can result in
severe, seriously disabling pain in the foot. This is
often described as a burning or shooting sensation
that is frequently worse at night, when there is less dis-
traction, making it more difficult to distinguish from
atypical ischemic rest pain. (It should be noted that
this type of pain is seen in the relatively early ‘neuritic’
phase of diabetic neuropathy, often before diabetic
neuropathy has been clinically recognized.) Diagnostic
features that may be helpful in distinguishing diabetic
neuropathy from ischemic rest pain are a symmetrical
distribution in both legs, association with cutaneous
hypersensitivity and failure to relieve it by depen-
dency of the foot. The patient may have other signs
of a diabetic neuropathy, such as decreased vibratory
sensation and decreased reflexes.
D4.2 Complex regional pain syndrome
Patients with complex regional pain syndrome (for-
merly named causalgia or reflex sympathetic dystro-
phy) are often referred to vascular specialists for
evaluation of their limb circulation. In general, the cir-
culation is adequate (ABI, toe-brachial index [TBI]
normal). One form of complex regional pain
syndrome is caused by inadvertent ischemic damage
to peripheral nerves that may be associated with
delayed revascularization and, therefore, may be clas-
sified as a postoperative complication. This is one ofEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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may be indicated.
D4.3 Nerve root compression
A number of spinal conditions may result in nerve root
compression, giving rise to continuous pain. It is typi-
cally associated with backache and the pain distribu-
tion following one of the lumbosacral dermatomes.
D4.4 Peripheral sensory neuropathy other than
diabetic neuropathy
Any condition giving rise to isolated sensory neuro-
pathy can produce pain in the foot, which can be
confused with ischemic rest pain. Peripheral neuro-
pathy other than that caused by diabetic neuropathy
may be caused by vitamin B12 deficiency, or syringo-
myelia. Leprosy also may rarely result in a neuro-
pathic ulcer. Alcohol excess, toxins, and some
commonly used drugs, such as some cancer chemo-
therapy agents, may on rare occasion produce a
peripheral neuropathy.
D4.5 Night cramps
Night cramps, as opposed to restless legs, are very
common and occasionally difficult to diagnose. They
are usually associated with muscle spasm and usually
involve the calf, very rarely the foot alone. They may
be associated with chronic venous insufficiency, but
their precise cause is unknown.
D4.6 Buerger’s disease (thrombangitis obliterans)
Buerger’s disease also may present with rest pain in
the toes or feet, usually in younger smokers, and is
no longer exclusively seen in male patients. The path-
ophysiology is distal limb ischemia, due to an occlu-
sive, inflammatory vascular process involving both
arteries and veins.
D4.7 Miscellaneous
A number of other miscellaneous conditions can
give rise to pain in the foot, including local inflamma-
tory diseases such as gout, rheumatoid arthritis,
digital neuroma, tarsal tunnel nerve compression or
plantar fasciitis.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007D5 Investigations of Critical Limb Ischemia
D5.1 Physical examination
As a majority of patients with CLI have not suffered
earlier symptoms of PAD (intermittent claudication)
it is important to have the diagnosis of CLI in
mind when examining any patient with leg pain or
ulcer development.
A first step is to document the location and quality
of the pulses. Other less specific findings may include
hair loss, muscle atrophy, atrophy of subcutaneous
tissues and skin and appendages, dry fissured skin,
discoloration and dependant hyperemia.
In patients with ulcers there may be other etiologies
besides arterial disease (see Fig. D1 and Table D2).
Swelling is usually only a feature when there is active
infection or rest pain that prevents patients from
elevating their foot in bed at night.
D5.2 Investigations
 General investigations of atherosclerotic disease
(see section B)
 Physiologic e Confirmation of the diagnosis and
quantification of the arterial flow
B Ankle pressure e In patients with ischemic ulcers
the ankle pressure is typically 50e70 mmHg, and
in patients with ischemic rest pain it is typically
30e50 mmHg
B Toe pressures e should include toe pressures in
diabetic patients (critical level <50 mmHg)
B tcPO2 (critical level <30 mmHg)
B Investigation of microcirculation (usually used as
a research tool) e CLI is associated with redu-
ced total flow as well as maldistribution of flow
and activation of an inflammatory process. A com-
bination of tests to assess healing and quantify
flow may be indicated due to the rather poor sen-
sitivity and specificity of the single test. Tests
include:
 Capillaroscopy
 Fluorescence videomicroscopy
 Laser Doppler fluxometry
 Anatomic (Imaging) e Refer to section G.
Recommendation 19. Diagnosis of critical limb
ischemia (CLI)
 CLI is a clinical diagnosis but should be
supported by objective tests [C].
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As with all forms of systemic atherosclerosis, early
detection of PAD and aggressive management of car-
diovascular risk factors should reduce the incidence
and severity of CLI. For example, smoking cessation
is associated with a decreased risk of progression
from earlier stages of PAD to CLI130 (see section B).
D6.1 Risk factors associated with the foot
Early identification of the patient who is at risk for
CLI is essential in order to recognize potential prob-
lems and develop preventive intervention strategies
to avoid complications. Patients with atherosclerotic
PAD, Buerger’s disease, diabetes and any other condi-
tion that can cause a loss of protective sensation to
the foot or interferes with wound healing are at risk
of developing ulcerations and a future amputation.
Persons with diabetes are at a higher risk for develop-
ing lower extremity complications. A thorough foot
examination will assist in identifying those patients
who are at risk. Once an individual is classified
as high risk, a visual foot inspection should be
performed at every visit and referral to a foot care
specialist for further assessment is recommended.
D6.2 The role of peripheral neuropathy
Loss of protective sensation or peripheral neuropathy
places the patient at a higher risk for developing foot
related complications. Foot deformities may be the
result of motor neuropathy. Therefore, recognition of
structural deformities such as hammer toes and
bunions, or altered biomechanics such as callus for-
mation due to prominent bony deformity, as well as
limited joint mobility identify the patient as high
risk. Footwear should be inspected to determine if it
provides adequate support and protection for the
foot. Properly fitting shoes must accommodate any
foot deformities. Improper or poorly fitting shoes are
a major contributor to foot ulcerations, especially for
people with diabetes.
Preventive foot care strategies for patients at risk
of developing foot complications is essential for
Recommendation 20. Indications for evaluation
for critical limb ischemia
 All patients with ischemic rest pain symptoms
or pedal ulcers should be evaluated for CLI [B].limb preservation. These strategies include patient
education and appropriate management of high-risk
patients. Patients should be educated on the impor-
tance of self-care of the feet, including proper foot
care and footwear assessment. Early detection of foot
problems and early intervention may decrease the fre-
quency and severity of lower extremity complications.
Soft, conforming rather than correctional orthotics are
valuable. Therefore, patients (or their family if their
vision is impaired) should be performing daily foot
inspections at home.
D7 Treatment of Critical Limb Ischemia
D7.1 Overall strategy (Fig. D4)
The primary goals of the treatment of CLI are to relieve
ischemic pain, heal (neuro)ischemic ulcers, prevent
limb loss, improve patient function and quality of
life and prolong survival. A primary outcome would
be amputation-free survival. In order to achieve these
outcomes, most patients will ultimately need a revas-
cularization procedure requiring referral to a vascular
specialist. Other components of treatment of patients
with CLI are medical interventions to control pain
and infection in the ischemic leg, prevention of
progression of the systemic atherosclerosis, and
optimization of cardiac and respiratory function. For
some CLI patients with severe co-morbidities or
a very limited chance of successful revascularization,
a primary amputation may be the most appropriate
treatment. Cardiovascular risk factor control is man-
datory in CLI patients as well as in all PAD patients
(see section B).
D7.2 Basic treatment: pain control
Pain management is essential in improving function
and quality of life. The hallmark of CLI is ischemic
rest pain and painful ulceration. Pain is usually
located to skin and possibly bone structures. Pain
Recommendation 21. Importance of early identi-
fication of peripheral arterial disease (PAD)
 Early identification of patients with PAD at risk
of developing foot problems is essential for
limb preservation [C]. This can be achieved
by daily visual examination by the patient or
their family and, at every visit, referral to the
foot specialist.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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revascularization; revascularization not technically possible; benefit cannot be expected (i.e. widespread ulceration-
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tomographic angiography.control is a critical aspect of the management of these
patients. Ideally, relief of pain is achieved by reperfu-
sion of the extremity. However, while planning the re-
vascularization, adequate pain control must be a goal
of management in all patients. Furthermore, in pa-
tients for whom revascularization is not an option,
narcotic pain relief is commonly needed.
Physicians should assess pain severity and ade-
quacy of pain relief in all patients at regular visits.
Initial attempts at pain relief should include the use
of acetaminophen/paracetamol or nonsteroidal anti-
inflammatory medications, although the latter are
rarely effective and narcotic medications are fre-
quently required. Caution should be used in the
latter in patients with hypertension, or renal insuffi-
ciency. Control of pain is usually more effective if
analgesia is given regularly rather than on demand.
Placing the affected limb in the dependent position
provides partial relief of ischemic pain in some
patients. Therefore, tilting the bed downward may
be a helpful measure in addition to analgesia.
Patients with CLI are often depressed and pain con-
trol can be improved by use of antidepressant
medications.
Recommendation 22. Early referral in critical
limb ischemia (CLI)
 Patients with CLI should be referred to a vascu-
lar specialist early in the course of their disease
to plan for revascularization options [C].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007D7.3 Revascularization
Thenatural history ofCLI is such that intervention is in-
dicated to salvage a useful and pain-free extremity. The
treatment chosen depends upon the pre-morbid
condition of the patient and the extremity as well as
estimating the risk of intervention based on co-morbid
conditions and the expected patency and durability
of the reconstruction. In CLI, multi-level disease is
frequently encountered. Adequate inflow must be
established prior to improvement in the outflow.
After revascularization, ulcer healing may require
adjunctive treatments that may be best achieved in
collaboration between the vascular specialist and
specialists in foot care.
(See also section F.)
D7.4 Management of ulcers
The management of the patient with CLI and foot
ulcers illustrates the need for a multidisciplinary
approach to the treatment of CLI patients. These
patients should be treated according to the follow-
ing principles.
Recommendation 23.Multidisciplinary approach
to treatment of critical limb ischemia
 Amultidisciplinary approach is optimal to con-
trol pain, cardiovascular risk factors and other
co-morbid disease [C].
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The successful treatment of a foot ulcer rests with
the possibility of increasing the perfusion to the foot.
The determination of whether or not a revasculariza-
tion procedure is possible will set the tone for the en-
suing treatment. A revascularization procedure
should be considered if clear signs of CLI are present
or if healing does not occur in a neuro-ischemic ulcer
despite optimal off-loading, treatment of infection, if
present, and intensive wound care. After revasculari-
zation, local wound care and possibly foot salvage
procedures must be considered.
Local ulcer care and pressure relief
Prior to a revascularization procedure the ulcer can
be treated with a non-adherent gauze and should be
off-loaded if there is an increase in pressure or shear
stress. Off-loading can be achieved by several methods
including shoe modifications, orthotics and casting
techniques,16,131,132 depending on the localization of
the ulcer and the severity of the ischemia. Once perfu-
sion is improved, adequate off-loading becomes more
important as the increase in blood flow may not com-
pensate for the repetitive tissue trauma due to poorly
fitted shoes. The local treatment of a revascularized
foot ulcer can be carried out in many fashions and
a multitude of products exist. An in-depth discussion
of each ulcer care product is beyond the scope of this
work but the basic principles of wound care should
be adhered to. These principles include: removing
necrotic/fibrotic tissue from the ulcer, keeping a moist
wound environment and eliminating infection, as
discussed below.
Treatment of infection
Local infection is a severe complication of a neuro-
ischemic ulcer, as it tends to run a more severe course
and should be treated urgently. Signs of systemic tox-
icity, such as fever or elevated C-reactive protein, are
uncommon. The infection should be identified as
early as possible and its level of involvement assessed
and aggressively treated. Severe foot infections in di-
abetic patients are usually polymicrobial with gram
positive cocci, gram negative rods and anaerobic or-
ganisms.133 Once the clinical diagnosis of an infection
is made and cultures of the wound obtained, empiric
antibiotic treatment should be initiated immediately.
Broad spectrum antibiotic therapy can be adjusted
once the causative micro-organisms are determined
and results of the culture sensitivity have been
obtained. A growing concern is the rise in the inci-
dence of multidrug-resistant Staphylococcus aureus,
which is up to 30% in some studies.134 Management
of a deep infection usually also includes drainage
and debridement of necrotic tissue. Antibiotic therapy
is believed to be important in the prevention offurther spreading of infection in patients with CLI.
Once the acute infection is under control, a revascular-
ization procedure can be performed in a second stage.
Salvage procedures
Limb salvage after revascularization is defined as
preservation of some or all of the foot. An attempt at
a foot salvage procedure should take place after a
revascularization procedure has been performed if
possible. A waiting period of at least 3 days has been
suggested, this allows for sufficient time for the resto-
ration of perfusion and for demarcation to occur.
The level of adequate circulation, extent of infec-
tion, if any and remaining function of the foot are fac-
tors considered when choosing the level of a foot
salvage procedure. Foot salvage procedures can be di-
vided into two categories. The first category involves
amputation of some part of the foot. Table D4 shows
the different levels of local foot amputations.
The natural history of a minor foot amputation
should be considered when choosing the appropriate
level of amputation in order to account for the sub-
sequent changes in mechanical force and pressure
on the foot. For example, a hallux or partial first
ray amputation increases the resultant vector of
force on the second ray (through metatarsal shaft).
This increase in force traversing through the second
ray can cause a contracture of the second toe, lead-
ing to an increased pressure at both the sub
Table D4. Different levels of local foot amputations
Digit (partial or total)
Ray (digit and metatarsal)
Midfoot (transmetatarsal; tarso-metatarsal; transverse tarsal)
Symes (ankle)
Recommendation 24. Optimal treatment for
patients with critical limb ischemia (CLI)
 Revascularization is the optimal treatment for
patients with CLI [B].
Recommendation 25. Treatment for infections in
critical limb ischemia (CLI)
 Systemic antibiotic therapy is required in CLI
patients who develop cellulitis or spreading
infection [B].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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These changes in pressure require appropriate shoe
and insole modifications to avoid foot complications.
A high percentage of patients with a great toe
and/or first ray amputation go on to have a second
amputation either on the same foot or the contra-
lateral foot.
Amputation of the lateral toes and rays (fourth and
fifth digits) does not cause the same increase in me-
chanical force and pressure on the adjacent digits as
described above. Hence, the considerations of shoe
wear and inner sole modifications are different with
this scenario.
When multiple medial rays are involved or the is-
chemia is proximal to the metatarsal heads, but distal
to the tarso-metatarsal joint, a mid foot amputation
should be considered. A transmetatarsal amputation
provides a stump adequate for walking with minimal
shoe and innersole modifications.
The second category of foot salvage involves the
debridement of the wounds, including excision of
bone. These procedures permit the foot to keep its
general outward appearance intact, while disturbing
the internal architecture that is causing the increased
pressure. Foot salvage procedures, short of amputa-
tion, that can be used in the revascularized foot
include exostectomy, arthroplasty, metatarsal head
excision and calcanectomy.
Diabetes control and treatment of co-morbidity
As in all patients with diabetes, those with concom-
itant CLI should have optimization of glycemic con-
trol. Diabetic patients with a neuro-ischemic foot
ulcer frequently have a poor health status. Factors
that can negatively affect wound healing such as
cardiac failure or poor nutritional status should be
evaluated and treated appropriately.
D7.5 Amputation
Major amputation (above the ankle) in CLI is neces-
sary and indicated when there is overwhelming infec-
tion that threatens the patient’s life, when rest pain
cannot be controlled, or when extensive necrosis has
destroyed the foot. Using these criteria, the number
of major limb amputations should be limited.
Recommendation 26. Multidisciplinary care in
critical limb ischemia (CLI)
 Patients with CLI who develop foot ulceration
require multidisciplinary care to avoid limb
loss [C].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007Primary amputation is defined as amputation of
the ischemic lower extremity without an antecedent
attempt at revascularization. Amputation is consid-
ered as primary therapy for lower limb ischemia
only in selected cases. Unreconstructable arterial dis-
ease is generally due to the progressive nature of the
underlying atherosclerotic occlusive disease.
Revascularization of the lower extremity remains the
treatment of choice for most patients with significant
arterial occlusive disease.
Unreconstructable vascular disease has become the
most common indication for secondary amputation,
accounting for nearly 60% of patients. Secondary am-
putation is indicated when vascular intervention is no
longer possible or when the limb continues to deteri-
orate despite the presence of a patent reconstruction.
Persistent infection despite aggressive vascular
reconstruction is the second most common diagnosis.
Many amputations can be prevented and limbs pre-
served through a multi-armed, limb-salvage treatment
of ischemic necrosis with antibiotics, revascularization
and staged wound closure that may necessitate the use
of microvascular muscle flaps to cover major tissue
defects. On the other hand, and very importantly,
amputation may offer an expedient return to a useful
quality of life, especially if a prolonged course of treat-
ment is anticipated with little likelihood of healing.
Non-ambulatory elderly patients with CLI represent
a particularly challenging group. These patients fre-
quently have flexion contractures that form from the
prolonged withdrawal response to the pain. Aggres-
sive vascular reconstruction does not provide these
patients with a stable and useful limb, and primary
amputation is a reasonable option.135 Therefore, the
important issue is to identify a subgroupofCLI patients
better served by an amputation than attempts of
revascularization. Technical aspects, foot wound
healing issues and co-morbidities of the patients
should be considered.
It is the implicit goal of amputation to obtain pri-
mary healing of the lower extremity at the most
distal level possible. The energy expenditure of am-
bulation increases as the level of amputation rises
from calf to thigh. Preservation of the knee joint
and a significant length of the tibia permits the use
of lightweight prostheses, minimizes the energy of
ambulation, and enables older or more frail patients
to walk independently.136 Therefore, the lowest
level of amputation that will heal is the ideal site
for limb transection.
Clinical determination of the amputation level
results in uninterrupted primary healing of the
below-knee stump in around 80% and the above-knee
stump in around 90% of cases.137 Measurement of tcPO2
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to predict healing at various levels of amputation.138
Figures from specialized centers are better than the
global figures shown in Fig. A6.Amputations have var-
iable outcome andmore risk with higher proximal am-
putations. Ambulatory status of patients after
amputation is shown in Table D5.
A major amputation that is above the foot will re-
quire a prosthesis. Meticulous technique is essential
to ensure a well-formed and well-perfused stump
with soft tissue covering the transected end of the
bone. Major amputations are usually performed at
the below-knee (preferred) or above-knee level de-
pending on the level of arterial occlusion and tissue
ischemia. A return to independent ambulation is the
ultimate challenge for patients undergoing major
amputation of the lower extremity. Patients with
a well-healed below-knee amputation stump
have a greater likelihood of independent ambulation
with a prosthesis than those with an above-knee
amputation, who have a less than 50% chance of
independent ambulation.
D7.6 Pharmacotherapy for critical limb ischemia
When open or endovascular intervention is not tech-
nically possible or has failed, the question arises as
to whether pharmacological treatment is an option.
The consequences of the severely reduced perfusion
pressure on the distal microcirculation have to be
overcome. Pharmacotherapy, or any other treatment
Recommendation 27. Amputation decisions in
critical limb ischemia (CLI)
 The decision to amputate and the choice of the
level should take into consideration the poten-
tial for healing, rehabilitation and return of
quality of life [C].that produces modest improvements in circulation,
is more likely to be successful in patients who were
asymptomatic before developing their foot lesion
and in those with shallow foot lesions where the level
of ischemia is close to the margin (i.e. those with
borderline perfusion pressures).
D7.6.1 Prostanoids
Prostanoids prevent platelet and leukocyte activation
and protect the vascular endothelium, which could
play a role in the management of CLI. These drugs
are administered parenterally over several weeks.
Side effects include flushing, headache, and hypoten-
sion of a transient nature. Nine double-blind random-
ized trials on prostanoid treatment have been
published.146e154 Three PGE1 studies showed a benefit
on reducing ulcer size, but these studies did not show
favorable outcomes on other critical clinical end-
points. Six studies of the stable PGI2 analog, iloprost,
were performed, not all of which were positive. A
meta-analysis of the data demonstrated that patients
on active treatment had a greater chance (55% vs.
35%) to survive and keep both legs during the
follow-up period. In clinical practice, iloprost seems
to be of benefit to about 40% of patients in whom
revascularization is not possible. In a recent trial of
lipo-ecraprost versus placebo, this prostanoid failed
to reduce death and amputation during 6 months fol-
low-up.155 Prediction of response is, however, difficult
and prostanoids are rarely used due to these facts.
D7.6.2 Vasodilators
Direct-acting vasodilators are of no value, as they will
primarily increase blood flow to non-ischemic areas.
D7.6.3 Antiplatelet drugs
Although long-term treatment with aspirin/ASA and
ticlopidine may reduce progression of femoral athero-
sclerosis and exert a beneficial effect on the patency of-
peripheral by-passes (Cochrane review156) there is no
evidence that these drugs would improve outcomesTable D5. Ambulatory status 6e12 months following amputation
Author (year) N Percentage fitted
with a prosthesis
Percentage*
Ambulatory
Comments
Ruckley (1991)139 191 80% 74% Randomized trial
Siriwardena (1991)140 267 e 63% US VAMC Data
Hagberg (1992)141 24 100% 96%
Houghton (1992)142 193 e 16% 20% LFU
Stirnemann (1992)143 126 70% 70% Primary versus Failed bypass
McWhinnie (1994)144 61 66% 52%
Nehler (2003)145 94 e 39% 11% LFU
*Time intervals are 6e12 months postoperatively from below-knee amputation (BKA). Modest ambulatory results are due to 1) mortality
prior to rehabilitation; 2) failure to heal BKA; 3) failure to complete rehabilitation program.
LFU e lost to follow up; VAMC e Veterans Affairs Medical Center.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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let drugs do reduce the risk of systemic vascular events.
D7.6.4 Anticoagulants
Unfractionated heparin is frequently used as prophy-
laxis and as adjuvant treatment to vascular surgical
procedures, but has not been tried for symptoms of
CLI. Two studies have looked at low molecular weight
heparin (LMWH) in CLI patients with ulcers. These
were negative trials. Vitamin K antagonists have not
been tried for the treatment of symptoms of CLI.
Defibrinating agents have not been shown to im-
provehealingof ischemiculcers or to reduce thenumber
of amputations.
D7.6.5 Vasoactive drugs
A Cochrane review157 evaluated eight trials on intra-
venous naftidrofuryl for CLI. The drug was not effec-
tive in reducing the symptoms of CLI. Pentoxifylline
was evaluated in two placebo controlled studies in
patients with CLI, with inconclusive results.158,159
D7.7 Other treatments
D7.7.1 Hyperbaric oxygen
A Cochrane review160 concluded that hyperbaric ther-
apy significantly reduced the risk of major amputation
in patients with diabetic ulcers. However, the results
should be interpreted with caution because of method-
ological shortcomings. Other pathologies related to
PAD and diabetes were not evaluated using this kind
of treatment. Therefore, given the absence of proven
benefit and high cost, this therapy is not generally rec-
ommended. Nonetheless, hyperbaric oxygen may be
considered in selected patients with ischemic ulcers
who have not responded to, or are not candidates
for, revascularization.
D7.7.2 Spinal cord stimulation
A Cochrane review161 of six studies including patients
with CLI concluded that spinal cord stimulation was
Recommendation 28. Use of prostanoids in criti-
cal limb ischemia (CLI)
 Previous studies with prostanoids in CLI sug-
gested improved healing of ischemic ulcers
and reduction in amputations [A].
 However, recent trials do not support the ben-
efit of prostanoids in promoting amputation-
free survival [A].
 There are no other pharmacotherapies that can
be recommended for the treatment of CLI [B].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007significantly better than conservative treatment in im-
proving limb salvage in patients without any option
to vascular reconstruction.
D8 Health Economics
Studies published on the cost of treating CLI present
data on surgical revascularization, percutaneous
transluminal angioplasty and stenting and primary
amputation.162e166
Whatever the treatment considered, the costs are
multiplied by a factor 2 to 4 when the procedure ini-
tially planned has failed, for example angioplasty
requiring immediate or delayed crossover grafting,
bypass requiring revision after thrombosis or second-
ary amputation, and when renal and pulmonary co-
morbidities or complications are present. Results are
consistent across countries, although individual costs
of procedures vary. The order of magnitude for the
cost of PTA is $10,000 ($20,000 if the procedure fails
initially or later), the cost for bypass grafting is
$20,000 ($40,000 if revision is required), the cost for
amputation is $40,000. Adding rehabilitation will
usually double the costs.
D9 Future Aspects of Treatment of Critical
Limb Ischemia
The most striking feature of CLI is the dismal progno-
sis for both life and limb outcomes no matter what
treatment is employed. This is because most patients
have generalized atherosclerosis. One may, therefore,
consider what magnitude of treatment options is real-
istic for the single patient. A successful revasculariza-
tion may reduce pain and improve quality of life for
a limited period of time, but frequently this goal is
not achieved. Amputation may be a good alternative
to reduce pain, though amputees may have an even
more reduced life expectancy. Medical treatment
that favorably modifies cardiovascular risk is recom-
mended for all patients, while symptomatic treatment
of the limb has to be individualized.
Preliminary trials of intramuscular gene transfer
utilizing naked plasmid DNA encoding phVEGF165
have given promising results on symptoms of CLI167
while others have been negative. Several trials are us-
ing viral vectors to increase gene transfer efficiency.
Besides vascular endothelial growth factor (VEGF),
fibroblast growth factor, angiopoietin and other growth
factors are under investigation.168 Preliminary trials of
intramuscular injection of autologous bone-marrow
mononuclear cells to stimulate vascular growth169
have been promising. Most trials are in Phase I or II
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practice remains to be proven.
In conclusion, there is low-level evidence for spinal
cord stimulation to improve outcome of patients with
CLI, should revascularization not be possible. Prosta-
noid treatment may also be of value; however, only
a limited proportion of patients will respond to this
treatment, as mentioned. Results of other pharmaco-
therapies are far from good.170,171 Gene therapy has
shown promising early efficacy but further trials
are warranted.
SECTION E e ACUTE LIMB ISCHEMIA
E1 Definition and Nomenclature for
Acute Limb Ischemia
E1.1 Definition/etiology of acute limb ischemia
Acute limb ischemia (ALI) is any sudden decrease in
limb perfusion causing a potential threat to limb via-
bility. Presentation is normally up to 2 weeks follow-
ing the acute event. Fig. E1 shows the frequency of
different etiologies for ALI.
Timing of presentation is related to severity of
ischemia and access to healthcare. Patients with em-
bolism, trauma, peripheral aneurysms with emboli
and reconstruction occlusions tend to present early
(hours) due to lack of collaterals, extension of throm-
bus to arterial outflow, or a combination of both. On
the other hand, later presentations e within days e
tend to be restricted to those with a native thrombosis
or reconstruction occlusions (Fig. E2).
E2 Evaluation
E2.1 Clinical evaluation of acute limb ischemia
E2.1.1 History
The history should have two primary aims: querying
leg symptoms relative to the presence and severity of
limb ischemia (present illness) and obtaining back-
ground information (e.g. history of claudication, recentintervention on the proximal arteries or diagnostic
cardiac catheterization), pertaining to etiology, differ-
ential diagnosis and the presence of significant con-
current disease.
Present illness
Leg symptoms in ALI relate primarily to pain or
function. The abruptness and time of onset of the
pain, its location and intensity, as well as change in
severity over time, should all be explored. The
duration and intensity of the pain and presence of
motor or sensory changes are very important in clini-
cal decision-making and urgency of revascularization.
For example, thrombolysis may be less effective for
thrombosis of >2 weeks duration compared with
more acute thrombosis (post hoc analysis of the
STILE data174).
Past history
It is important to ask whether the patient has had
leg pain before (e.g. a history of claudication),
whether there have been interventions for ‘poor circu-
lation’ in the past, and whether the patient has been
diagnosed as having heart disease (e.g. atrial fibrilla-
tion) or aneurysms (i.e. possible embolic sources). The
patient should also be asked about serious concurrent
disease or atherosclerotic risk factors (hypertension,
diabetes, tobacco abuse, hyperlipidemia, family
history of cardiovascular disease, strokes, blood clots
or amputations). A more complete discussion of risk
factors can be found in section A.
E2.1.2 Physical examination
The findings of ALI may include ‘‘5 P’s’’:
 Pain: time of onset, location and intensity, change
over time
 Pulselessness: the accuracy of pedal pulse palpation
is highly variable and, therefore, absent pulse find-
ings are suggestive but not diagnostic of ALI and
palpable pulses alone do not rule it out. Bedside
measurement of ankle blood pressure should be
performed immediately (technique see section C).
Usually, very lowpressure is obtained or theDoppler
signal may be absent. If performed correctly, theFig. E1. Etiology of acute limb ischemia. (Summarizes Berridge et al. 2002 and Campbell et al. 1998172,173).Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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highly consistent with a diagnosis of ALI
 Pallor: change in color and temperature is a com-
mon finding in ALI (although temperature may be
subject to environmental conditions); the finding is
most important when different from the contralat-
eral limb. Venous filling may be slow or absent
 Paresthesia: numbness occurs in more than half of
patients
 Paralysis: is a poor prognostic sign.
Recommendation 29. Assessment of acute limb
ischemia (ALI)
 Due to inaccuracy of pulse palpation and the
physical examination, all patients with sus-
pected ALI should have Doppler assessment
of peripheral pulses immediately at presenta-
tion to determine if a flow signal is present [C].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007E2.1.3 Clinical classification of acute limb ischemia
The main question to be answered by the history and
physical examination is the severity of the ALI, which
is the major consideration in early management deci-
sions. Is the limb viable (if there is no further progres-
sion in the severity of ischemia), is its viability
immediately threatened (if perfusion is not restored
quickly), or are there already irreversible changes
that preclude foot salvage?
The three findings that help separate ‘threatened’
from ‘viable’ extremities (Table E1) are:
 Presence of rest pain,
 Sensory loss, or
 Muscle weakness
Muscle rigor, tenderness, or findings of pain with
passive movement are late signs of advanced ischemia
and probable tissue loss.Table E1. Separation of threatened from viable extremities175
Category Description/prognosis Findings Doppler signalsy
Sensory loss Muscle weakness Arterial Venous
I. Viable Not immediately threatened None None Audible Audible
II. Threatened
a. Marginal Salvageable if promptly
treated
Minimal (toes) or none None (Often) inaudible Audible
b. Immediate Salvageable with immediate
revascularization
More than toes, associated
with rest pain
Mild, moderate (Usually) inaudible Audible
III. Irreversible Major tissue loss or
permanent nerve damage
inevitable
Profound, anesthetic Profound,
paralysis (rigor)
Inaudible Inaudible
yObtaining an ankle pressure is very important. However, in severe ALI, blood flow velocity in the affected arteries may be so low that
Doppler signals are absent (see section C for technical description of method). Differentiating between arterial and venous flow signals
is vital: arterial flow signals will have a rhythmic sound (synchronous with cardiac rhythm) whereas venous signals are more constant
and may be affected by respiratory movements or be augmented by distal compression (caution needs to be taken not to compress the ves-
sels with the transducer). Reproduced with permission from Rutherford RB et al. J Vasc Surg 1997;26(3):517e538.
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cal trial data and show the frequency of different cat-
egories of acute limb ischemia on presentation
(Fig. E3).
 Category III: all patients from registries who un-
dergo primary amputation
 Category II: all patients from randomized trials who
present with sensory loss
 Category I: all patients from randomized trials who
present without sensory loss
E2.1.4 Differential diagnosis of acute limb ischemia
There are three levels of differential diagnosis in ALI:
1. Is there a condition mimicking arterial occlusion?
2. Are there other non-atherosclerotic causes of arte-
rial occlusion present and, if not,
3. Is the ischemia caused by an arterial thrombosis or
embolus?
The conditions that can cause or mimic acute
arterial occlusion are listed in Table E2.
Arterial trauma or dissection
Overt arterial trauma is not difficult to diagnose,
but iatrogenic trauma, especially as a result of recent
arterial catheterization, is often overlooked. It should
be considered in all hospitalized patients undergoing
invasive diagnosis and treatment who present with
femoral artery occlusion.
Recommendation 30. Cases of suspected acute
limb ischemia (ALI)
 All patients with suspected ALI should be eval-
uated immediately by a vascular specialist who
should direct immediate decision making and
perform revascularization because irreversible
nerve and muscle damage may occur within
hours [C].Thoracic aortic dissections may progress distally to
involve the abdominal aorta and also an iliac artery.
Tearing interscapular or back pain associated with hy-
pertension would obviously point to such a thoracic
aortic dissection, but these may be obscured by other
events and the patient’s inability to give a good his-
tory. It should be considered when faced with acute
unilateral or bilateral iliac occlusion.
Ergotism
Ergotism is rare. It may affect almost any artery
and may progress to thrombosis but rarely presents
as an immediately threatened limb.
HIV arteriopathy
HIV patients with severe immune compromise and
CD4 counts less than 250/cm3 can develop acute
ischemia of upper or lower extremities. This entity
involves the distal arteries with an acute and chronic
cellular infiltrate in the vasa vasorum and viral protein
in the lymphocytes. Occasionally, a hypercoaguable
focus is found, but primarily the occlusion appears
due to theunderlyingvasculopathy. Standard therapies
including thrombectomy, bypass and thrombolysis
have been used, with relatively high reocclusion and
amputation rates.
Popliteal adventitial cysts and popliteal entrapment
Popliteal adventitial cysts and popliteal entrap-
ment may be discovered before they induce throm-
bosis if they cause claudication, but they sometimes
first present with thrombosis. Like a thrombosed
popliteal aneurysm, the degree of ischemia is often
severe. Popliteal entrapment affects younger pa-
tients, but popliteal adventitial cysts can present at
an older age and may be indistinguishable from
peripheral arterial disease (PAD). The absence of ath-
erosclerotic risk factors and the location of the
obstruction, best ascertained by duplex scan, should
suggest the etiology.
Thrombosed popliteal artery aneurysm
Thrombosed popliteal artery aneurysms are com-
monlymistaken for acute arterial embolism. The popli-
teal artery is the sole axial artery traversing the knee.
Severe ischemia results either because thrombosisFig. E3. Categories of acute limb ischemia on presentation. *Some of these patients are moribund. In some series this group
is up to 15%.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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and the lack of collateral vessels or because prior
asymptomatic or symptomatic embolization has oc-
cluded the majority of the tibial outflow. As popliteal
aneurysms are bilateral in approximately 50% of cases,
detecting a prominent popliteal pulse in the opposite
leg may help to identify the cause. These patients also
tend to have dilated femoral arteries and may have
abdominal aortic aneurysms. Once suspected, duplex
ultrasound is thequickestway to confirm thediagnosis.
Thromboembolism
Arterial embolism is suspected in patients with
atrial arrhythmia (flutter/fibrillation), congestive heart
failure, or valvular heart disease. A rare cause can
be paradoxical embolization in a patient with venous
thromboembolism and a cardiac septal defect. The
contralateral limb is often normal. Patients usually do
not have any antecedent claudication symptoms.
Arteriographic findings include multiple areas with
arterial filling defects (particularly at bifurcations),
morphology (meniscus sign) consistent with embolus,
lack of collaterals and absence of atherosclerotic
disease in unaffected segments. Echocardiography
(often transesophageal) is useful to locate the source
of thromboemboli.
Table E2. Differential diagnosis of acute limb ischemia
* Conditions mimicking acute limb ischemia
- Systemic shock (especially if associated with chronic
occlusive disease)
- Phlegmasia cerulea dolens
- Acute compressive neuropathy
Differential diagnosis for acute limb ischemia (other than
acute PAD)
- Arterial trauma
- Aortic/arterial dissection
- Arteritis with thrombosis (e.g. giant cell arteritis,
thromboangiitis obliterans)
- HIV arteriopathy
- Spontaneous thrombosis associated with a hypercoagulable
state
- Popliteal adventitial cyst with thrombosis
- Popliteal entrapment with thrombosis
- Vasospasm with thrombosis (e.g. ergotism)
- Compartment syndrome
Acute PAD
- Thrombosis of an atherosclerotic stenosed artery
- Thrombosis of an arterial bypass graft
- Embolism from heart, aneurysm, plaque or critical stenosis
upstream (including cholesterol or atherothrombotic emboli
secondary to endovascular procedures)
- Thrombosed aneurysm with or without embolization
*Two of the three conditions (deep vein thrombosis, neuropathy)
that may mimic arterial occlusion should be expected to have arte-
rial pulses, except if occult chronic peripheral arterial disease
existed prior to the acute event. Low cardiac output makes the
chronic arterial ischemia more manifest in terms of symptoms
and physical findings.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007Atheroembolism
Embolism of cholesterol crystals and other debris
from friable atherosclerotic plaques in proximal ar-
teries may lodge in the distal circulation and infarct
tissue. Although also called ‘‘blue toe syndrome’’ for
the appearance of painful cyanotic lesions on the
toes of affected patients, more proximal organs such
as the kidneys, bowel and pancreas may also be
affected by atheroemboli.
Thrombosed arterial segment
Patients with thrombosed arterial segments often
have atherosclerotic disease at the site of thrombosis.
They may have an antecedent history of claudication
and the contralateral limb often has abnormal circula-
tion. Some hypercoagulable states, such as antiphos-
pholipid antibody syndrome or heparin-induced
thrombocytopenia can also cause thrombosis in situ,
and these should be considered in patients without
other overt risk factors for arterial disease.
Thrombosed arterial bypass graft
Patients with thrombosed arterial bypass grafts
have a prior history of vascular disease, limb incisions
from previous surgery and a thrombosed graft that
can be visualized on duplex imaging.
Compartment syndrome
See section E3.7.1.
E2.2 Investigations for acute limb ischemia
Patients with ALI should be evaluated in the same
fashion as those with chronic symptoms (see section
G) but the severity and duration of ischemia at the
time of presentation rarely allow this to be done at
the outset. Ideally, all patients with acute ischemia
should be investigated with imaging, however, the
clinical condition and access to appropriate medical
resources may preclude such investigations.
E2.2.1 Other routine laboratory studies
The following laboratory studies should be obtained
in patients with ALI: electrocardiogram, standard
chemistry, complete blood count, prothrombin time,
partial thromboplastin time and creatinine phosphoki-
nase level. Patients with a suspected hypercoagulable
state will need additional studies seeking anticardioli-
pin antibodies, elevated homocysteine concentration
and antibody to platelet factor IV.
E2.2.2 Imaging e arteriography
Arteriography is of major value in localizing an ob-
struction and visualizing the distal arterial tree. It
also assists in distinguishing patients who will
S49TASC II Inter-Society Consensus on Peripheral Arterial Diseasebenefit more from percutaneous treatment than from
embolectomy or open revascularization procedures.
In limb-threatening ischemia, an important consider-
ation is whether the delay in performing formal angio-
graphy in an angiographic suite can be tolerated.
Angiographymakes themost sensewhencatheter-based
treatment is an option.
E2.2.3 Other imaging techniques
Computed tomographic angiography/Magnetic
resonance angiography
Computed tomographic angiography (CTA) and
magnetic resonance (MR) angiography may also be
used in the setting of ALI to diagnose and delineate
the extent of disease. MR imaging of the vasculature
can be cumbersome and time-consuming which may
delay treatment. The advantages of CTA include its
speed, convenience and ability for cross-sectional im-
aging of the vessel. The main disadvantage of CTA is
its dependence on iodinated contrast media. In
patients with ALI who may also require catheter angi-
ography and intervention, this added load of contrast
might increase the risk of renal injury to the patient.
Recommendation 31. Anticoagulant therapy in
acute limb ischemia (ALI)
 Immediate parenteral anticoagulant therapy is
indicated in all patients with ALI. In patients
expected to undergo imminent imaging/
therapy on arrival, heparin should be given [C].E3 Treatment of Acute Limb Ischemia
The initial goal of treatment forALI is to prevent throm-
bus propagation and worsening ischemia. Therefore,
immediate anticoagulation with heparin is indicated.
The standard therapy (except in cases of heparin anti-
bodies) is unfractionated heparin intravenously
(Fig. E4). Based on the results of randomized trials,172
there is no clear superiority for thrombolysis versus
surgery on 30 day limb salvage or mortality. Access to
each is a major issue, as time is often critical. National
registry data from Europe176 and the United States177
indicate that surgery is used three- to five-fold more
frequently than thrombolysis.
E3.1 Endovascular procedures for acute limb ischemia
E3.1.1 Pharmacologic thrombolysis
Three randomized studies have confirmed the impor-
tant role of catheter-directed thrombolytic therapy
in the treatment of ALI.174,178,179 The less invasive
nature of a catheter-based approach to this patient
population can result in reduced mortality and mor-
bidity compared with open surgery. Thrombolytic
therapy is, therefore, the initial treatment of choice
in patients in whom the degree of severity allows
time (i.e. severity levels I and IIa). More recent ad-
vances in endovascular devices and techniques, how-
ever, allow for more rapid clot removal and may
permit treatment of patients with more advanced
degree of ischemia. Advantages of thrombolytic ther-
apy over balloon embolectomy include the reduced
risk of endothelial trauma and clot lysis in branch
vessels too small for embolectomy balloons. GradualFig. E4. Algorithm for management of acute limb ischemia. Category I e Viable Category IIA e Marginally Threatened
Category IIB e Immediately Threatened; a Confirming either absent or severely diminished ankle pressure/signals;
*In some centers imaging would be performed.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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the sudden, high-pressure reperfusion associated
with balloon embolectomy. Systemic thrombolysis
has no role in the treatment of patients with ALI.
The choice of lytic therapy depends onmany factors
such as location and anatomy of lesions, duration of
the occlusion, patient risk factors (co-morbidities)
and risks of procedure. Because emboli newly arrived
in the leg may have previously resided for some time
at their site of origin, these ‘old’ emboli may be more
resistant to pharmacological thrombolysis than ‘re-
cent’ in-situ thrombus. Contraindications to pharma-
cologic thrombolysis must be taken into consideration.
E3.1.2 Contraindications to thrombolysis
See Table E3
E3.1.3 Other endovascular techniques
When thrombolysis reveals underlying localized
arterial disease, catheter-based revascularization be-
comes an attractive option. Stenoses and occlusions
are rarely the sole cause of ALI or even severe chronic
symptoms but these commonly lead to superimposed
thrombosis and, therefore, should be treated to avoid
recurrent thrombosis.
Percutaneous aspiration thrombectomy (PAT) and
percutaneous mechanical thrombectomy (PMT) pro-
vide alternative non-surgical modalities for the treat-
ment of ALI without the use of pharmacologic
thrombolytic agents. Combination of these techniques
Table E3. Contraindications to thrombolysis
Absolute contraindications
1. Established cerebrovascular event (excluding TIAwithin previous
2 months)
2. Active bleeding diathesis
3. Recent gastrointestinal bleeding (within previous 10 days)
4. Neurosurgery (intracranial, spinal) within previous 3 months
5. Intracranial trauma within previous 3 months
Relative contraindications
1. Cardiopulmonary resuscitation within previous 10 days
2. Major nonvascular surgery or trauma within previous 10 days
3. Uncontrolled hypertension (systolic >180 mmHg or diastolic
>110 mmHg)
4. Puncture of noncompressible vessel
5. Intracranial tumor
6. Recent eye surgery
Minor contraindications
1. Hepatic failure, particularly those with coagulopathy
2. Bacterial endocarditis
3. Pregnancy
4. Active diabetic proliferative retinopathy
These contraindications were established for systemic thrombolysis.
The markedly improved safety profile of regional thrombolysis is
well recognized, and the risk benefit of regional thrombolysis in
various above conditions is highly dependent on individual physi-
cian practice/experience. The only contraindication in the TOPAS
trial was pregnancy.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007with pharmacologic thrombolysis may substantially
speed up clot lysis, which is important in more ad-
vanced ALI where time to revascularization is critical.
In practice, the combination is almost always used.
Percutaneous aspiration thrombectomy (PAT)
PAT is a technique that uses thin-wall, large-lumen
catheters and suction with a 50-mL syringe to remove
embolus or thrombus from native arteries, bypass
grafts and run-off vessels. It has been used together
with fibrinolysis to reduce time and dose of the
fibrinolytic agent or as a stand-alone procedure.
Percutaneous mechanical thrombectomy (PMT)
Most PMT devices operate on the basis of hydro-
dynamic recirculation. According to this concept, dis-
solution of the thrombus occurs within an area of
continuous mixing referred to as the ‘‘hydrodynamic
vortex.’’ This selectively traps, dissolves, and evacu-
ates the thrombus. Non-recirculation devices, which
function primarily by direct mechanical thrombus
fragmentation, have been used less frequently for pe-
ripheral arterial disease because of the higher risk of
peripheral embolization and higher potential for vas-
cular injury. The efficiency of PMT depends mainly on
the age of the thrombus; fresh thrombus responds
better than older organized clot. Small clinical series
have demonstrated short-term (30 day) limb salvage
of 80%e90%.
E3.2 Surgery
E3.2.1 Indications
Immediate revascularization is indicated for the pro-
foundly ischemic limb (class IIb) (Table E1). It may
also be considered in those with profound sensory
and motor deficits of very short duration, as revascu-
larization completed within a few hours of onset of
severe symptoms may produce remarkable recovery.
Beyond this short window, major neuromuscular
damage is inevitable. The method of revascularization
(open surgical or endovascular) may differ depending
on anatomic location of occlusion, etiology of
ALI, contraindications to open or endovascular treat-
ment and local practice patterns. Previously, urgency
of treatment made surgery the treatment of choice
in many cases. However, recent methodological
advances within endovascular management, and rec-
ognition that improved circulation significantly pre-
cedes patency with this approach, have made the
time factor less important if endovascular service is
readily available.
In considering operative versus percutaneous re-
vascularization, it must be recognized that the time
from the decision to operate until reperfusion may
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factors outside of the surgeons’ control (e.g. operating
theater availability, anesthesia preparation, technical
details of the operation).
Anatomic location of the acute occlusion
In cases of suprainguinal occlusion (no femoral
pulse) open surgery may be the preferred choice of
treatment. For instance, a large embolus in the com-
mon proximal iliac artery or distal aorta may most
effectively be treated with catheter embolectomy.
Also, suprainguinal graft occlusion may best be
treated with surgery in most cases. Endovascular
management with femoral access of a proximal lesion
(often involving thrombosis) may not be possible/
appropriate or available (see below).
Infrainguinal causes of ALI, such as embolism or
thrombosis, are often treated with endovascular
methods. Initial therapywith catheter-based thrombol-
ysis should be considered in cases of acute thrombosis
due to vulnerable atherosclerotic lesions or late bypass
graft failures. In this manner, the underlying occlusive
disease is revealed and appropriate adjunctive
management may be chosen.
In cases of trauma, for many reasons, surgery will
be the treatment of choice in the majority of cases.
Infrainguinal grafts often occlude due to obstructive
lesions proximal to, within and distal to the graft,
thus, simple thrombectomy will not solve the under-
lying lesion. Catheter-based thrombolysis, on the
other hand, will dissolve clot and identify the
responsible underlying lesion. Endovascular treatment
of these lesions may then be employed. If the lesion is
discrete this may suffice, and even if the underlying
disease is diffuse and extensive, it may serve as a
temporizing measure, a bridge to a later bypass.
E3.2.2 Surgical technique
Emboli are preferentially removed surgically if they
are lodged proximally in the limb or above the ingui-
nal ligament. Surgery may also be considered if the
involved limb has no underlying atherosclerosis.
When no further clot can be retrieved, some form of
intraoperative assessment of the adequacy of clot re-
moval is required. The most common of these is
‘completion’ angiography; alternatively, ultrasound-
based methods may be used.
Distal clot may be treated by intraoperative throm-
bolysis with instillation of high doses of thrombolytic
agents for a brief period followed by irrigation or addi-
tional passages of the balloon catheter. Repeat angio-
graphy followed by clinical and Doppler examination
of the patient should be performed on the operating
table. However, as described in section E3.2.1,catheter-directed thrombolysis may have advantages
if conditions allow its use.
In patients with arterial thrombosis, an underlying
local lesion and residual thrombus must be sought af-
ter clot extraction. Often this may be suspected from
the tactile sensations and need for deflation at points
during the withdrawal of the inflated balloon catheter.
Here completion angiography will help decide be-
tween proceeding with a bypass or PTA. Fortunately,
arterial thrombosis superimposed on an already nar-
rowed artery will ordinarily cause a less severe degree
of ischemia because of predeveloped collaterals. Un-
der these circumstances, patients may not be operated
on initially but rather undergo catheter-directed
lytic therapy.
In patients with suprainguinal occlusion extra-
anatomic bypass surgery may be required.
E3.3 Results of surgical and endovascular procedures
for acute limb ischemia
Catheter-directed thrombolysis (CDT) has become
a commonly employed technique in the treatment of
ALI. Between 1994 and 1996, three large, prospective,
randomized trials174,178,179 were reported that focused
on the comparison of CDT and surgical revasculariza-
tion for treatment of ALI. Limb salvage and mortality
rates are recognized as the most important outcome,
and the 1-year data are summarized in Table E4.172
Comparison of these studies is limited by certain
differences in protocol and case mix (e.g. acute vs.
subacute or chronic limb ischemia; thrombotic vs.
embolic occlusion; native vs. bypass graft occlusion;
proximal vs. distal occlusions). End points in each
of the studies also vary: the Rochester study used
‘‘event free survival’’; the STILE trial used ‘‘compos-
ite clinical outcome’’; and the TOPAS study used
‘‘arterial recanalization and extent of lysis.’’ Only
the Rochester trial showed any advantage for CDT
by primary end points. However, the late end point
of limb salvage, required in these trials, may have
favored surgery, as CDT was naturally linked with
endovascular treatment of the underlying lesions
(the patient being in a radiology suite at the time).
Recommendation 32. Completion arteriography
 Unless there is good evidence that adequate
circulation has been restored, intraoperative
angiography should be performed to identify
any residual occlusion or critical arterial lesions
requiring further treatment [C].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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Results at Catheter-Directed Thrombolysis (CDT) Surgical Revascularization
Patients Limb salvage Mortality Patients Limb salvage Mortality
Rochester178 12 months 57 82% 16% 57 82% 42%
STILE174 6 months 246 88.2% 6.5% 141 89.4% 8.5%
TOPAS179 12 months 144 82.7% 13.3% 54 81.1% 15.7%Except for discrete lesions, PTA is not as durable as
bypass, the inevitable result of being randomized to
surgery. Such linkage may be inevitable in
randomized trials, but in practice the underlying le-
sion(s) should be treated by the method giving the
most durable results.
The data from the randomized, prospective studies
in ALI, suggest that CDT may offer advantages when
compared with surgical revascularization. These ad-
vantages include reduced mortality rates and a less
complex surgical procedure in exchange for a higher
rate of failure to avoid persistent or recurrent ische-
mia, major complications and ultimate risk of ampu-
tation. In addition, it appears that reperfusion with
CDT is achieved at a lower pressure and may reduce
the risk of reperfusion injury compared to open
surgery. Thus, if the limb is not immediately or irrevers-
ibly threatened, CDT offers a lower-risk opportunity
for arterial revascularization. Using this approach, the
underlying lesions can be further defined by angiogra-
phy, and the appropriate percutaneous or surgical
revascularization procedure can be performed. There-
fore, it seems reasonable to recommend CDT as initial
therapy in these particular settings, to be potentially
followed by surgical revascularization as needed.
E3.4 Management of graft thrombosis
In general, at least one attempt to salvage a graft
should be done, although individual considerations
may apply. When treating late graft thrombosis, the
main goals are to remove the clot and correct the un-
derlying lesion that caused the thrombosis. Alteration
in the inflow and outflow arteries is usually caused
by the progression of atherosclerosis and should be
treated with either PTA/stent or bypass grafting, as
detailed elsewhere. Lesions intrinsic to the graft are
dependent on the type of conduit. Venous bypass
grafts may develop stenoses, typically at the site of
a valve. After thrombolysis and identification of the
lesion, it may be treated with either PTA/stent or
surgical revision, the latter usually being favored for
its superior long-term results. Prosthetic grafts de-
velop intimal hyperplasia, typically at the distalEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007anastomosis. These rubbery lesions respond differ-
ently to PTA than do the typical eccentric atheroscle-
rotic plaque and do not yield as durable results.
Many surgeons have suggested that treatment should
be exposure of the involved anastomosis, with graft
thrombectomy and patch angioplasty of the narrowed
graft/artery anastomosis or replacement of the graft.
However, in case of the latter, the expected patency
using another type of graft should be considered (i.e.
replacing a failing vein graft).
E3.5 Management of a thrombosed popliteal aneurysm
Patients with thrombosed popliteal artery aneurysms
initially undergo arteriography. If a distal tibial target
is present, then they are treated as a critical limb
ischemia case with tibial bypass. If no tibial targets
are identified on arteriography, regional thrombolysis
is the treatment of choice providing the limb is viable.
Small series demonstrate successful identification of
tibial targets in over 90% and successful surgical
revascularization.
E3.6 Amputation
Amputation in ALI may be complicated by bleeding
due to an increased prevalence of concomitant antico-
agulation. In addition, the site of amputation is more
often proximal, as the calf muscle is usually compro-
mised. The ratio of above-knee to below-knee ampu-
tation is 4:1 compared to the usual 1:1 for critical
limb ischemia. The incidence of major amputation is
up to 25%. When further evaluated, 10%e15% of pa-
tients thought to be salvageable undergo therapy
and ultimately require major amputation, and 10%
of patients with ALI present unsalvageable.
E3.7 Immediate post-procedural issues
E3.7.1 Reperfusion injury
Compartment syndrome
Fasciotomy following successful revascularization
for ALI was required in 5.3% of cases in the United
States from 1992e2000. Fasciotomy for presumably
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25%.177 With extremity reperfusion, there is increased
capillary permeability, resulting in local edema and
compartment hypertension. This leads to regional ve-
nule obstruction, nerve dysfunction and, eventually,
capillary and arteriolar obstruction and muscle and
nerve infarction. Clinical presentation includes pain
out of proportion to physical signs, paresthesia and
edema. Compartment pressures can be measured,
and pressures of 20 mmHg are a clear indication
for fasciotomy. The anterior compartment is most
commonly involved, but the deep posterior compart-
ment (in which the tibial nerve is located) is the most
functionally devastating if affected.
Rhabdomyolysis
Laboratory evidence for myoglobinuria is observed
in up to 20%. Half of patients with creatine kinase
levels >5000 units/L will develop acute renal failure.
Urine myoglobin >1142 nmol/L (>20 mg/dL) is also
predictive of acute renal failure. The pathophysiology
involves tubular necrosis by myoglobin precipitates
(favored in a acidic urine), tubular necrosis due to
lipid peroxidation and renal vasoconstriction (exacer-
bated by fluid shifts into the damage muscle compart-
ment). Clinical features include tea colored urine,
elevated serum creatine kinase and positive urine
myoglobin assay. Therapy is primarily hydration, al-
kalinizing the urine and eliminating the source of
myoglobin. Mannitol and plasmapheresis have not
been found to be beneficial.
E4 Clinical Outcomes
E4.1 Systemic/limb
Mortality rates for ALI range from 15%e20%. The
cause of death is not provided in most series and ran-
domized trials. Major morbidities include major
bleeding requiring transfusion/and or operative in-
tervention in 10%e15%, major amputation in up to
25%, fasciotomy in 5%e25% and renal insufficiency
Recommendation 33. Treatment of choice for
compartment syndrome
 In case of clinical suspicion of compartment
syndrome, the treatment of choice is a four-
compartment fasciotomy [C].in up to 20%. Functional outcomes have at present
not been studied.
Improvement in arterial circulation is relatively sim-
ple to assess in that the vast majority of patients with
ALI have no pedal Doppler signals at presentation
or they have an ankle-brachial index (ABI) 0.20.
Therefore, any improvement in these parameters
postoperatively is considered successful.
E4.2 Follow-up care
All patients should be treated with heparin in the im-
mediate postoperative period. This should be fol-
lowed by warfarin often for 3e6 months or longer.
Patients with thromboembolism will need long-term
anticoagulation, from years or life long. However,
there are no clear guidelines regarding duration of
therapy. The risk of recurrent limb ischemia in the
randomized trials was high during the follow-up
interval.174,178,179 Therefore, prolonged warfarin
therapy is an appropriate strategy, despite the cumu-
lative bleeding risk. It is important to seek the source
of embolism after revascularization, whether cardiac
or arterial; however, in many cases no source
is identified.
Certainly, if long-term anticoagulation is contrain-
dicated, due to bleeding risk factors, platelet inhibi-
tion therapy should be considered. Appropriate
systemic therapies as outlined above (see section B)
should be provided.
E5 Economic Aspects of Acute Limb Ischemia
The recent literature has added very little to the find-
ings presented in the first TASC document. When
thrombolysis is used in association with angioplasty,
the costs are identical to those of surgical revasculari-
zation at roughly $20,000. The relative benefits of
surgery have been discussed above. The choice of
strategy is based on availability and outcome rather
than on cost considerations.180
E6 Future Management
The increased use of percutaneous therapies with or
without surgical revascularization is the trend for fu-
ture therapy in ALI. The use of protection devices to
prevent embolization, as in the carotid circulation,
will also become part of therapy. Alternative oral
therapies for anticoagulation may hold promise.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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F1 Localization of Disease
The determination of the best method of revasculari-
zation for treatment of symptomatic peripheral arte-
rial disease (PAD) is based upon the balance
between risk of a specific intervention and the degree
and durability of the improvement that can be ex-
pected from this intervention. Adequate inflow and
appropriate outflow are required to keep the revascu-
larized segment functioning. The location and mor-
phology of the disease must be characterized prior
to carrying out any revascularization to determine
the most appropriate intervention. A variety of
methods yielding both anatomic and physiologic
information are available to assess the arterial cir-
culation. (Refer to section G for preferred imaging
techniques.)
In a situation where a proximal stenosis is of ques-
tionable hemodynamic significance, pressuremeasure-
ments across it to determine its significance (criteria:
threshold peak systolic difference 5e10 mmHg pre-
vasodilatation and 10e15 mmHg post-vasodilatation)
may be made. A recent development, that is yet to be
validated, is direct flowmeasurements using a thermo-
dilution catheter rather than pressure gradients.
Hyperemic duplex scanning has also been suggested.
In general, the outcomes of revascularization de-
pend upon the extent of the disease in the subjacent
arterial tree (inflow, outflow and the size and length
of the diseased segment), the degree of systemic
disease (co-morbid conditions that may affect life ex-
pectancy and influence graft patency) and the type
of procedure performed. Results of large-scale clinical
trials must be considered within the context of the
individual patient’s situation, considering all co-
morbidities when deciding upon a recommended
treatment course for that individual.
The endovascular techniques for the treatment of
patients with lower extremity ischemia include bal-
loon angioplasty, stents, stent-grafts and plaque
Recommendation 34. Intra-arterial pressure mea-
surements for assessment of stenosis
 If there is doubt about the hemodynamic signif-
icance of partially occlusive aortoiliac disease,
it should be assessed by intra-arterial pressure
measurements across the stenosis at rest and
with induced hyperemia [C].Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007debulking procedures. Thrombolysis and percutane-
ous thrombectomy have been described in the section
on acute limb ischemia. Surgical options include au-
togenous or synthetic bypass, endarterectomy or an in-
tra-operative hybrid procedure.
Outcomes of revascularization procedures depend
on anatomic as well as clinical factors. Patency follow-
ing percutaneous transluminal angioplasty (PTA) is
highest for lesions in the common iliac artery and
progressively decreases for lesions in more distal ves-
sels. Anatomic factors that affect the patency include
severity of disease in run off arteries, length of the
stenosis/occlusion and the number of lesions treated.
Clinical variables impacting the outcome also include
diabetes, renal failure, smoking and the severity of
ischemia.
F1.1 Classification of lesions
While the specific lesions stratified in the following
TASC classification schemes have been modified
from the original TASC guidelines to reflect inevitable
technological advances, the principles behind the clas-
sification remain unchanged. Thus ‘A’ lesions repre-
sent those which yield excellent results from, and
should be treated by, endovascular means; ‘B’ lesions
offer sufficiently good results with endovascular
methods that this approach is still preferred first,
unless an open revascularization is required for
other associated lesions in the same anatomic area;
‘C’ lesions produce superior enough long-term results
with open revascularization that endovascular
methods should be used only in patients at high risk
for open repair; and ‘D’ lesions do not yield good
enough results with endovascular methods to justify
them as primary treatment. Finally it must be under-
stood that most PAD requiring intervention is charac-
terized by more than one lesion, at more than one
level, so these schemes are limited by the necessity
to focus on individual lesions.
Recommendation 35. Choosing between tech-
niques with equivalent short- and long-term clin-
ical outcomes
 In a situation where endovascular revasculari-
zation and open repair/bypass of a specific
lesion causing symptoms of peripheral arterial
disease give equivalent short-term and long-
term symptomatic improvement, endovascular
techniques should be used first [B].
S55TASC II Inter-Society Consensus on Peripheral Arterial DiseaseF1.2 Classification of inflow (aorto-iliac) disease
(Fig. F1, Table F1)
F1.3 Classification of femoral popliteal disease
(Fig. F2, Table F2)
F2 Aortoiliac (Supra Inguinal) Revascularization
F2.1 Endovascular treatment of aorto-iliac
occlusive disease
Although aortobifemoral bypass appears to have
better long-term patency than the currently available
endovascular strategies for diffuse aortoiliac occlusive
Recommendation 36. Treatment of aortoiliac
lesions
 TASC A and D lesions: Endovascular therapy is
the treatment of choice for type A lesions and
surgery is the treatment of choice for type D
lesions [C].
 TASC B and C lesions: Endovascular treatment
is the preferred treatment for type B lesions
and surgery is the preferred treatment for
good-risk patients with type C lesions. The
patient’s co-morbidities, fully informed patient
preference and the local operator’s long-term
success rates must be considered when
making treatment recommendations for type B
and type C lesions [C].
Recommendation 37. Treatment of femoral popli-
teal lesions
 TASC A and D lesions: Endovascular therapy is
the treatment of choice for type A lesions and
surgery is the treatment of choice for type D
lesions [C].
 TASC B and C lesions: Endovascular treatment
is the preferred treatment for type B lesions
and surgery is the preferred treatment for
good-risk patients with type C lesions. The
patient’s co-morbidities, fully informed patient
preference and the local operator’s long-term
success rates must be considered when
making treatment recommendations for type B
and type C lesions [C].disease, the risks of surgery are significantly greater
than the risks of an endovascular approach, in terms
of not only mortality but also major morbidity and
delay in return to normal activities. Therefore, the
assessment of the patient’s general condition and
anatomy of the diseased segment(s) become central
in deciding which approach is warranted.
The technical and initial clinical success of PTA of
iliac stenoses exceeds 90% in all reports in the litera-
ture. This figure approaches 100% for focal iliac
lesions. The technical success rate of recanalization
of long segment iliac occlusions is 80%e85% with or
without additional fibrinolysis. Recent device devel-
opments geared towards treatment of total occlusions,
however, have substantially improved the technical
success rate of recanalization.181
Becker et al. found 5-year patency rate of 72% in an
analysis of 2697 cases from the literature, noting a bet-
ter patency of 79% in claudicants.182 Rutherford and
Durham found a similar 5-year patency of 70%.183
A recent study reported a primary patency of 74%
(primary assisted patency of 81%) 8 years after stent
placement suggesting durability of patency of iliac
artery stenting.184 Factors negatively affecting the
patency of such interventions include quality of run
off vessels, severity of ischemia and length of diseased
segments. Female gender has also been suggested
to decrease patency of external iliac artery stents.185
Table F3 presents the estimated success rate of iliac
artery angioplasty from weighted averages (range)
from reports of 2222 limbs.
Choice of stent versus PTA with provisional stent-
ing was addressed in a prospective randomized,
multicenter study.186 Results showed that PTA with
provisional stenting had a similar outcome to primary
stenting with 2-year reintervention rates of 7% and
4%, respectively, for PTA and primary stenting (not
significant). The 5-year outcomes of the groups were
also similar with 82% and 80% of the treated iliac
artery segments remaining free of revascularization
procedures after a mean follow-up of 5.6 years
1.3.187 A meta-analysis by Bosch and Hunink com-
pared the results of aortoiliac PTA versus aortoiliac
stenting using a Medline search of the post-1989 liter-
ature and yielded only six articles (including 2116
patients) with sufficient detail to allow stratification
over subgroups with various risk levels for long-
term patency.188 Technical success was higher for
stenting, whereas complication rates and 30-day mor-
tality rates did not differ significantly. In patients with
intermittent claudication the severity-adjusted 4-year
primary patency rates (95% confidence intervals)
after excluding technical failures, for PTA and stent-
ing, were: 68% (65%e71%) and 77% (72%e81%),Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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femoral artery; AAA e abdominal aortic aneurysm.respectively. Including technical failures, the 4-year
primary patency rates are 65% (PTA) versus 77%
(stent) for stenosis and 54% (PTA) versus 61% (stent)
for occlusion. The relative risk of long-term failure
was reduced by 39% after stent placement compared
with PTA. This robust report uses data from older
studies and it is reasonable to expect that the newer
techniques and equipment available today would
lead to even better results.
The outcome of two different self-expanding stents
for the treatment of iliac artery lesions was comparedEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007in a multicenter prospective randomized trial.189 The
1-year primary patencies were 94.7% and 91.1% (not
significant), respectively, with similar complication
and symptomatic improvement rates regardless of
the type of stent.
F2.2 Surgical treatment of aorto-iliac occlusive disease
Bilateral surgical bypass from the infra-renal abdomi-
nal aorta to both femoral arteries is usually
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Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007recommended for diffuse disease throughout the aor-
toiliac segment (Fig. F3). The aorta may be ap-
proached via a transperitoneal or retroperitoneal
approach. Interest is increasing in laparoscopic ap-
proach. The configuration of the proximal anastomo-
sis (end-to-end versus end-to-side) has not been
reliably shown to influence patency. The use of
PTFE versus Dacron as a conduit in this position is
based on the preference of the surgeon. Younger pa-
tients (<50 years of age) with lower primary and sec-
ondary patency have a greater need for secondary
bypass.190
Recent interest in endarterectomy has been revived
although it is not as widely practiced as bypass
grafting and may be more technically challenging. Re-
ported 5-year primary patency rates range from 60%
to 94%, reflecting a degree of variability depending
upon the operator.
In some situations, when an abdominal approach is
to be avoided due to anatomic considerations (‘hostile
abdomen’) or cardiac and/or pulmonary risks, a
Table F1. TASC classification of aorto-iliac lesions
Type A lesions
- Unilateral or bilateral stenoses of CIA
- Unilateral or bilateral single short (3 cm)
stenosis of EIA
Type B lesions
- Short (3 cm) stenosis of infrarenal aorta
- Unilateral CIA occlusion
- Singleormultiple stenosis totaling3e10 cm
involving the EIA not extending into the
CFA
- Unilateral EIA occlusion not involving the
origins of internal iliac or CFA
Type C lesions
- Bilateral CIA occlusions
- Bilateral EIA stenoses 3e10 cm long not
extending into the CFA
- Unilateral EIA stenosis extending into the
CFA
- Unilateral EIA occlusion that involves the
origins of internal iliac and/or CFA
- Heavily calcified unilateral EIA occlusion
with or without involvement of origins of
internal iliac and/or CFA
Type D lesions
- Infra-renal aortoiliac occlusion
- Diffuse disease involving the aorta and
both iliac arteries requiring treatment
- Diffuse multiple stenoses involving the
unilateral CIA, EIA and CFA
- Unilateral occlusions of both CIA and EIA
- Bilateral occlusions of EIA
- Iliac stenoses in patients with AAA re-
quiring treatment and not amenable to
endograft placement or other lesions re-
quiring open aortic or iliac surgery
CIA e common iliac artery; EIA e external iliac artery; CFA e
common femoral artery; AAA e abdominal aortic aneurysm.modified retroperitoneal approach or a unilateral by-
pass with a femoro-femoral crossover may be used.
Consideration should be given to using an axillo (bi)
femoral (Fig. F4) or cross-over femoral (Fig. F5)
bypass in patients with increased co-morbidities,
making a transabdominal approach less desirable.
Patency rates depend upon the indication for the
reconstruction and the justification for the unilateral
bypass (normal inflow artery versus high surgical
risk). In some cases, patency of unilateral bypass can
be supplemented by endovascular means. The
thoracic aorta has also been used as an inflow artery.
Extra-anatomic bypass rarely performs as well as
aortobifemoral bypass in diffuse disease and, there-
fore, is seldom recommended for claudication. Evi-
dence is lacking in recommending the preferred
material for anatomic or extra-anatomic prosthetic
bypass procedures. Table F4 summarizes the patency
at 5 and 10 years after aortobifemoral bypass and
Table F5 the patency rates at 5 years after extra-
anatomic bypass.
F3 Infrainguinal Revascularization
F3.1 Endovascular treatment of infrainguinal arterial
occlusive disease
Endovascular treatment of infrainguinal disease in
patients with intermittent claudication is an estab-
lished treatment modality. The low morbidity and
mortality of endovascular techniques such as PTA
makes it to the preferred choice of treatment in lim-
ited disease such as stenoses/occlusions up to 10 cm
in length.
The technical and clinical success rate of PTA of
femoropopliteal artery stenoses in all series exceeds
95% (range 98%e100%, standard error 1.0%).192 De-
vice developments such as hydrophilic guide wires
and technical developments, such as subintimal re-
canalization, provide high recanalization rates in to-
tal occlusions of more than 85% (range 81%e94%,
standard error 2.9%).193 The technique of subintimal
angioplasty is not as dependent on length, but
rather on the presence of normal vessel above and
below the occlusion to allow access.194 Table F6
summarizes pooled results of femoral popliteal
dilatations.
The mid- and long-term patency rates were
summarized in a meta-analysis by Muradin192 and
in three randomized studies assessing the efficacy
of stents.195e197
Risk factors for recurrence were analyzed by multi-
variate stepwise backward regression analyses in
S58 L. Norgren and W. R. Hiatt et al.Fig. F2. TASC classification of femoral popliteal lesions. CFA e common femoral artery; SFA e superficial femoral artery.various studies. Clinical stage of disease (intermittent
claudication versus critical limb ischemia), length of
lesion and outflow disease were most commonly
found as independent risk factors for restenoses.
Recently, a study by Schillinger of 172 patients suc-
cessfully undergoing PTA of the superficial femoral
and popliteal arteries observed that 6-month patency
rates were related to hs-CRP levels at baseline andEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007at 48 hours after intervention.198 SSA and fibrinogen
level were not significantly predictive.
There is general agreement that for acute failure of
PTA of an SFA lesion, stent placement is indicated. A
recent randomized trial has demonstrated signifi-
cantly higher primary patency rates of stenting vs.
PTA of femoropopliteal artery lesions TASC A and B
at 1-year follow up.199
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surgery (BP) in infrainguinal arterial obstructive dis-
ease are almost nonexistent. This can be explained
partially by the following facts: BP is more commonly
performed in extensive disease with long lesions and
CLI. PTA is more commonly performed in limited dis-
ease with IC and short obstructions (following the
original TASC recommendations 34 and 35). However,
Wolf et al. published a multicenter, prospective ran-
domized trial comparing PTA with BP in 263 men
who had iliac, femoral or popliteal artery obstruc-
tion.200 This study of patients randomly assigned to
BP or PTA showed no significant difference in out-
comes during a median follow-up of 4 years (survival,
patency and limb salvage). In 56 patients, cumulative
1-year primary patency after PTA was 43% and after
bypass surgery was 82%, demonstrating that for
long superficial femoral artery (SFA) stenoses or oc-
clusions, surgery is better than PTA. This contrasts
a recent randomized study of 452 patients which
Table F2. TASC classification of femoral popliteal lesions
Type A lesions
- Single stenosis 10 cm in length
- Single occlusion 5 cm in length
Type B lesions
- Multiple lesions (stenoses or occlusions),
each 5 cm
- Single stenosis or occlusion 15 cm not
involving the infra geniculate popliteal
artery
- Single or multiple lesions in the absence
of continuous tibial vessels to improve
inflow for a distal bypass
- Heavily calcified occlusion 5 cm in
length
- Single popliteal stenosis
Type C lesions
- Multiple stenoses or occlusions totaling
>15 cm with or without heavy
calcification
- Recurrent stenoses or occlusions that need
treatment after two endovascular
interventions
Type D lesions
- Chronic total occlusions of CFA or SFA
(>20 cm, involving the popliteal artery)
- Chronic total occlusion of popliteal artery
and proximal trifurcation vessels
CFA e common femoral artery; SFA e superficial femoral artery.
Table F3. Estimated success rate of iliac artery angioplasty from
weighted averages (range) from reports of 2222 limbs
% Claudication Technical
success
Primary patency
1 yr 3 yr 5 yr
76% (81e94) 96% (90e99) 86%
(81e94)
82%
(72e90)
71%
(64e75)demonstrated no difference in amputation-free sur-
vival at 6 months; however, surgery was somewhat
more expensive.201
Medical treatment after PTA and stent placement
is recommended to prevent early failure because of
thrombosis at the site of intervention. Standard
therapy is heparinization during the intervention to
increase activated clotting time to 200e250 seconds.
After PTA and stenting of femoropopliteal arteries,
a life-long antiplatelet medication is recommended to
promote patency (acetylsalicylic acid or clopidogrel).
Life-long antiplatelet therapy is also recommended
to prevent cardiovascular events as recommended in
section B. Much of the supporting evidence for
peri-procedural antiplatelet and adjuvant therapy is
extrapolated from that related to the coronary
circulation.
Fig. F3. Bilateral bypass from infra renal abdominal aorta to
both femoral arteries.
Fig. F4. Axillo (bi) femoral bypass.
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occlusive disease
Endovascular procedures below the popliteal artery
are usually indicated for limb salvage and there are
no data comparing endovascular procedures to
bypass surgery for intermittent claudication in
this region.
Angioplasty of a short anterior or posterior tibial
artery stenosis may be performed in conjunction
with popliteal or femoral angioplasty. Use of this
technique is usually not indicated in patients with
intermittent claudication.
There is increasing evidence to support a recom-
mendation for angioplasty in patients with CLI and
infrapopliteal artery occlusion where in-line flow to
the foot can be re-established and where there is
medical co-morbidity. In the case of infrapopliteal
angioplasty, technical success may approach 90%
with resultant clinical success of approximately 70%
in some series of patients with CLI. Salvage rates are
reported as being slightly higher.
Predictors of successful outcome include a shorter
length of occlusion and a lesser number of vessels
treated. The complication rate (2.4%e17% depending
upon the definition) can usually be treated by
Table F4. Patency at 5 and 10 years after aortobifemoral bypass191
Indication 5-year % patency
(range)
10-year % patency
(range)
Claudication CLI Claudication CLI
Limb based 91 (90e94) 87 (80e88) 86 (85e92) 81 (78e83)
Patient based 85 (85e89) 80 (72e82) 79 (70e85) 72 (61e76)
CLI e critical limb ischemia.
Fig. F5. Cross-over femoral bypass.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007endovascular or surgical techniques and a failed an-
gioplasty does not preclude subsequent bypass.
It remains controversial whether infrapopliteal PTA
and stenting should be performed in patients with IC
for improvement of outflow and for an increased
patency of proximal PTA, stenting and bypass surgery.
There is insufficient evidence to recommend infra-
popliteal PTA and stenting in patients with inter-
mittent claudication.
F3.3 Surgical treatment of infrainguinal occlusive disease
In the case ofmultilevel disease, the adequacy of inflow
must be assessed anatomically or with pressure
measurements and occlusive disease treated prior to
proceeding with an outflow procedure. In some situa-
tions, a combined approachwith dilatation of proximal
lesions and bypassing of distal lesions should
be performed.
A recent study has shown a trend towards increas-
ingly complex bypass grafts (composite and spliced
vein) to more distal arteries in patients with greater
co-morbidities, such as diabetes, renal failure and cor-
onary artery disease; however, mortality rates have re-
mained constant.202 A recent large study showed that
gender did not adversely affect the morbidity or
mortality of lower extremity revascularization.
F3.3.1 Bypass
Infrainguinalbypassproceduresneed toarise fromapat-
ent and uncompromised inflow artery although the
actual level (common femoral artery versus superficial
femoral or popliteal artery) does not correlate with
patency. If the infrainguinal bypass is constructed fol-
lowing an inflow procedure, patency is improved by
Table F5. Patency rates at 5 years after extra-anatomic bypass
Procedure 5-year % patency (range)
Axillo uni femoral bypass 51 (44e79)
Axillo bi femoral bypass 71 (50e76)
Femoral femoral bypass 75 (55e92)
Table F6. Pooled results of femoral popliteal dilatations
1-year %
patency
(range)
3-year %
patency
(range)
5-year %
patency
(range)
PTA: stenosis 77 (78e80) 61 (55e68) 55 (52e62)
PTA: occlusion 65 (55e71) 48 (40e55) 42 (33e51)
PTAþ stent:
stenosis
75 (73e79) 66 (64e70)
PTAþ stent:
occlusion
73 (69e75) 64 (59e67)
PTA e Percutaneous Transluminal Angioplasty.
S61TASC II Inter-Society Consensus on Peripheral Arterial Diseasemaking the proximal anastomosis to a native artery
rather than the inflow graft (usually limb of aortobife-
moral bypass).203 The quality of the outflow artery is
amore important determinant of patency than the actual
levelwhere the distal anastomosis is performed.Adistal
vessel of the best quality should be used for the distal
anastomosis. There is no objective evidence to preferen-
tially select either tibial or peroneal artery, since they
are typicallyof equal caliber.Theresultsof femoral crural
bypass have not been subjected to meta-analysis.
Five-year assisted patency rates in grafts constructed
with vein approach 60% and those constructed with
prosthetic material are usually less than 35%. Reports
have documented the suitability of constructing bypass
grafts to plantar arteries with reasonable success rates
(5-year salvage 63%, 5-year primary patency 41%).
F3.3.2 Conduit
Vein has better long-term patency than prosthetic in
the infra inguinal region (Table F7). Over the short
term, PTFE has delivered near equivalent results in
the above-knee position (Fig. F6). A meta-analysis
suggests much less satisfactory results of polytetra-
fluoroethylene-coated grafts (PTFE) to the infra-
popliteal arteries (5-year patency: primary 30.5%,
Recommendation 38. Inflow artery for femoro-
distal bypass
 Any artery, regardless of level (i.e. not only the
common femoral artery), may serve as an in-
flow artery for a distal bypass provided flow
to that artery and the origin of the graft is not
compromised [C].
Recommendation 39. Femoral distal bypass out-
flow vessel
 In a femoral tibial bypass, the least diseased
distal artery with the best continuous run-off
to the ankle/foot should be used for outflow re-
gardless of location, provided there is adequate
length of suitable vein [C].
Table F7a. 5-year patency following femoral popliteal bypass191
Claudication CLI
Vein 80 66
Above-knee PTFE 75 47
Below-knee PTFE 65 65
CLI e critical limb ischemia; PTFE e polytetrafluoroethylene graft.secondary 39.7%).204 The consequences of a prosthetic
graft occlusion may be more severe than a vein graft
occlusion.205 A recent study questioned the wisdom
of using a prosthetic graft when acceptable vein was
available in order to ‘save the vein’. Using this strat-
egy, up to 33% of subsequent secondary bypass grafts
did not have adequate vein available at that time. The
long saphenous vein (also known as the greater sa-
phenous vein), either in a reversed or in situ configu-
ration offers the best match of size and quality. In its
absence, other venous tissue including contralateral
long saphenous vein, short (lesser) saphenous vein,
femoral vein and arm vein have been used (Fig. F7).
There is no difference in patency rates between in
situ and reversed vein grafts. Differences in outcome
will depend upon indications for surgery, the quality
of the vessels, and co-morbidities. Venous grafts all
have better results than prosthetic materials.
F3.3.3 Adjunct procedures
When a prosthetic bypass graft is placed into the
below-knee popliteal or distal artery adjunct proce-
dures, such as arteriovenous fistula at or distal to
the bypass and the use of a vein interposition/cuff,
have been suggested. However, randomized trials210
have shown that the addition of a distal arteriovenous
fistula adds no benefit with respect to patency and,
therefore, cannot be recommended. The use of a ve-
nous cuff or patch has been promising in the below-
knee popliteal or distal anastomosis in some series,
although no comparison trials indicate the best type
of patch technique.211
F3.3.4 Profundoplasty
Stenosis at the origin of the profunda femoris
artery may lead to decreased flow through collateral
vessels in the presence of a SFA occlusion and may
Table F7b. Randomized trials of types of conduits206e209
Above-knee femoral popliteal bypass 5-year patency
Vein 74e76%
PTFE 39e52%
PTFE e polytetrafluoroethylene graft.
Recommendation 40. Femoral below-knee popli-
teal and distal bypass
 An adequate long (greater) saphenous vein is
the optimal conduit in femoral below-knee
popliteal and distal bypass [C]. In its absence,
another good-quality vein should be used [C].
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inflow operation. In the presence of SFA occlusion it
is recommended that a stenosis of the profunda fem-
oris artery be corrected during inflow procedures. Iso-
lated profundoplasty as an inflow procedure (sparing
a femoral distal bypass) may be considered in the
presence of: 1) excellent inflow; 2) >50% stenosis of
the proximal 1/3 profunda; and 3) excellent collateral
flow to the tibial vessels.
F3.3.5 Secondary revascularization procedures
Secondary patency results from the salvage of an oc-
cluded bypass and assisted patency results from
pre-occlusion intervention. The non-tolerance of vein
grafts to thrombosis and the success of assisted pa-
tency support the previous recommendations that all
Fig. F6. Above-knee femoral popliteal bypass.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007venous bypass grafts be followed by a regular regime
of duplex scanning with set parameters for interven-
tion including angioplasty (open or transluminal) or
short segment interposition. This recommendation
has recently been questioned by a randomized, con-
trolled trial showing no cost benefit of such an
approach.212 In the presence of an occluded but
established graft, thrombolysis may be indicated in
the very early stages to remove clot and reveal the
cause of the thrombosis. When limb salvage is as-
sessed following failure of an infrainguinal bypass
the original indication for surgery is an important fac-
tor. The 2-year limb salvage rates for occluded grafts
done for claudication is 100%, for rest pain is 55%
and when done for tissue loss is 34%. The early occlu-
sion of a graft (<30 days occlusion) led to a very poor
2-year limb salvage rate of 25%.213
Fig. F7. Femoral tibial bypass.
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Adjuvant therapy has been recommended to improve
the patency rate following lower extremity bypass
grafts. Antiplatelet agents have a beneficial effect
that is greater in prosthetic than in autogenous
conduits.156 A meta-analysis published in 1999 dem-
onstrated that the relative risk of infra inguinal graft
occlusion in patients on aspirin/ASA was 0.78.214
The recommendation for aspirin/ASA therapy is sim-
ilar for patients undergoing lower extremity balloon
angioplasty.59 The addition of dipyridamole or ticlopi-
dine has been supported by some studies but larger
randomized trials will be necessary to make a firm rec-
ommendation.215 Autogenous grafts may be treated
with warfarin216 but this is accompanied by a risk of
hemorrhage and this decision must be made on an in-
dividual patient basis.59 All patients should receive
antiplatelet therapy following a revascularization.
For those receiving anticoagulation, and in those few
treated with both antiplatelet agents and anticoagu-
lants, extra vigilance is required due to the increased
risk of bleeding. Recent articles have been published
expressing concern that patients undergoing inter-
vention for PAD are not receiving the optimal care for
their atherosclerotic process. As previously stated, all
patients should undergo assessment and treatment
for their underlying atherosclerosis regardless of the
need for intervention for limb salvage.
F5 Surveillance Programs Following
Revascularization
Following construction of an infrainguinal autoge-
nous bypass graft, it has been recommended in the
past that a program of regular graft review with du-
plex scanning be undertaken.217 The purpose of this
is to identify lesions that predispose to graft thrombo-
sis and allow their repair prior to graft occlusion. A
recent multicentered, randomized, controlled trial
has shown that duplex surveillance after venous
femoral distal bypass grafts leads to no significant
clinical benefit or quality of life improvement at 18
Recommendation 41. Antiplatelet drugs as adju-
vant pharmacotherapy after revascularization
 Antiplatelet therapy should be started preoper-
atively and continued as adjuvant pharmaco-
therapy after an endovascular or surgical
procedure [A]. Unless subsequently contraindi-
cated, this should be continued indefinitely [A].months. The previous recommendation of routine
duplex scanning following autogenous lower extremity
bypass has proven to be not cost-effective according to
this study.212 In practice, many surgeons continue a
program of vein graft surveillance awaiting further
confirmation of the findings of this trial.
F6 New and Advancing Therapies
Newer surgical techniques have tended to involve min-
imally invasive arterial reconstructions including lapa-
roscopic aortic reconstructions. The use of combined
therapies (transluminal andoperative)may lead to ‘min-
imally’ invasive surgery. In infrainguinal reconstruction
Recommendation 42. Clinical surveillance pro-
gram for bypass grafts
 Patients undergoing bypass graft placement in
the lower extremity for the treatment of claudi-
cation or limb-threatening ischemia should be
entered into a clinical surveillance program.
This program should consist of:
B Interval history (new symptoms)
B Vascular examination of the leg with palpa-
tion of proximal, graft and outflow vessel
pulses
B Periodic measurement of resting and, if possi-
ble, post-exercise ankle-brachial indices
 Clinical surveillance programs should be per-
formed in the immediate postoperative period
and at regular intervals (usually every 6
months) for at least 2 years [C].
Table F8. Cumulative observed morbidity outcomes for bypass in
critical limb ischemia
Parameter Short term
(first year)
Long term
(3e5 years)
Mean time to pedal wound healing 15e20 weeks e
Incisional wound complications* 15%e25% e
Persistent severe ipsilateral
lymphedemax
10%e20% Unknown
Graft stenosis** 20% 20%e30%
Graft occlusion 10%e20% 20%e40%
Graft surveillance studies 100% 100%
Major amputation 5%e10% 10%e20%
Ischemic neuropathy Unknown Unknown
Graft infectiony 1%e3% e
Perioperative death (primarily
cardiovascular)
1%e2% e
All death (primarily cardiovascular) 10% 30%e50%
*Not all requiring reoperation.
xNot well-studied.
**Greater in series of composite and alternate vein conduit.
yGreatest in prosthetic grafts.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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interest. Additionally, in the attempt to reduce the mor-
bidity of wound complications and the negative effects
of this on patency, the use of endoscopic vein prepara-
tion and/or harvest is being investigated.
Recentlydrug-eluting stentswere tested ina random-
ized study against bare stents in femoropopliteal artery
obstructive disease in claudicants.218 This study evalu-
ated the effectiveness of nitinol self-expanding stents
coated with a polymer impregnated with sirolimus
(rapamycin) versus uncoated nitinol stents in patients
with IC and SFA obstructions. The in-stent mean lumen
diameter was significantly larger in the sirolimus-
eluting stent group (4.95 mm versus 4.31 mm in the
uncoated stent group; p¼ 0.047). The results of this trial
require further confirmation and longer-term follow up.
Results of a recent small randomized trial suggest early
results of primary nitinol stenting of SFAdilatations had
a superior result to dilatation alone.199
The impact of ePTFE coated stents (stentgrafts) was
tested in a randomized trial by Saxon et al.219 At
2 years follow-up, primary patency remained 87%
(13 of 15 patients) in the stentgraft group versus only
25% (three of 12 patients) in the PTA group ( p¼ 0.002).
Endovascular brachytherapy (BT) with g-emitting
sources such as 192Ir was investigated with respect
to the rate of intimal hyperplasia and restenoses.220
Minar et al. tested endovascular BT in femoropopliteal
obstructions and IC in a randomized trial. The overall
recurrence rate after 6 months was significantly
lower (28.3% versus 53.7%) for the PTAþ BT group
compared with the PTA. Cumulative patency was
also significantly higher at 12 months (63.6% versus
35.5%). Advice for general use will require more
extensive and longer-term study.
Fig. F8. Results summary: Average results for surgical
treatment. Ao-bi-fem e Aortobifemoral bypass; Fem-pop e
femoropopliteal; BK e below knee; Ax-bi-fem e Axillobife-
moral; PTA e Percutaneous Transluminal Angioplasty;
Ax-uni-fem e Axillounifemoral bypass; pros e prosthetic.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007The focus of newer adjuvant therapies is to increase
the robustness of percutaneous interventions making
them more applicable and durable to a broader range
of lesions. These local therapies must be combined with
systemic management of the atherosclerotic process.
Table F8 summarizes the cumulative observed
morbidity outcomes for bypass in critical limb ische-
mia, and Fig. F8 summarizes the average results for
surgical treatment.
SECTION G e NON-INVASIVE VASCULAR
LABORATORY AND IMAGING
G1 Non-invasive Vascular Laboratory
The routine evaluation of patients with peripheral
arterial disease (PAD) can include a referral to the
vascular laboratory. Non-invasive hemodynamic mea-
surements can provide an initial assessment of the loca-
tion and severity of the arterial disease. These tests can
be repeated over time to follow disease progression.
G1.1 Segmental limb systolic pressure measurement
Segmental limb pressure (SLP) measurements are
widely used to detect and segmentally localize hemo-
dynamically significant large-vessel occlusive lesions
in the major arteries of the lower extremities. Segmen-
tal pressure measurements are obtained in the thigh
and calf in the same fashion as the ankle pressure. A
sphygmomanometer cuff is placed at a given level
with a Doppler probe over one of the pedal arteries,
and the systolic pressure in the major arteries under
the cuff is measured. The location of occlusive lesions
is apparent from the pressure gradients between the
different cuffs. Limitations of the method include:
(1) missing isolated moderate stenoses (usually iliac)
that produce little or no pressure gradient at rest;
(2) falsely elevated pressures in patients with diabetes
calcified, incompressible arteries; and (3) the inability
to differentiate between arterial stenosis or occlusion.
G1.2 Segmental plethysmography or pulse
volume recordings
A plethysmograph is an instrument that detects and
graphically records changes in limb volume. Limb cuffs
are placed around the leg at selected locations and con-
nected to a plethysmograph, which produces a pulse
volume recording (PVR). Normally, a single large thigh
cuff isusedalongwith regular-sized calf and ankle cuffs,
plus abrachial cuff that reflects theundampenedcardiac
S65TASC II Inter-Society Consensus on Peripheral Arterial Diseasecontribution to arterial pulsatility. The latter is useful in
standardizing the lower-limbPVRand indetecting poor
cardiac function as a cause of low-amplitude tracings. To
obtain accurate PVR waveforms the cuff is inflated
tow60e65 mmHg, which is sufficient to detect volume
changes without resulting in arterial occlusion.
SLP and PVR measurements alone are 85% accu-
rate compared with angiography in detecting and lo-
calizing significant occlusive lesions. Furthermore,
when used together, the accuracy approached
95%.221 For this reason, these two diagnostic methods
are commonly used together when evaluating PAD.
Using SLP and PVR in combination ensures that pa-
tients with diabetes who have calcified arteries suffi-
cient to produce falsely elevated SLP will be readily
recognized and correctly assessed by PVR.
G1.3 Toe pressures and the toe-brachial index
Patients with long-standing diabetes, renal failure and
otherdisorders resulting invascular calcification cande-
velop incompressible tibial arteries, which cause falsely
high systolic pressures. Non-compressible measure-
ments are defined as a very elevated ankle pressure
(e.g. 250 mmHg) or ankle-brachial index (ABI) >1.40.
In this situation,measurement of toe pressures provides
an accurate measurement of distal limb systolic pres-
sures in vessels that do not typically become non-com-
pressible. A special small occlusion cuff is used
proximally on the first or second toe with a flow sensor,
such as that used for digital plethysmography. The toe
pressure is normally approximately 30 mmHg less
than the anklepressure and anabnormal toe-brachial in-
dex (TBI) is<0.70. Themeasurement of toe pressures re-
quires a non-invasive vascular laboratorywith standard
environmental conditions, expertise and equipment
necessary to make the measurement. False positive re-
sultswith theTBI areunusual.Themain limitation inpa-
tients with diabetes is that it may be impossible to
measure toe pressure in the first and second toes due
to inflammatory lesions, ulceration, or loss of tissue.
G1.4 Doppler Velocity Wave Form analysis
Arterialflowvelocity canbeassessedusingacontinuous-
wave Doppler at multiple sites in the peripheral
circulation. Doppler waveforms evolve from a normal
triphasic pattern to a biphasic and, ultimately,monopha-
sic appearance in those patients with significant
peripheral arterial disease (PAD). When assessed over
the posterior tibial artery, a reduced or absent forward
flow velocity was highly accurate for detecting PAD
(and also isolated tibial artery occlusive disease thatmay occur in patients with diabetes).12 While the test is
operator-dependent, it provides anothermeans to detect
PAD in patients with calcified tibial arteries.
G2 Imaging Techniques
G2.1 Indications for and types of imaging in patients with
intermittent claudication or critical limb ischemia
Imaging is indicated if some form of revascularization
(endovascular or open surgical) would be advised if
a suitable lesion is demonstrated. The patient’s dis-
ability and functional limitations due to impaired
walking ability should be the major determinant in
deciding on revascularization. This is considered in
terms of claudication distance and the effect of this
limitation on the patient’s lifestyle, as well as their
independence and capacity for self care. In cases of
critical limb ischemia (CLI), imaging and revasculari-
zation are mandatory, provided contraindications do
not prohibit surgical or endovascular intervention.
The expense andmorbidity rate for duplex scanning
and other non-invasivemethods are far less than for in-
vasive angiography. With the introduction of magnetic
resonance angiography (MRA) and computed tomo-
graphic angiography (CTA), it is now possible to use
non-invasive imaging in many situations to assess the
suitability of theunderlying lesions for theproposed in-
tervention before committing to invasive angiography.
G2.2 Choice of imaging methods
The main reason for imaging is to identify an arterial
lesion that is suitable for revascularization with either
an endovascular or open surgical technique. The
current options for imaging are angiography, duplex
ultrasound, MRA and CTA. Potential side effects
and contraindications should be considered in choos-
ing the imaging modality. Intra-arterial angiography
requires contrast medium that is potentially nephro-
toxic. Multidetector computed tomographic angiogra-
phy (MDCTA) requires a contrast medium load of
>100 mL. Several methods exist to reduce renal injury,
including hydration and protective drugs such as
N-acetylcysteine. The usage of alternate contrast
agents (see G2.2.1) may also be considered. Where
the use of iodinated contrast medium is to be re-
stricted or avoided, MRA and also duplex ultrasonog-
raphy may allow planning for surgery.
G2.2.1 Angiography
Angiography, considered the ‘‘gold standard’’ imaging
test, carries certain risks: approximately 0.1% risk ofEur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007
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risk severe enough to alter patient management,
and 0.16% mortality risk and significant expense.
Other complications include arterial dissection, athe-
roemboli, contrast-induced renal failure and access
site complications (i.e. pseudoaneurysm, arteriove-
nous fistula and hematoma). These problems have
been greatly mitigated by technological improvements
in the procedure, including the use of nonionic contrast
agents, digital subtraction angiography, intra-arterial
pressure measurements across a stenosis with
and without vasodilator (significance peak systolic
difference 5e10 mmHg pre-vasodilatation and
10e15 mmHg post-vasodilatation), and more sophisti-
cated image projection and retention. Alternatively,
carbon dioxide andmagnetic resonance contrast agents
(i.e. gadolinium) can be used instead of conventional
contrast media. In high-risk (e.g. renal impairment) pa-
tients, restriction to a partial study with selected views
rather than visualizing the entire infrarenal arterial tree
has decreased the contrast load, length of study and as-
sociated risks.Despite this, full angiography,with visu-
alization from the level of the renal arteries to the pedal
arteries using digital subtraction angiography (DSA)
techniques, remains the choice in most cases.
G2.2.2 Color-assisted duplex ultrasonography
Color-assistedduplex imaginghas beenproposedas an
attractive alternative to angiography. In addition to be-
ing completely safe and much less expensive, duplex
scanning, in expert hands, can provide most of the es-
sential anatomic information plus some functional in-
formation (for instance, velocity gradients across
stenoses). The lower extremity arterial tree can be visu-
alized, with the extent and degree of lesions accurately
assessed and arterial velocities measured. Disadvan-
tages include the length of the examinations and vari-
ability of skill of the technologist. In addition, crural
arteries are challenging to image in their entirety.
G2.2.3 Magnetic resonance angiography
In many centers, MRA has become the preferred
imaging technique for the diagnosis and treatment
planning of patients with PAD. The advantages of
MRA include its safety and ability to provide rapid
high-resolution three-dimensional (3D) imaging of
the entire abdomen, pelvis and lower extremities in
one setting. The 3D nature of magnetic resonance im-
aging implies that image volumes can be rotated and
assessed in an infinite number of planes. MRA is use-
ful for treatment planning prior to intervention and in
assessing suitability of lesions for endovascular ap-
proaches. Pre-procedure MRA may minimize use of
iodinated contrast material and exposure to radiation.Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007The high magnetic field strength in MRA excludes
patients with defibrillators, spinal cord stimulators,
intracerebral shunts, cochlear implants etc., and the
technique also excludes the <5% patients affected by
claustrophobia that is not amenable to sedation. Stents
within segments of peripheral vessels may produce
a susceptibility artifact that can render evaluation of
these segments difficult. However, the signal loss
with stents is extremely dependent on the metallic al-
loy, with nitinol stents producing minimal artifact. In
contrast to CTA (see section G2.2.4), the presence of
calcium in vessels does not cause artifacts on MRA
and this may represent a potential advantage in exam-
ining diffusely calcified vessels in patients with diabe-
tes and patients with chronic renal failure.
MRA techniques can be gadolinium contrast-based
(contrast-enhanced MRA or CE-MRA) or non-con-
trast-based (time-of-flight techniques). In general, CE-
MRA techniques utilize a moving table (floating table)
approach and sequentially following a bolus of con-
trast throughmultiple (usually 3e4) stations extending
from the abdomen to the feet. CE-MRA has replaced
non-contrast MRA for the assessment of peripheral
vessels, as this technique provides rapid imaging
with substantively better artifact-free images.222
Time-resolved CE-MRA is usually performed in con-
junction with moving table CE-MRA, providing an
additional examination of infra-inguinal vessels and
dynamic images free of venous contamination.
CE-MRA has a sensitivity and specificity of >93%
for the diagnosis of PAD compared with invasive angi-
ography.222 A number of studies have demonstrated
that CE-MRA has better discriminatory power than
color-guided duplex ultrasound for the diagnosis of
PAD. Recent advancements in CE-MRA methodolo-
gies that include refinements such as usage of a venous
occlusion cuff around the thigh to modulate contrast
delivery to the foot, and parallel imaging methods
have greatly improved the ability to image distal
vessels in a high resolution manner (<1 1 mm in
plane).223,224 MRA may consistently pick up more
patent vessels than DSA below the knee and could
potentiallyobviate theneed for invasive angiography.225
G2.2.4 Multidetector computed tomography angiography
Multidetector computed tomography angiography
(MDCTA) is being widely adopted for the initial diag-
nostic evaluation and treatment planning of PAD. The
rapid evolution of technology and the deployment
of fast MDCTA multislice systems in the community
and the familiarity with CT technology and ease of
use are some factors driving its popularity. Multi-
slice MDCTA enables fast imaging of the entire
lower extremity and abdomen in one breath-hold at
S67TASC II Inter-Society Consensus on Peripheral Arterial Diseasesub-millimeter isotropic voxel resolution. Although
prospectively designed studies with MDCTA are
currently lacking, there are emerging data that the
sensitivity, specificity and accuracy of this technique
may rival invasive angiography.226,227
The major limitations of MDCTA include the usage
of iodinated contrast (z120 mL/exam), radiation ex-
posure and the presence of calcium.226 The latter can
causea ‘bloomingartifact’ andcanprecludeassessment
of segments with substantive calcium. Stented seg-
ments can also cause significant artifact and may pre-
clude adequate evaluation. However, the ability to
evaluate vesselwall lumen in stented and calcified seg-
ments is dependent on the technique (window/level,
reconstruction kernel, and type of image [maximum in-
tensity projection versus multiplanar reformation etc]).
To summarize, if a patient qualifies for invasive
therapy, angiography will, ultimately, be required in
almost all elective cases, preoperatively for surgical
reconstruction and before or during catheter-based
interventions. Duplex scanning is used selectively
mainly to characterize specific lesions in regard to
their suitability for endovascular treatment. However,
it should be kept in mind that arterial reconstructive
surgery can be performed on the basis of duplex scan-
ning alone in some cases. The different imaging
methods are compared in Table G1.
Recommendation 43. Indications and methods to
localize arterial lesions
 Patients with intermittent claudication who
continue to experience limitations to their qual-
ity of life after appropriate medical therapy (ex-
ercise rehabilitation and/or pharmacotherapy)
or patients with critical limb ischemia, may be
considered candidates for revascularization if
they meet the following additional criteria: (a)
a suitable lesion for revascularization is identi-
fied; (b) the patient does not have any systemic
contraindications for the procedure; and (c) the
patient desires additional therapy [B].
 Initial disease localization can be obtained with
hemodynamic measures including segmental
limb pressures or pulse volume recording [B].
 When anatomic localization of arterial occlu-
sive lesions is necessary for decision making,
the following imaging techniques are recom-
mended: duplex ultrasonography, magnetic
resonance angiography and computed tomo-
graphic angiography (depending on local
availability, experience, and cost) [B].T
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